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ABSTRACT
The aim of this project was to investigate pancreatic B-cell, GIF and GFF-t^.^am ide 
secretion and function in various hyperinsulinaemic, insulin-resistant states. A 
specific ELISA for insulin was developed as part of this, which was also used to 
investigate insulin production in a patient with a proinsulinoma tumour.
A study on a group of obese and lean subjects examined the effects of modulating 
their circulating NEFA levels, with heparin and acipimox, on G LF-l^.^am ide and 
other hormone secretion following oral glucose. Postprandial GLP-l^.^am ide 
secretion was found to be inversely related to plasma NEFA levels. An attenuated 
GLP-l(7 -3 6 )amide response to glucose was observed in obese subjects relative to 
control subjects, even when their NEFA levels were suppressed to a similar degree.
A second group of obese and lean subjects was investigated following a mixed test 
meal. The method of anthropometric measurement used to assess body fat distribution 
in the obese was found to influence the designation of subjects as having either an 
android or a gynoid fat distribution. This in turn affected the hormone and metabolite 
levels observed for each group. It was postulated that the android obese subjects 
exhibited increased des-31,32 proinsulin and decreased ! j proinsulin
relative to gynoid obese subjects. GIP hypersecretion was seen in the obese, being 
more marked in the gynoid obese, consistent with its role as an incretin producing 
increased proinsulin : levels in this group. GLP-l^.^am ide
responses were similar between obese and control groups following the mixed test 
meal and not attenuated in obese subjects as in the first study in response to 
carbohydrate alone. This suggests that GLP-l^.^amide may be less important as a 
satiating factor in the normal physiological situation of mixed nutrient consumption.
Responses to a mixed test meal were examined in groups of severely, moderately and 
normo-triglyceridaemic subjects They were also examined in another group of hyper- 
and normo-triglyceridaemic subjects in response to a sucrose load with and without 
the oc-glucosidase inhibitor, acarbose. GIP hypersecretion was observed in 
hypertriglyceridaemic subjects; this was greater in those subjects with lower insulin 
levels, consistent with the hypothesis of feedback inhibition of insulin on fat 
stimulated-GIP secretion.
Determining factors of GIP and GLP-l^.^amide circulating levels appeared to be the 
nutrient content of the meal, body fat distribution (GIP) and degree of 
hyperinsulinaemia (GIP). The studies suggested that GIP may play a minor part in the 
hyperinsulinaemia of obesity and hypertriglyceridaemia, but there was no evidence of 
a role for GLP-l^.^amide. An overactive enteroinsular axis did not appear to be 
involved in polycystic ovarian syndrome.
The specific ELISA for insulin, developed during this project, proved useful in 
clarifying insulin production in obesity and in a patient with a proinsulinoma tumour, 
where proinsulin or des 31,32-proinsulin production was abnormal.
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ABBREVIATIONS
AUC Area under the curve
B Bound counts per minute (or bound absorbance)
BMI Body mass index
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BSA Bovine serum albumin
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m Metres
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n Number
NAD Nicotinamide adenine dinucleotide
NADH Nicotinamide adenine dinucleotide (reduced)
iii
NEFA Non-esterified fatty acids
NIDDM Non-insulin-dependent diabetes mellitus
NSB Non-specific binding
PCOS Polycystic ovarian syndrome
PEG Polyethylene glycol
pmol/L Picomoles per litre
RIA Radioimmunoassay
R.O. Reverse osmosis
rpm Revolutions per minute
S.D. Standard deviation
S.E.M. Standard error of the mean
TAG Triacylglycerol
TAUC Total area under the curve
pmol/L Micromoles per litre
VLDL Very low density lipoprotein
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CHAPTER 1.
In t r o d u c t io n .
i
1.1 INTRODUCTION
Insulin is essential to the body because it is a major anabolic hormone involved in 
carbohydrate, fat and protein metabolism. Proinsulin and the proinsulin fragments are 
polypeptides produced during the biosynthesis of insulin in the pancreas. Intact 
proinsulin and the fragments have some biological activity, with respect to glucose 
homeostasis, but are much less potent than insulin in producing the same effects.
The absolute amount of proinsulin and fragments released into the circulation and the 
amount relative to insulin is low in normal weight, healthy subjects; however, they are 
thought to increase in certain conditions such as diabetes mellitus and obesity. 
Knowledge of the actual amounts of these peptides circulating in the blood and thus 
the possible aetiology and pathogenesis of certain diseases has been confounded by a 
lack of reliable assay methods to measure the peptides. With the advance in novel 
technology, more specific and sensitive assays are being developed which should help 
elucidate this problem.
Several gut factors can alter postprandial insulin secretion. The expression 
enteroinsular axis is used to embrace these. Glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 ^ .^am ide (GKP-l^.^amide) are the 
two main hormones of the axis involved in increasing circulating insulin levels. These 
two hormones will be concentrated on in any discussion of the enteroinsular axis.
Hyperinsulinaemia, accompanied by a decreased sensitivity to the biological actions 
of insulin, is often associated with many disease states, including obesity,
2
hypertriglyceridaemia and polycystic ovarian syndrome. Greater understanding of the 
role of the enteroinsular axis in contributing to the hyperinsulinaemia seen in these 
states may help clarify their aetiology.
This thesis investigates the inter-relationship between B-cell products, the gut 
hormones GIP and GBP-l^.^amide and the hyperinsulinaemic states of obesity, 
hypertriglyceridaemia, and polycystic ovarian syndrome. It also examines B-cell 
function in a case study of a patient with a Proinsulinoma tumour using a novel, 
specific assay for insulin.
1.2. THE PANCREAS AND INSULIN
1.2.1. Pa nc r ea s  S tru ctu re
The pancreas has both exocrine and endocrine functions. Embedded throughout the 
exocrine pancreas are approximately one million clusters of cells, which can be 
differentiated histologically. These are known as islets of Langerhans and perform the 
endocrine functions of the pancreas. The islets make up only about 1-2% of the total 
pancreatic mass (Stefan et al., 1982). They secrete a number of polypeptides in 
response to certain stimuli.
The islet comprises several types of cell. B-cells predominate and constitute more than 
60% of human islet cells (Rahier et al, 1983). In man B-cells occur mainly centrally 
within the islet and produce, store and secrete the polypeptides insulin and C-peptide 
and their precursors, the proinsulin intermediates/fragments and proinsulin from the
prohormone preproinsulin. The other major cell types are A cells which produce 
glucagon, D cells which produce somatostatin and PP cells which produce pancreatic 
polypeptide.
1.2.2. F u nc tio n s  o f  In sulin
The structure of insulin is highly conserved between species, indicating that it plays an 
important biological role (Wood and Mcleod, 1991). It is the main hormone capable of 
reducing blood glucose concentration, which is why a deficiency in its secretion or 
action can give rise to the metabolic defects associated with uncompensated diabetes 
mellitus. It is a major anabolic hormone, the main target sites being adipose tissue, 
muscle and liver, promoting the synthesis and reducing the breakdown of 
carbohydrate, fat and protein. The major effects of insulin are summarised below 
(from Newsholme et al., 1992):
Effects o f insulin on carbohydrate metabolism
♦ Insulin increases the glucose transport rate into adipose tissue and muscle from the 
circulation.
♦ Insulin increases the muscle and adipose tissue glycolysis rate.
♦ Insulin stimulates the rate of glycogenesis in tissues such as adipose tissue, muscle 
and liver.
♦ Insulin inhibits the rate of glycogenolysis and gluconeogenesis in the liver.
♦ Insulin increases the rate of oxidation of glucose by the pentose phosphate 
pathway in liver and adipose tissue.
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Effects o f insulin on lipid metabolism
♦ Insulin inhibits the adipose tissue lipolysis rate by suppression of hormone 
sensitive lipase.
♦ Insulin stimulates fatty acid and triacylglycerol synthesis in adipose tissue and 
liver.
♦ Insulin stimulates action of the enzyme lipoprotein lipase (LPL) which is situated
on the adipocyte endothelial membrane, promoting the breakdown of circulating
TAG for uptake into the adipocyte.
Effects o f insulin on protein metabolism
♦ Insulin increases the transport rate of some amino acids into muscle, adipose 
tissue, liver and other cells.
♦ Insulin increases the protein synthesis rate in muscle, adipose tissue, liver and 
other tissues.
♦ Insulin decreases the protein breakdown rate.
♦ Insulin decreases the rate of urea formation.
1.2.3. D isc o v e r y  of  Insulin
Insulin was first discovered in 1921 by Banting, Best, Macleod and Collip (cited Bliss,
1991). The tertiary structure was not fully distinguished until the early 1970's. 
Proinsulin, the precursor of insulin, was identified and sequenced in the 1960's when 
several workers reported a single-chain insulin precursor found in human, porcine and 
bovine tissue (Steiner and Oyer, 1967; Chance et al., 1968). A scheme was proposed 
for the processing of proinsulin via a branched pathway, through conversion
intermediates to insulin, which was clarified in later work (Given et a l, 1985).
1.2.4 In su l in  B io sy n t h e sis , S to r ag e  a n d  Secr etio n
The first step in insulin biosynthesis is conversion of the prohormone preproinsulin to 
proinsulin in the B-cell (Howell, 1991). Translation of messenger RNA from the 
insulin gene gives rise to the 11.5 kDa polypeptide preproinsulin. Removal of the 
signal sequence occurs during translocation to the cisternal space of the rough 
endoplasmic reticulum, generating the 9kDa proinsulin (Bailyes et al., 1992a). Figures 
1.1a. and 1.1b. show the folded structure of the preproinsulin molecule and the amino 
acid sequence of proinsulin.
Proinsulin contains the A- and B-chains of the insulin molecule joined by a 
connecting peptide (C-peptide). A major function of C-peptide is to facilitate correct 
folding of the A- and B-chains and alignment of their disulphide bridges. The folded 
proinsulin molecule is then transferred to the Golgi apparatus of the cell, by 
microvesicles, where it is packaged and surrounded by membranes containing an 
ATP-dependent proton pump (Howell, 1991). The conversion to insulin is initiated 
and continues within the maturing secretory granule. Studies in the rat have shown 
that the vast majority of proinsulin molecules are targeted to the granules of the 
regulated secretory pathway (Rhodes and Halban, 1987). B-cell hormone release can 
also occur via the constitutive pathway, although conversion is not as efficient as in 
the regulated pathway (Halban, 1991; Vollenweider et a l, 1992) and this route 
appears to play only a minor role in hormone secretion from islets of healthy subjects 
(Rhodes and Halban, 1987).
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Figure 1.1a. The folded preproinsulin molecule
Signal peptide
A - C h a i n
CO OH
B-chain
C-peptidc from Ashcroft and Ashcroft (1992)
Figure 1.1b. The amino acid sequence o f  proinsulin
N H , -
C V )  •*
C H A I N UU! )f
- C O O H
C O N N E C T I N G  )4
P E P T ID E  / p
B C H A I N  10
"  'T , 4  T  <« "  ' *
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from Chance et al. (1968)
Proinsulin is cleaved by peptidases into insulin and C-peptide (Steiner, 1977). Given 
et a l, (1985) proposed a branched pathway, with two routes for the conversion of 
proinsulin to insulin and C-peptide (see Figure 1.2.). They used trypsin and 
carboxypeptidase-B for the conversion, but these enzymes cannot be involved in vivo, 
because they are not present in the B-cell (Bailyes et al., 1992a). The initial cleavage 
of proinsulin forms the two split proinsulins - split-32,33- and split-65,66-proinsulin. 
Processing by Carboxypeptidase-H leads to the formation of des-31,32- and des- 
64,65-proinsulin respectively (Rhodes et a l, 1992). The presence of relatively large 
quantities of Carboxypeptidase-H in the B-cell ensure rapid processing of the split 
forms and consequently these are rarely detected in vivo (Hutton, 1989). The split and 
des forms are not always distinguishable. Further proteolytic processing produces 
insulin and C-peptide in equimolar amounts.
Studies have implicated two calcium dependent endopeptidases in the conversion 
process with a type 1 and a type 2 activity which cleave on the C-terminal side of 
Arg31-Arg32 (B-chain/C-peptide junction) and Lys64-Arg65 (C-peptide/A-chain 
junction), respectively (Bailyes et a l, 1991). These have been further identified as 
being related to mammalian homologues of the eukaryotic subtilisin family - PC2 
having type 2 endopeptidase activity and PC3 (also known as PCI) exhibiting 
properties of the type 1 proinsulin-converting endopeptidase (Bailyes et al., 1992b; 
Bennett et al., 1992).
Insulin, C-peptide and the proinsulin intermediates are stored in clathrin coated 
secretory granules. Insulin co-precipitates with zinc ions as microcrystals within the
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granules (Howell, 1991). As the secretory granules mature, they lose their coating and 
are transported to the edge of the cell for secretion. In healthy subjects, the proportion 
of products in the granules are: insulin and C-peptide, 94%; proinsulin and proinsulin 
intermediates 6% (Steiner, 1977). The secretory granules are then translocated to the 
cell membrane via the cytoskeleton. The granule contents are released by exocytosis 
i.e. fusion of the granule membrane with the B-cell membrane.
1.2.5. PROINSULIN AND THE PROINSULIN INTERMEDIATES
Insulin has the greatest biological activity of the B-cell secretory products and 
proinsulin the least, with respect to its effects on glucose homeostasis. This was 
demonstrated by Yu and Kitabchi (1973), who found that porcine proinsulin had 1/20 
to 1/10 the biological activity of insulin, based on molar ratios. The activity of 
proinsulin and the intermediates appears to be related to their affinity for the insulin 
receptor. A lower affinity will lead to a decreased biological activity. Peavy et a l, 
(1984) demonstrated that proinsulin binds to insulin receptors with approximately 1- 
3% of the affinity of insulin. Cleavages and/or dibasic amino acid deletions in the C- 
peptide region, as occurs in the intermediates leads to an increased affinity for the 
insulin receptor (Peavy et a l, 1985). This is especially true of the derivatives that are 
cleaved in the C-peptide/A-chain region (des-64,65-proinsulin), which have been 
demonstrated to have a greater potency than other intermediates. In summary, 
biological activity of the B-cell products from greatest to least is: insulin > des 64,65- 
proinsulin > des 31,32-proinsulin > proinsulin.
Under normal circumstances, only small amounts of proinsulin and the intermediates
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are released into the circulation. Studies on healthy non-diabetic subjects have shown 
fasting levels of proinsulin-like molecules to comprise approximately 10-25% of 
fasting immunoreactive insulin concentrations (Ward et ah, 1987; Yoshioka et al., 
1988; Temple et ah, 1989). This figure will vary depending on the specificity of the 
assays employed. The less biologically active des-31,32-proinsulin has been shown to 
be present in greater quantities than the other intermediates (Bowsher et ah, 1992; 
Sizonenko et al., 1993). Given et al. (1985) found that the ratio of des-31,32- 
proinsulin to des-64,65-proinsulin was 3:1 at steady state in vitro in the normal 
human pancreas. However proinsulin-like molecules are found at much higher levels 
in certain conditions e.g. non-insulin-dependent diabetes, obesity and impaired 
glucose tolerance (Nagi et al., 1990; Davies et al., 1993).
Alarcon et al., (1993) demonstrated in isolated rat pancreatic cells that the 
biosynthesis of PC3 was specifically stimulated by glucose relatively parallel to that of 
proinsulin. However, PC2 biosynthesis was not found to be glucose-regulated. They 
suggested that co-ordinated stimulation of PC3 biosynthesis, along with that of its 
proinsulin substrate, constitutes an additional control point by which the mechanism 
of proprotein processing may be regulated.
Rhodes et al., (1992) investigated the processing of intact proinsulin, des-31,32- 
proinsulin and des-64,65-proinsulin by the two endopeptidases and found that PC3 
processed des-64,65-proinsulin and intact proinsulin at a similar rate. In contrast PC2 
cleaves the C-peptide/A-chain junction of intact proinsulin relatively slowly compared 
with its action on des-31,32 proinsulin. This and other experiments led them to 
conclude that PC3 recognised des-64,65-proinsulin and intact proinsulin as similar
substrates, whereas PC2 has a stronger affinity to des-31,32-proinsulin as opposed to 
intact proinsulin. They also suggested that there is a constraint to efficient processing 
in intact proinsulin that is relieved following PC3 processing. It appears that structural 
flexibility, in addition to the presence of Lys64-Arg65 is important for PC2 specificity 
and may provide a molecular basis for a preferential route of proinsulin conversion via 
des-31,32-proinsulin.
1.2.6. In su l in  Se c r etio n
The main determinant of insulin (and thus proinsulin) production and the rate of 
insulin release is the circulating blood glucose level. Glucose or other metabolic 
secretagogues must be metabolised by the B-cell to induce insulin secretion. This is 
called the ‘substrate-site hypothesis’ (Ashcroft and Ashcroft, 1992).
Gut regulatory peptides, including GIP and GBP-l^.^amide (see Section 1.3.) 
potentiate glucose-induced insulin secretion by binding to specific receptors on the B- 
cell (Flatt, 1996). GTP-binding proteins mediate effects on the activity of adenylate 
cyclase, phospholipase C, ion channels or later events involved in the discharge of 
insulin by exocytosis.
Glucose-stimulated insulin release is biphasic, with a rapid first phase and a prolonged 
second phase lasting for the duration of the stimulus (Howell, 1991). Hormones and 
neurotransmitters act to modulate the secretory response to glucose. Insulin 
secretagogues may be initiators, which are effective alone e.g. glucose and some 
amino acids, or potentiators which increase the response to stimulators.
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1.2.7. In su l in  R ecepto rs
Insulin acts by binding to a specific receptor on a cell membrane. The receptor 
contains two distinct subunits, a  and (3. The a-subunit is extracellular and contains 
two insulin-binding sites. Theoretically, two insulin molecules could bind to one 
receptor, but occupancy of one binding site decrease the affinity of the other site by 
almost 100-fold. The p-subunit is a transmembrane protein, with the intracellular part 
being a tyrosine-specific protein kinase that is activated by insulin, leading to an 
autophosphorylation cascade. The insulin is internalised with the receptor and is 
passed to lysosomes leaving the receptor to be recycled to the cell membrane (Taylor,
1991).
1.2.8. M e a su r e m e n t  o f  B -C e l l  P ro d uc ts
A major obstacle to understanding the metabolic abnormalities associated with 
conditions such as diabetes and obesity has been the lack of specific, sensitive and 
precise assays for insulin and other B-cell secretory products. This has led to 
confusion in the interpretation of some studies and conflicting views of what actually 
occurs. Is the "hyperinsulinaemia" that is seen in certain subjects due to insulin 
resistance or are the subjects actually normo- or hypoinsulinaemic because what is 
being measured is a combination of insulin, proinsulin and the proinsulin 
intermediates?
The advent of radioimmunoassays over thirty years ago has allowed the measurement 
of low hormone concentrations with relative ease. The first radioimmunoassay
developed that was sensitive enough to detect endogenous hormone levels in blood, 
was an assay for insulin (Yalow and Berson, 1960). The late 1970s and early '80s saw 
the development of non-isotopic immunological techniques and with the increasing 
demand for stable reagents and automation of immunoassays, these are often 
becoming the methods of choice (Pettersson, 1993). Production of human proinsulin 
and the intermediates by recombinant DNA technology marked a major advance by 
allowing greater standardisation of assays. (Galloway et a l, 1992; Temple et a l,
1992). Alternative and original assays are being designed utilising novel technology 
e.g. monoclonal antibodies which should have greater specificity for insulin and 
proinsulin than polyclonal antibodies. Assays for proinsulin intermediates have also 
been developed using this technique (Sobey et a l, 1989).
Immunologically based assays are now mainly used to measure B-cell products and 
involve the measurement of an antigen using its specific reaction with an antibody, 
usually a class G immunoglobulin (IgG). These assays differ from other 
immunological methods of analysis in that the initial antigen-antibody reaction does 
not result in the formation of a precipitate (Morris, 1985). This means that once 
formed, the antigen-antibody complex can dissociate and the reaction obeys the Law 
of Mass Action. There are two basic types: the competitive 'immunoassay', where the 
antibody is used at a limited concentration and the non-competitive 'immunometric 
assay', where the antibody is used in excess. Different labels, either isotopic or non­
isotopic are bound to either the antigen or antibody and used to follow the reaction, 
for quantitation purposes. Techniques include radioimmunoassay, enzyme-linked 
immunosorbent assay (ELISA), chemiluminescence and fluoroimmunoassay.
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The techniques of radioimmunoassay (RIA) and ELISA with colorimetric and 
chemiluminescent end-points are used in this thesis. The ELISA method offers 
advantages over RIA in that the reaction can be read visually if necessary and 
detection equipment is cheaper than for RIA; the labelled reagents are stable and can 
be stored without loss of activity; there are not the same hazards as those associated 
with the use of radioisotopes and importantly, the potential sensitivity is greater with 
ELISA because many molecules of product can be generated by a single molecule of 
enzyme coupled to an antigen or antibody (Kemeny and Chantier, 1988).
Cross-reactivity is a major problem in B-cell product assays. When assaying blood for 
one particular B-cell product, others are likely to be present, some at high 
concentrations, relative to the substance being measured. This can lead to spurious 
results (Temple et a l, 1992). Proinsulin and the intermediates contain the structures of 
both insulin and C-peptide and may therefore cross-react in assays for either insulin or 
C-peptide. Conversely, insulin and C-peptide may cross-react in proinsulin assays. 
The presence of intermediates might lead to an overestimation of proinsulin in 
competitive assays and an underestimation in two-site sandwich assays (Dhahir et al.,
1992). In normal individuals, circulating levels of proinsulin and intermediates are 
low, relative to insulin and C-peptide, so the cross-reactivity is less of a problem than 
it would be in individuals such as non-insulin-dependent diabetics or obese subjects 
who have higher levels. Care has to be taken when interpreting cross-reactivity data 
because it is often determined under different experimental conditions. Cross­
reactivity of the intermediates varies greatly between assays, which probably explains 
the considerable variation in basal intact proinsulin levels reported. Tables 1.1. and 
1.2. show the characteristics of some of the more recent assays for insulin, proinsulin
and the intermediates.
A recent report (Robbins et ah, 1996) which assessed the comparability of blood 
insulin measurements between laboratories found that identical samples measured in 
different laboratories produced widely disparate values. This makes comparison of 
absolute values between studies impossible.
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Table 1.1. Comparison of insulin Assays
Authors Method Sensitivity Cross-reactivity Control 
Subjects 
(fasting, mean)
Morris et a l ,  
(1993)
2-site ELISA 
(monoclonals: 
HUI-018, 0X1-005)
13 pmol/L None with intact1. 
Intermediates not 
reported.
39 pmol/L
Andersen et 
a l, (1993)
2-site ELISA 
(monoclonals: 
HUI-018, 0X1-005)
5 pmol/L None with intact, 
split-32,332 or des- 
31,323.
Split-65,66^:30%; 
Des-64,655: 63%
18 pmol/L
Sobey et a l ,  
(1989)
immunoradiometric 
(monoclonals: 
iodinated 3B1, 
cellulose-bound 
14B)
2.3 pmol/L Intact: 5.3%; 
split-65,66: 62%; 
split-32,33: 5%
20 pmol/L
Storch et a l,  
(1993).
fluoroimmunoassay 
(monoclonals: P15, 
biotinylated P8. 
Fluorophore: 
europium- 
streptavidin)
29 pmol/L None with intact. 
Intermediates not 
reported.
Not reported.
Wood and
Donovan,
(1993)
immunofluorometric 
(monoclonals: 
HUI-001 (capture), 
biotinylated OXI- 
005 (detection)
0.3 pmol/L intact: < 2%; 
split-32,33: < 2%; 
split-65,66:79%
Not reported.
1 intact proinsulin
2 split-32,33 proinsulin
3 des-31,32 proinsulin
4 split-65,66 proinsulin
5 des-65,65 proinsulin
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Table 1.2.Comparison ofproinsulin and intermediate assays
Authors Method Sensitivity Cross-reactivity Control 
subjects 
(fasting, mean)
Dhahir et a l, 
(1992)
Proinsulin assay. 
Amplified ELISA 
(polyclonal coating 
antibody, PEP-001 
monoclonal alkaline 
phosphatase labelled 
antibody)
0.1 pmol/1 None with human 
C-peptide, porcine 
or bovine 
proinsulin.
Split- 32,33: 200%; 
split-65,66: 68%
4.73 pmol/1
S obey et a l,  
(1989)
Proinsulin assay. 
2-site immunoradio­
metric assay 
(monoclonals: 
iodinated A6, 
cellulose bound 
3B1)
1.8 pmol/1 None with human 
insulin or split- 
32,33.
Split-65,66: 66%.
2.3 pmol/1
Split-65,66 assay. 
2-site immunoradio­
metric assay 
(monoclonals: 
iodinated A6, 
cellulose bound 
14B)
0.8 pmol/1 None with insulin, 
intact proinsulin or 
split-32,33.
Undetectable 
(<1 pmol/1)
Split-32,33 assay. 
2-site immunoradio­
metric assay 
(monoclonals: 
iodinated PEP- 001, 
cellulose bound 
3B1)
2.5 pmol/1 Intact proinsulin: 
84%;
Split-65,66: 60%.
2.1 pmol/1
Hampton et 
a l,  (1988)
Proinsulin assay
radioimmunoassay
(polyclonals)
4.0 pmol/1 < 0.01% with 
human insulin and 
C-peptide.
6.7 pmol/1
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Measurements of C-peptide are usually made as well as insulin because peripheral C- 
peptide levels can be a more reliable indication of insulin secretion than peripheral 
insulin levels. Insulin and C-peptide are secreted in equimolar amounts from the 
pancreas, but they are cleared from the circulation in different ways. The liver is the 
major site of insulin metabolism, extracting approximately 50% of insulin transported 
there on first pass (Rubenstein et al, 1972; Horwitz et a l, 1975), however,
this rate is variable. C-peptide is cleared from the circulation by the kidneys at a 
constant rate. It is therefore not subject to this variable hepatic extraction and its 
clearance rate is not affected by meal ingestion (Licinio-Paixao et a l, 1986). These 
factors have led to C-peptide being used as a marker for changes in insulin secretion, 
because peripheral insulin levels reflect a balance between secretion and hepatic 
extraction. However it has the disadvantage of a longer half life in plasma than insulin 
and is therefore less sensitive to rapid fluctuations in insulin secretion.
C-peptide:insulin molar ratios have been used as an indicator of hepatic insulin 
extraction in several published papers. However this method has been criticised 
(Polonsky and Rubenstein, 1984), because of the number of assumptions made and 
different factors involved in the secretion, metabolism and distribution of insulin and 
C-peptide. Conclusions drawn using this method, therefore, must be speculative.
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1.3. GASTROINTESTINAL HORMONES
1.3.1 In t r o d u c t io n
It was observed back in the 19* century that more glucose could be given orally than 
by intravenous injection without causing glycosurea (cited Morgan, 1992). It was not 
until the 1960's that two groups of workers (Elrick et a l, 1964; McIntyre et a l, 1964) 
provided evidence that gut factors were capable of modifying the insulin response to 
oral glucose. Both groups demonstrated that when glucose was administered either 
orally or intravenously to produce a similar level of arterial glucose, oral glucose was 
more effective at raising circulating insulin levels than intravenous glucose. McIntyre 
and co-workers suggested that insulin secretion could be stimulated by hormones 
produced in the gastrointestinal tract, which themselves were stimulated by ingested 
nutrients. Amino acids administered orally are also more effective at stimulating 
insulin secretion than intravenous amino acids (Dupré et a l, 1969).
The expression ‘enteroinsular axis’ (EIA) was first used by Unger and Eisentraut in 
1969 to cover all the gut factors that alter postprandial insulin secretion. The axis has 
both an endocrine and a neural component; much less is known about the latter, but it 
is less important in man than other species. Pancreatic transplantation studies where 
the pancreas is denervated have produced conflicting results in animals, with one 
study indicating that the enteroinsular axis is almost entirely preserved (Nauck et a l, 
1985) and another showing that it is abolished (Jakob et a l, 1970). However studies 
on human subjects with denervated pancreatic transplants have demonstrated that the 
incretin effect was preserved (Clark et a l, 1989).
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The EIA is thought to contribute to approximately 50% of the insulin response to 
ingested nutrients (Berthoud, 1984). This study of insulin responses to a liquid test 
meal in rats estimated that hormonal factors accounted for 30% and neural factors 
20% of insulin levels.
Several different peptides with the ability to stimulate insulin secretion in 
pharmacological doses are produced in the gastrointestinal tract. In 1979, Creutzfeldt 
proposed the incretin concept. In order to be considered as an incretin, Creutzfeldt 
suggested criteria that a peptide should meet: it must be released in response to 
nutrient ingestion, particularly glucose, and should reach a postprandial concentration 
in vivo that is sufficient to elicit an insulinotropic response at elevated glucose 
concentrations.
The major components of the EIA are glucose dependent insulinotropic polypeptide 
(GIF) and glucagon-like peptide-l^.^amide (GEP-l^.^amide). These hormones also 
have a direct anabolic action e.g. in the activation of lipoprotein lipase and stimulation 
of de novo fatty acid synthesis (Oben et al., 1991; Knapper et a l, 1995). Other gut 
hormones e.g. secretin, gastrin and cholecystokinin are only weak stimulators of 
insulin secretion and do not play a major role in the endocrine arm of the EIA in 
humans (Morgan, 1992). The studies described in this thesis have therefore been 
confined to the measurement of GIF and GEF-l^.^amide. These are discussed in 
further detail below. Insulin can also be inhibited via the EIA by hormones such as 
galanin.
If the incretin hormones GIF and GEF-1 ^ .^am ide are important in regulating
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postprandial insulin secretion, it would be expected that postprandial secretion of 
these gut hormones would correlate with insulin secretion. This was demonstrated by 
0rskov et al. (1996a), who followed six normal subjects over a 15-hour period in 
which they consumed 3 mixed meals. There was a significant correlation between 
plasma insulin and both GIF and GLP-l(7 .36 )amide concentrations. A poorer 
correlation was seen in a study by Elliott et al. (1993), who studied secretion patterns 
over a 24 hour period and found that gut hormones remained raised between meals 
when insulin had returned to basal or near basal levels. This may be partly due to the 
subjects in the latter study consuming snack meals in between the main meals and the 
different nutrient content of the meals.
Studies using arterialized plasma which is more representative than venous plasma of 
any stimulus reaching the B-cell (Hampton et a l, 1986; Shuster et a l, 1988) have 
shown alterations in insulin and C-peptide that indicate that the effect of the 
enteroinsular axis is mediated through both increased insulin secretion and decreased 
hepatic insulin extraction.
1.3.2. Gl u c o se -De pe n d e n t  In sulin o tro pic  P o ly peptide
Glucose-dependent Insulinotropic Polypeptide (GIP), was previously known as gastric 
inhibitory polypeptide because of its ability to inhibit gastric acid secretion (Brown et 
a l, 1970). It was renamed following studies that demonstrated it was insulinotropic at 
glucose levels greater than 5.5-6.0 mmol/L (Andersen et a l, 1978; Elahi et a l, 1979). 
GIP is a 42 amino acid polypeptide secreted mainly in the upper intestine, by the K 
cells in the duodenum and jejunum (Bloom and Polak, 1981). The major circulating
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form of GIP, as separated by gel filtration is a 5 kDa polypeptide. This component is 
biologically active and stimulated by nutrient ingestion. A larger, 8 kDa, constituent 
of circulating immunoreactive GIP has been identified, but this responds only slightly 
to nutrient ingestion, does not alter insulin levels and does not contain the complete 
GIP amino acid sequence (Krarup, 1988).
GIP secretion is stimulated by actively absorbed nutrients e.g. glucose (Sykes et a l,
1980), certain amino acids (Penman et a l, 1981) and long-chain fatty acids 
(Kwasowski et a l, 1985). On a equicaloric basis, fat is a more potent stimulant to GIP 
secretion than carbohydrate in humans, but this differs in other species (Falko et a l, 
1975; Penman et a l, 1981, Morgan et a l, 1995). Protein is a poor stimulus because 
relatively little is hydrolysed to amino acids before absorption. Fructose, which is 
absorbed passively is also a poor stimulus (Sykes et a l, 1980).
As its name suggests, glucose levels greater than basal are necessary for GIP to 
stimulate insulin secretion (Andersen et a l, 1978). This prevents inappropriate insulin 
secretion and the consequent hypoglycaemia that might occur if GIP could stimulate 
insulin secretion following the ingestion of fat or amino acids alone.
The insulinotropic action of GIP in humans has been demonstrated by several workers
| :
(Dupré et a l, 1973; Anderson et a l, 1978; Elahi et a l, 1979). A greater insulin 
response and improved glucose tolerance were obtained when intravenous porcine 
GIP was administered simultaneously with intravenous glucose compared with a 
glucose infusion alone. Infusion of anti-GIP antiserum reduced this effect in rats 
(Ebert and Creutzfeldt, 1982).
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GIP also has direct anabolic effects, other than those mediated through enhanced 
insulin secretion. It activates adipose tissue lipoprotein lipase, promoting lipogenesis 
(Knapper et al., 1995); can stimulate de novo fatty acid synthesis in rat adipose tissue 
(Oben et a l, 1991) and suppresses hepatic glycogenolysis in the presence of insulin 
(Hartmann et al., 1986)
1.3.3. G lu c a g o n -L ik e  Pe pt id e - I ^ ^ A m id e
In mammals, the glucagon precursor proglucagon, a 160 amino acid residue peptide 
(Bell et al., 1983), undergoes different post-translational processing in the pancreas 
and small intestine (Mojsov et a l, 1986; Conlon, 1988). In the gut, the main products 
are glicentin, oxyntomodulin, glucagon-like peptide-1 (GLP-1), with 37 amino acid 
residues corresponding to proglucagon (72-108) and glucagon-like peptide-2 (GLP-2) 
with 35 amino acid residues corresponding to proglucagon (126-158) (0rskov et a l, 
1989). GLP-1 can be processed further by amidation of the C-terminal end to form 
GLP-1 (i_3 6 )amide and removal of the N-terminal hexapeptide to form GLP-l^.^am ide 
(Holst et a l, 1987). Not all GLP-1 is fully processed (Kreymann et a l,  1988) and 
other forms of circulating GLP-1 can also be detected e.g. G L P -l^ .^  and GLP-1 (7 .3 7 ). 
GLP-l(7  36)amide is the major form circulating postprandially in humans (0rskov et
a l, 1989). GLP-1 (7 .3 7 ) and GLP-1^.3 ^amide are the most potent of all the glucagon­
like peptides in stimulating insulin secretion (Holst et a l, 1987) and are more potent 
than GIP, on a molar basis (Shima et a l, 1988).
GLP-l(7 -3 6 )amide is secreted from the L cells in the ileum, colon and rectum
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(Kreymann et ah, 1988). GLP-l(7 _3 6 )amide levels peak approximately 30 minutes 
postprandially. It is unlikely that nutrients will have reached the site of GLP-1(7. 
3 6 )amide release in the distal part of the intestine in such a short time, so some sort of 
signalling mechanism must be involved in the early phase of GLP-l(7.3 6 )amide release. 
Studies in rodents have suggested that GIP secretion is necessary for GLP-l(7.36)amide 
secretion via an ‘enteroendocrine loop’ (Roberge and Brubaker, 1993), although this 
was not demonstrated by another group in human studies (Nauck et a l, 1993) who 
found that GLP-l(7_3 6)amide levels did not increase after GIP infusion at physiological 
concentrations. Fukase et a l, (1992) have found that presence of a nutrient, sucrose, 
in the gut lumen triggered GLP-l(7-36)amide release. This may be more important in 
the later postprandial phase.
GLP-l(7 36)amide levels have been shown to rise following ingestion of glucose,
protein, fat and mixed meals in healthy human subjects (Kreymann et a l, 1987; 
0rskov et a l, 1991; Elliott et a l, 1993). GIP and GLP-1 (7_3 6 )amide together have an 
additive and possibly synergistic effect on insulin secretion (Fehmann et a l, 1989; 
Nauck gfaZ., 1993).
GLP-l(7-3 6 )amide has been shown to inhibit glucagon secretion (0rskov et a l, 1986).
This, together with its insulinotropic effect causes blood with an increased ratio of
insulimglucagon to reach the liver, decreasing hepatic gluconeogenesis (Holst, 1996)
and consequent plasma glucose concentration. Like GIP, G L P-l^^am ide stimulation
of insulin secretion is glucose dependent. When glucose levels fall below
approximately 4.5 mmol/L, its effects are small or non-existent (Hvidberg et a l,
1994), preventing hypoglycaemia. Administration of exendin^.3 ^amide, a GLP-1
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receptor antagonist, inhibits postprandial insulin increases (Kolligs et a l, 1995), 
further establishing its role as an incretin.
GLP-l(7 .3 6 )amide may affect peripheral and hepatic glucose metabolism directly, at 
physiological concentrations, by altering tissue uptake of glucose and glycogenesis, as 
well as through insulin-mediated effects (D’Alessio et al., 1994; Valverde and 
Villanueva-Penacarrillo, 1996). Receptors for GLP-l(7.3 6 )amide have been found on 
pancreatic B-cells (Gôke and Conlon, 1988), adipose tissue (Valverde et a l, 1993) 
and muscle cells (Delgado et a l, 1995), which would fit with this theory. Gromada 
and co-workers (1995) found that pre-treatment of an insulin secreting B-cell line with 
GLP-l(7 _3 6 )amide caused a greater increase in intracellular free calcium ions following 
glucose stimulation, indicating greater sensitivity of the cells to glucose.
The direct effect of GDP-1 ^ ^am id e  on glucose disposal and glucagon secretion, in 
addition to its insulinotropic effects, has led to it being proposed as a treatment for 
non-insulin dependent diabetes mellitus (Gutniak et a l, 1992; Nauck et a l,  1993; 
Gutniak et a l, 1996; Ahren et a l, 1997) where its administration in pharmacological 
doses has been demonstrated to normalise fasting plasma glucose levels. GLP-1(7. 
3 6 )amide also lowers fasting and postprandial glucose levels in insulin-dependent 
diabetics (Dupre et a l, 1995; Creutzfeldt et a l, 1996). The degree of the reduction 
appears dependent on whether the subjects had any residual C-peptide secretion i.e. 
could respond to insulinotropic stimuli. Lowering of glucose levels was probably 
mainly due to inhibition of glucagon secretion in these subjects.
As well as its effect on insulin release, G LP-l^^am ide, in common with GIP, has a
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direct anabolic role in stimulating de novo fatty acid synthesis (Oben et al., 1991) and 
may also stimulate LPL (Chapman, 1996). GLP-l(7 _3 6)amide has recently been shown 
to have an anticatabolic effect on protein metabolism, mediated through GLP-1(7. 
3 6 )amide-induced stimulation of insulin secretion in healthy human subjects (Shalev et 
al., 1997). A physiological role for GLP-2 has not been established.
1.4. INSULIN RESISTANCE
The most common cause of high circulating insulin levels is a compensatory 
mechanism consequent to a decreased sensitivity to the biological actions of insulin. 
The classical definition of insulin resistance is impaired insulin-mediated glucose 
uptake into skeletal muscle, however the term is often used to describe any defect in 
the insulin sensitivity of an organ, in which a ‘normal’ level of insulin produces a 
subnormal biological response. This defect can vary between organs to differing 
degrees and obviously, the consequences will depend on the function of the organ(s) 
involved.
As already stated in section 1.2.2, insulin has a role in several pathways relating to the 
metabolism of carbohydrate, protein and fat. An abnormality in the effects of insulin 
is therefore capable of altering many important processes including hepatic 
glycogenolysis and gluconeogenesis; peripheral glycogenolysis, glycogen storage, 
proteolysis, lipolysis and lipogenesis.
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Insulin resistance has been linked with many diseases including non-insulin dependent 
diabetes, obesity, hyperlipidaemia, hypertension and cardiovascular disease (CVD). In 
1988, Reaven proposed a concept linking several metabolic changes with insulin 
resistance - ‘Syndrome X’ or ‘Reaven’s syndrome’. The characteristics of this 
syndrome are:
♦ resistance to insulin-stimulated glucose uptake
♦ glucose intolerance
♦ hyperinsulinaemia
♦ increased VLDL-TAG concentration
♦ decreased HDL-cholesterol concentration
♦ hypertension
Insulin resistant subjects have also been shown to exhibit disproportionately elevated 
proinsulin levels (Haffner et a l, 1994), and raised proinsulin has itself been proposed 
as a CVD risk factor (Haffner et a l, 1993).
1.5. OBESITY
1.5.1. Intr o d u c tio n
When energy intake is greater than energy expenditure, the surplus is stored in adipose 
tissue as triacylglycerol (TAG). Whilst a certain reserve of body fat is necessary, 
excessive amounts are associated with both increased morbidity and mortality.
1.5.2. Classific a tio n  of  O besity
Body fat mass is difficult to quantify in the field, so an approximation is usually made 
using the Body Mass Index (BMI), or Quetelet’s Index, which relates body weight to
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height (weight [kg] /  height2 [m2]). The classifications are:
Underweight
Normal
Overweight
Obese
Morbidly obese
BMI <18.5 
BMI 18.5-24.9 
BMI 25 - 29.9 
BMI 30-39.9 
BMI >40
The relationship between BMI and mortality has been shown to be U-shaped or J- 
shaped in many different studies, with minimum mortality occurring at BMI 24-25 
(review: WHO, 1995). The causes of death at either end of the curve are quite 
different. At a low BMI, the main causes of mortality are digestive and pulmonary 
disease (this may be related to the confounding factor of smoking and disease). 
Mortality in subjects with a high BMI is related mainly to cardiovascular disease, 
diabetes mellitus and gallbladder disease.
1.5.3. O b e s ity  a n d  D is e a s e
Obesity is a known risk factor in many diseases, including non-insulin-dependent 
diabetes mellitus (NEDDM) and cardiovascular disease (CVD) (Larsson et a l, 1981; 
Donahue et a l, 1987; Kissebah and Peiris 1989). Obesity is often linked with both 
fasting and stimulated hyperinsulinaemia and insulin resistance (Rossell et a l, 1983; 
Bjomtorp, 1987; Moller and Flier, 1991; Kohrt et a l, 1993; Reaven et a l, 1993) and 
has been shown to correlate strongly with both hepatic and peripheral tissue 
insensitivity to insulin (DeFronzo et a l, 1978; Campbell and Carlson, 1993; Kohrt et 
a l, 1993). Increasing amounts of insulin must be secreted to have the same blood 
glucose lowering effect. This in turn causes other metabolic complications that may 
lead to the development of diseases such as NIDDM and CVD (Reaven, 1988; Moller 
and Flier, 1991). Raised plasma proinsulin and intermediate levels have also been
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reported in obesity (Temple et a l, 1989; Hampton and Withey, 1993).
1.5.4. O b e s ity  a n d  G a s t r ic  E m p ty in g
Studies on gastric emptying in obesity have produced conflicting results. The rate of 
emptying has been shown to be increased (Tosetti et a l, 1996), decreased (Maddox et 
a l, 1989) and unchanged (Sasaki et a l, 1984) in obesity. Tosetti and co-workers 
(1996), found that the rate of gastric emptying in their subjects was less following a 4 
month weight loss programme. The different type and form of nutrients given will 
confound results. The form of the food i.e. liquid, solid or mixed will affect the rate of 
emptying, as will the nutrient type and energy density of the meal. Hyperinsulinaemia, 
which is often a feature of obesity, has been demonstrated to delay gastric emptying 
(Eliasson et a l, 1995).
1.5.5. B o d y  F a t  D is tr ib u t io n
Body fat distribution appears to be an important and possibly independent determinant 
when considering the potential risk of morbidity due to obesity (Kissebah et a l, 1982; 
Ohlson et a l, 1985). Differences in body shape have been noticed for many years - 
Hippocrates classified people into two body shapes, habitus apoplecticus and habitus 
phthisicus (cited Kaplan, 1989). The importance of body fat distribution was not 
realised until the middle of this century when Vague published his work on the ‘index 
of masculine differentiation’ (Vague, 1956). He demonstrated that the male (android) 
fat distribution pattern was more likely to be associated with diseases such as diabetes, 
atherosclerosis and gout than the female (gynoid) pattern in both men and women.
30
Abdominally located adipose tissue (android distribution), especially the deep-seated 
visceral type has been linked with several metabolic disturbances. These include 
increased levels of insulin and triacylglycerol, decreased levels of HDL-cholesterol, 
increased VLDL and DDL and small, dense LDL particles with elevated apolipoprotein 
B (Evans et al., 1984, Despres et a l, 1989; Kissebah and Peiris, 1989; Terry et a l, 
1989; Despres, 1993). Visceral fat accumulation is also linked with elevated cortisol 
and androgen levels and decreased growth hormone levels in women and decreased 
testosterone in men (review: Bjomtorp, 1996). Peripheral obesity (gynoid distribution) 
is generally associated with a lesser disease risk.
Boyko and co-workers (1995) in a prospective 5-year follow up among initially non­
diabetic Japanese-American men, found that greater insulin resistance and reduced 
insulin secretion as measured in an oral glucose tolerance test, preceded visceral fat 
accumulation determined by a CAT scan in this group.
The ratio of waist to hip circumference (WHR) can be used to give a measure of 
abdominal fat deposition. It correlates more strongly with visceral than subcutaneous 
fat deposits (Seidell et al., 1987). However, investigators measure waist and hip 
circumferences at different sites, confounding results (see Chapter 4). A positive 
association has been found between WHR and the occurrence of stroke, myocardial 
infarction, angina pectoris and death (Lapidus et a l, 1984; Larsson et a l, 1984). 
Haffner et a l, (1993) found a significant relationship between WHR and both fasting 
insulin and proinsulin levels.
A study by Kortelainen and Sarkioja (1997) on female cadavers with no ante mortem
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clinical evidence of cardiovascular disease, demonstrated that abdominal 
accumulation of fat was associated with the severity of coronary atherosclerosis and 
myocardial hypertrophy.
1.5.6. O b e s ity  a n d  I n s u lin
Visceral adipose tissue has been linked with disorders of glucose and lipid metabolism 
in obese subjects (Fujioka et al., 1987). A correlation has also been found between the 
amount of visceral adipose tissue and plasma insulin levels (Seidell et al., 1990). 
Abdominally obese have been shown to be more insulin resistant than those who are 
peripherally obese (Evans et a l, 1984; Macor et al., 1997). Kohrt et a l, (1993) 
looking at the relationship between insulin resistance, age and abdominal adiposity 
found that waist girth accounted for more than 40% of the variance in insulin action, 
whereas age only explained 10-20% and less than 2% of total variance when the 
effects of waist circumference were statistically controlled, suggesting that insulin 
resistance is more closely related with abdominal adiposity than age.
1.5.7. O b e s ity  a n d  t h e  E n t e r o in s u la r  A x is
GIP and G E P -l^am ide both have a direct anabolic action on adipose tissue 
stimulating de novo lipogenesis (Oben et a l, 1991) suggesting a possible direct role in 
obesity (Marks et a l, 1991). Intra-abdominal fat is especially sensitive to GIP 
stimulation (Oben et a l, 1991). Some previous workers have found that GIP response 
to nutrient stimulation in obesity is increased compared to normal weight subjects 
(Sirinek et a l, 1986), but conflicting results have been obtained with different 
investigators (Service et al., 1984). GEP-l^.^amide secretion in obesity is less well
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characterised, mainly due to the lack of availability of analytical procedures to 
measure the low circulating levels of the hormone. Previous work in this laboratory 
has found that GLP-l(7.3 6 )amide levels are attenuated in obesity following a glucose 
load, but not after a fat load (Ranganath et a l, 1996). This contrasts with other 
workers who have found GTP-l^.^amide and GIP hypersecretion in obese diabetic 
subjects (Fukase etal., 1993).
1.6. HYPERTRIGLY CERIDAEMIA
1.6.1. H y pe r tr ig ly c e r id a e m ia  a n d  Insulin
Hypertriglyceridaemia is associated with peripheral hyperinsulinaemia and insulin 
resistance (Olefsky et a l, 1974; Reaven et a l, 1983; Gama et a l, 1995a). The 
metabolism of triacylglycerol (TAG) and non-esterified fatty acids (NEFA) is closely 
linked with insulin in vivo (see Section 1.2.2). Insulin resistance, as measured by 
glucose disposal, is correlated with plasma TAG levels even in normotriglyceridaemic 
subjects (Coppack et a l, 1989). Hypertriglyceridaemia is a characteristic of Reaven’s 
Syndrome X and is a risk factor for the development of CVD.
An increase in circulating NEFA levels, as occurs in hypertriglyceridaemia, enhances 
lipid oxidation and reduces glucose oxidation (Ebeling and Koivisto, 1994). Insulin 
resistance in hypertriglyceridaemia may by due to the increased levels of free fatty 
acids competing with glucose in the Randle cycle (Randle et a l,  1963), decreasing 
carbohydrate oxidation and glucose uptake. In normal subjects, elevated plasma free 
fatty acid levels, obtained by an intravenous lipid infusion, have been shown to inhibit
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insulin-stimulated glucose uptake in a dose-dependent manner (Boden, 1996). The 
mechanisms suggested for this were a fatty acid-related inhibition of glucose transport 
or phosphorylation, appearing after 3-4 hours of the fat infusion and a decrease in 
muscle glycogen synthase activity which appeared after 4-6 hours of the lipid 
infusion. Roden and co-workers (1996) also demonstrated this free fatty acid-induced 
insulin resistance effect on glucose transport/phosphorylation followed by an 
approximately 50% reduction in the rate of both muscle glycogen synthesis and 
glucose oxidation.
Kvapil et al (1993) compared control, hypertriglyceridaemic and 
hypertriglyceridaemic with NIDDM subject groups using the frequent sampling 
intravenous glucose tolerance test. The latter two groups both exhibited 
hyperinsulinaemia and insulin resistance relative to controls as expected, but the 
pattern of the insulin response was different between the two hypertriglyceridaemic 
groups. The normoglycaemic-hypertriglyceridaemic group appeared to compensate for 
their insulin resistance by increasing both phases of insulin secretion, whereas the 
NIDDM-hypertriglyceridaemic group had a significantly impaired first-phase insulin 
secretion, contributing to their hyperglycaemia. Failure of the compensatory 
adaptation mechanism in the normoglycaemic-hypertriglyceridaemic group would 
lead to glucose intolerance.
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1.7. POLYCYSTIC OVARIAN SYNDROME
1.7.1. I n t r o d u c t io n
Polycystic ovarian syndrome (PCOS) is the most commonly occurring endocrine 
disorder found in premenopausal women, possibly affecting up to 10% of that 
population (Poison et al., 1988; Dunaif et a l, 1992a), yet its aetiology is still not fully 
understood. It is characterised by hyperandrogenism and chronic anovulation, (with 
the exclusion of secondary causes) (Dunaif et a l, 1992a) which differentiates the 
syndrome from women with polycystic ovaries who do not have these symptoms. 
PCOS is also associated with hyperinsulinaemia, which is not generally a feature of 
other hyperandrogénie states (Dunaif et a l, 1987).
1.7.2 A n d r o g e n s
Androgens are normally present in women, synthesised by both the ovaries and 
adrenal glands as precursors of oestradiol and cortisol respectively (Mechanick and 
Dunaif, 1990; McKenna and Cunningham, 1995). The gonadotrophin lutenizing 
hormone (LH) controls ovarian androgen production. Stimulation of the ovaries, e.g. 
by insulin, can result in excessive androgen production (Conway and Jacobs, 1993).
The alterations seen in ovarian morphology in PCOS, are due to abnormal levels of 
LH and another gonadotrophin, follicle-stimulating hormone (FSH), which in turn 
affect androgen production and conversion. Increased levels of androgens appear in 
the peripheral circulation and feedback on the hypothalamic-pituitary axis (possibly by 
their conversion to oestradiol), producing gonadotrophin secretory abnormalities. This 
sustains the abnormal steroid manufacture, producing a vicious circle (Mechanick and
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Dunaif, 1990) of altered gonadotrophin and steroid production.
1.7.3. PC O S a n d  I n s u lin
The relationship between hyperandrogenism and altered carbohydrate metabolism was 
first recognised in the 1920s’ by the French physicians Achard and Thiers who 
christened this syndrome ‘le diabète des femmes à barbe’ (the diabetes of bearded 
women) (cited Dunaif, 1993). However it was not until 1980 that a link between 
PCOS and disordered insulin action was made (Burghen et a l, 1980). These workers 
found significantly higher insulin levels in women with PCOS than in weight-matched 
controls and a significant positive correlation between insulin and androgen 
concentrations.
Studies using adipocytes have shown that the main defect of insulin action in women 
with PCOS is a decrease in insulin sensitivity due to post-binding impairment of 
insulin-receptor mediated signal transduction, which may be genetic in origin. The 
capacity of the adipocyte to bind insulin is unchanged (Ciaraldi et a l, 1992; Dunaif et 
a l, 1992b). The defect is thought to be intrinsic because it is independent of other 
confounding factors such as obesity, body fat distribution, metabolic abnormalities 
and sex hormone levels (Dunaif et a l, 1992b). This correlates with some studies 
which have shown that treatment of hyperandrogenism generally fails to improve the 
insulin resistant state in PCOS women, indicating an intrinsic effect rather than one 
due to androgen excess (Dunaif et a l, 1990; Diamanti-Kandarakis et a l, 1995).
It has also been shown (Dunaif et a l, 1992b) that women with PCOS have decreased
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responsiveness to insulin as demonstrated by their decreased maximal rates of insulin- 
mediated glucose utilisation, due to a reduction in the number of GLUT4 adipocyte 
glucose transporters (Rosenbaum et a l, 1993).
Conflicting insulin results have been found in PCOS with both normal and increased 
insulin levels being seen. Tropeano et a l  (1994) found no significant differences in 
insulin levels between PCOS subjects and controls either fasting or following oral 
glucose. However, there were significantly higher C-peptide levels in both obese and 
non-obese PCOS compared to controls, indicating increased insulin secretion. Other 
studies (Mahabeer et a l, 1989; Conway et a l, 1993) have shown increased insulin 
levels. This could be due to the use of different assays with differing cross-reactivities. 
Conway et a l, (1993) showed that women with PCOS were hyperproinsulinaemic, 
but this was in proportion to their increased insulin levels and not disproportionately 
raised as has been shown in NIDDM by specific assays (Ward et a l, 1987).
PCOS also appears different from other common, less severe forms of insulin 
resistance e.g. obesity and NIDDM. This was illustrated by Açbay and Giindogdu 
(1996), who found that metformin did not decrease insulin resistance in women with 
PCOS, suggesting a different cellular mechanism, however, other workers have found 
that metformin does improve insulin resistance in women with PCOS (Velazquez et 
a l, 1994), although this may be as a result of weight loss (Crave et a l,  1995).
The degree of peripheral insulin resistance in women with PCOS, as measured by the 
euglycaemic clamp technique, is similar to that seen in non-insulin-dependent diabetes 
(Dunaif et a l, 1989) and is thought to be independent of obesity (dos Reis et a l.
1995), although some studies have shown that weight loss improves insulin sensitivity 
in women with PCOS (Andersen et al. 1995; Holte et al., 1995). The combination of 
PCOS and obesity appears to be synergistic in its effect on glucose metabolism 
(Dunaif et a l, 1989; Diamanti-Kandarakis et a l, 1995), i.e. obese women with PCOS 
have impaired glucose tolerance and a decreased suppression of hepatic glucose 
output more frequently than non-obese PCOS women (Dunaif et a l, 1992b).
1.8. B-CELL TUMOURS
Tumours of the B-cell (insulinomas) are rare, with estimates of approximately 1 case 
per million (Marks and Rose, 1981). They induce hypoglycaemia because of their 
inability to secrete insulin appropriately, rather than in large amounts and do not 
suppress insulin production in response to hypoglycaemia. The tumours consist almost 
entirely of islet tissue with varying morphology. Insulin content differs between 
tumours and the proportion of insulin to proinsulin is often higher than in normal islet 
tissue, but this also varies, with some tumours secreting more proinsulin. This latter 
group of tumours that secrete a greater amount of ‘proinsulin-like component’ 
(proinsulin and fragments) have been reported to show marked resistance to 
suppression of insulin secretion by somatostatin and diazoxide (Berger et a l, 1983). 
Treatment usually involves surgical removal of the tumour but if this is not 
appropriate, palliative therapy with diazoxide and chlorothiazide (Marks and Rose,
1981) can reduce hypoglycaemia, although this is not always successful
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1.9. AIMS AND SCOPE OF THE RESEARCH PROJECT
The aim of this research project was to investigate pancreatic B-cell and GIP and 
GLP-l(7 .3 6 )amide function in hyperinsulinaemic states. As part of this, an ELISA for 
insulin was developed that did not cross-react with the other major circulating B-cell 
products, to examine specific insulin production.
The hyperinsulinaemic conditions of obesity, hypertriglyceridaemia and polycystic 
ovary syndrome were examined in the postprandial state, with measurements 
undertaken of B-cell and gastrointestinal hormones, glucose, TAG and NEFA to 
determine the contribution of the enteroinsular axis to these various conditions.
A case study on a patient with a proinsulinoma tumour was re-examined using the 
newly developed insulin ELISA to see if this would provide a new perspective on this 
rare condition.
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CHAPTER 2.
M a t e r ia l s  a n d  M e t h o d s .
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2.1. MATERIALS
2.1.1. Eq uipm ent
Equipment
Cannulae (Y-Can 19g) 
Chemiluminescent plate reader 
Cobas Mira automated analyser
Dialysis tubing
ELISA plate reader (Multiskan with 
MultiCalc Level 4.M software) 
Fluoride/oxalate tubes (1ml)
Gamma counter (Wizard 1470 with 
Multicalc Level 4.M software) 
Immulon 2 (Flat bottom) microtitre 
plates
Lithium heparin tubes (5ml & 10ml) 
Microlite 2 microtitre plates
Sodium EDTA tubes (1ml)
Test tubes (polystyrene, LP3 & LP4)
Supplier
Medical Assist Ltd, Colchester 
Enfer Scientific Ltd, Dublin 
Roche Products Ltd, Welwyn Garden 
City
Sigma Chemical Company Ltd, Poole 
Labsystems, Life Sciences International, 
Basingstoke 
L.I.P. Ltd, Shipley 
Wallac Oy, Finland
Dynatech Laboriaories, Inc., 
Billingshurst 
L.LP. Ltd, Shipley 
Dynatech Laboriaories, Inc.
Billingshurst 
L.LP. Ltd, Shipley
H H
2.1.2. R eag ents
All standard laboratory chemicals were purchased from BDH Ltd, Poole or Fisher 
Scientific U.K. Ltd, Peterborough and were analytical grade unless otherwise stated. 
Specific chemicals ordered included:
Reagent
Albumin, Bovine Serum (BSA)
Fraction V powder 
Albumin, Human Serum (HSA)
Fraction V powder 
Agarose
Amerlite Reagent 
Aprotinin
Charcoal, activated (Norit PN5)
Chloramine T 
Gamma Globulin, Bovine
Supplier
Sigma Chemical Company Ltd, Poole
n n 
h  ii
Johnson & Johnson Clinical Diagnostics, 
Amersham 
Sigma Chemical Company Ltd, Poole 
BDH Ltd, Poole
Sigma Chemical Company Ltd, Poole
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Horseradish Peroxidase
Lactoperoxidase suspension 
Prosep-HC (Protein A)
Sephadex, G-15 for gel filtration 
Sephadex, QAE-A25, for anion exchange 
Silica, aldehyde activated porous 
125I-sodium iodide (3.7 GBq/ml) 
Streptavidin-biotinylated
horseradise peroxidase complex 
Sulfo-NHS-Biotin 
3,3',5,5' Tetramethylbenzidine
Tween 20
Unimate 5 GLUC HK test kit
Unimate 5 TRIG test kit 
WAKONEFAC test kit
Boehringer Mannheim GmBH 
Mannheim, Germany
ii »
Gift from Dr P. Kwasowski 
Sigma Chemical Company Ltd, Poole
h h
Clifinar Associates, Guildford 
ICN Biomedicals Ltd, Thame 
Amersham International pic., Little 
Chalfont
Pierce & Warriner (UK) Ltd, Chester 
Boehringer Mannheim GmBH, 
Mannheim, Germany 
Sigma Chemical Company Ltd, Poole 
Roche Diagnostic Systems, Welwyn 
Garden City
n h
Alpha Laboratories Ltd, Eastleigh
2.1.3. Pept id e s
C-peptide -
synthetic human 
tyrosylated 
GIP, synthetic human 
GLP-1 fragment 7-36 amide, 
synthetic human 
Insulin, biosynthetic human
Proinsulin, biosynthetic human 
Des-31,32 proinsulin, biosynthetic 
human
Des-64,65 proinsulin, biosynthetic 
human
Gift from Dr W. Hepner, Hoechst Ltd, 
Germany
Sigma Chemical Company Ltd., Poole
h H
Gift from Dr B. Franks, Eli Lilly & Co., 
Indianapolis, IN, USA
n  i i
h H
2.1.4. A n tiser a
C-peptide - 743, 1473 
G IP-RIC 34 iiiJ  
GLP-1 - G2-3 0/6/89 
Insulin -
HUI-018, 0X1-005 
GP2, C5/1, C5/4, Mab 64 
Proinsulin - 1313 
Donkey anti-Guinea Pig 
Donkey anti-Sheep 
Donkey anti-Rabbit 
Donkey anti-Rabbit Sac-Cel
Gift from Dr S.M.Hampton 
Gift from Dr L.M Morgan
IV It
Novo Nordisk, Denmark 
Gift from Dr S.M.Hampton
ii h
Guildhay Antisera Ltd, Guildford 
Gift from Dr P. Kwasowski 
Gift from Dr S.M.Hampton 
IDS Ltd., Boldon, Tyne & Wear
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2.1.5. S e r a
Normal Guinea Pig Serum Sera-Lab Ltd., Crawley Down, Sussex
Normal Mouse Serum 
Normal Rabbit Serum 
Normal Sheep Serum
Sigma Chemical Company Ltd., Poole 
Gift from Dr S.M. Hampton
i i  h
2.1.6. B u f f e r s
Reverse Osmosis (R.O.) water was used for preparing all buffers unless otherwise 
stated.
0.4 M(0.1 M 0.04 M) Acetate buffer (pH 5.6)
0.4 M (0.1 M, 0.04 M) sodium acetate titrated to pH 5.6 with 1 M glacial acetic
Antibody-detecting buffer
0.1 M Phosphate buffered saline (PBS) pH 7.4 containing:
350 mmol/L (NfL^SO^
10 g/L BSA
1 g/L bovine gamma globulin 
1 % normal mouse serum 
Prepared on day of use
0.1 M  Carbonate/Bicarbonate buffer (pH 9.6)
3.18gN a2C03 
5.88 gNaHC03
Made to 1 litre in R.O. water. Stored at 4°C.
0.1 M  Carbonate/Bicarbonate buffer (pH 9.8)
10.6 gNaaCOg
8.5 g NaHC03
Made to 1 litre with R.O. water. Stored at 4°C.
0.1 M  (0.05 mM) Carbonate/Bicarbonate buffer (pH 9.0)
0.1 M (0.05 mM) Na2 C0 3  A
0.1 M (0.05 mM ) NaHC03 B
7.74 ml A was added to 76.8 ml B and made to 1 litre with R.O. water. Stored 
at 4°C.
0.025 M  Citrate Buffer (pH 5.6)
7.1 g Na2 HP0 4  
5.22gC6H80 7.H20
Made to 1 litre with R.O. water. Stored at 4°C.
acid.
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0.1MHistidine Buffer (pH 6.1)
0.1 M Histdine titrated to pH 6.1 with 1 M HC1.
0.4 M  Phosphate buffer (pH 6.5 and pH  7.4)
0.4 M KH2P04 A
0.4M N a2HPO4 B
1 litre of each solution was prepared and solution A was added dropwise to 
solution B to give the required pH. Stored at 4°C.
0.04 M  Phosphate Buffer (pH 7.4)
23 gN a 2 HP0 4
5.97 g NaH2P 0 4.2H20
Made to 5 litres in R.O. water. Stored at 4°C.
0.1M Phosphate Buffered Saline (PBS; pH  7.4)
8.0 g NaCl 
0.2 g KC1 
0.2 g KH2P 0 4 
2.9 g Na2HP04
Made to 1 litre with R.O. water. Stored at room temperature.
Phosphate buffered saline with Tween (PBST)
As PBS with 0.5 ml/L Tween 20 added prior to use.
Phosphate buffered saline with Gelatine and Tween (PBSGT)
As PBST with 1 g/L gelatine added prior to use.
0.04 M  Tris buffer (pH 7.6)
Tris base (4.84 g) was added to 500 ml R.O. water. This was adjusted to pH
7.6 with 1 M HC1 before the addition of 400 mM (23.7g) NaCl and then made 
to 1 L with R.O. water. Stored at 4°C.
2.1.7. M isc ella neo u s
2.I.7.I. Standards
Insulin Standard
The ‘International Reference Preparation of insulin, human for immunoassay (1st 
IRP, established 1974)’ insulin standard (3IU per ampoule) was obtained from the 
National Institute for Biological Standards and Control. This was diluted in phosphate 
buffer containing 0.5 % BSA and 100 pi aliquots of 15000 pmol/L concentration were 
lyophilised and stored at -20°C under vacuum for subsequent use.
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Proinsulin standard
Biosynthetic human proinsulin. Standard produced as per Hampton et al. (1988). 
Aliquots containing 10 ng per vial were lyophilized and stored at -20°C under vacuum 
ready for use.
C-peptide standard
Synthetic human C-peptide. Standard produced as per Hampton (1983). Aliquots 
containing 20 ng per vial were lyophilized and stored at -20°C under vacuum ready 
for use.
GIP standard
Synthetic human GIP. Standard produced as per Elliot (1992). Aliquots containing 
100 ng per vial were lyophilized and stored at -20°C under vacuum ready for use.
GLP-1 standard
Synthetic human GLP-1 y^amide. Standard produced as per Kwasowski (1986). 
Aliquots containing 100 ng per vial were lyophilized and stored at -20°C under 
vacuum ready for use.
2.I.7.2. Charcoal Stripped Serum (CSS)
Agarose-coated charcoal was used to strip the serum. This was prepared by heating 
25 g agarose in 500 ml R.O. water to 70°C in a water bath in a fume cabinet. One 
hundred grams of activated charcoal was added, mixed and the mixture cooled to 
50°C, poured into 1 L of acetone and stirred. This was then filtered and dried at 37°C. 
Venous blood collected from fasted volunteers was allowed to clot, the serum 
collected and centrifuged at 450 g  for 10 minutes. To every 200 ml of pooled serum 
was added 25 g of agarose-coated charcoal. The slurry was stirred overnight at 4°C 
and then centrifuged for 10 minutes at 1300 g. The supernatant was filtered through a
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Seitz filter to remove the charcoal, aliquoted into 10ml volumes and stored at -20°C.
2.1.7.3. Quality Controls (QC)
Venous blood taken from volunteers, who had fasted and at 30 and 60 minutes after 
consuming a carbohydrate-rich snack, was centrifuged at 1850 g  for 10 minutes and 
the plasma collected. This was used to produce low, medium and high value quality 
controls for the insulin, proinsulin and C-peptide RIAs and the insulin ELISA. These 
were stored in 0.5 and 1 ml aliquots at -20°C until use. Quality controls for the GIP 
and GLP-1 assays were produced separately in a similar manner and contained 200 
KIU Aprotinin per millilitre of blood as a preservative.
2.1.7.4. Substrate TMB
Stock - 20 mg Tetramethylbenzidine (TMB) in 1 ml Dimethylformamide.
For use - 100 pi stock and 10 pi 30 % Hydrogen Peroxide were added to 20 ml Citrate 
buffer. After incubation on the plate, the reaction was stopped with 1 M  hydrochloric 
acid and any yellow colour production read at 450 run. Absorbance values can range 
up to approximately 3.0 (maximum linear absorbance).
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2.2. INSULIN ELISA DEVELOPMENT
An enzyme-linked immunosorbent assay (ELISA) for insulin using two mouse 
monoclonal antibodies (C5/1 and Mab 64) produced at the University was already 
established in the School of Biological Sciences when this PhD began. It was 
necessary, however, to further develop the assay because of problems of insufficient 
sensitivity and too much cross-reactivity with the proinsulin fragment des-31,32 
proinsulin in the established assay.
2.2.1. I n v e s t ig a t io n  o f  M o n o c lo n a l  A n tib o d y  C5/4
Initially, mouse monoclonal insulin antibody, C5/4 was assessed. This had been 
produced in the late 1980’s in the School of Biological Sciences and stored in liquid 
nitrogen. The antibody producing cells were resuscitated and expanded using aseptic 
cell culture techniques. The supernatant produced by the cells was assessed by ELISA 
for insulin binding capacity and ability to bind to an ELISA plate. Both were found to 
be unacceptably low.
The next step was to produce ascitic fluid in mice, because this usually contains a 
greater concentration of antibody than cell culture supernatant (Harlow and Lane, 
1988). The ascitic fluid was assessed as before, but again found to be inadequate. 
Another ELISA using a donkey anti-mouse pre-coated plate showed that there were 
murine antibodies present in the ascitic fluid. This suggested that cells other than 
those producing insulin antibodies had become the dominant clone, so the antiserum 
was of no practical use in an insulin assay.
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2.2.2. C5/1 /  M ab 64 ELISA D e v e lo p m e n t
The next step was to return to the original mouse monoclonal C5/1 / Mab 64-HRP 
(Mab 64 conjugated to horseradish peroxidase label) sandwich ELISA. Assay 
conditions were altered in an attempt to increase both the specificity and sensitivity of 
the assay. The initial conditions were:
♦ C5/1 diluted 1:6000 in 1 M carbonate/bicarbonate buffer (pH 9.6) (200 p 1/well). 
Incubated for 1 hr, 37°C in a moist chamber. Plate washed with PBSGT.
♦ Insulin standards (0, 12, 23, 47, 94, 188, 375, 750, 1500 pmol/L) diluted in 
CSS (100 pi added to appropriate wells), plus 100 pl/well PBSGT were added 
to all wells and the plate incubated for 15 mins, 37°C in a moist chamber. Plate 
washed with PBSGT.
♦ Mab 64-HRP diluted 1:2000 in PBSGT (200pl/well). Incubated 1 hr, 37°C in a 
moist chamber. Plate washed with PBSGT.
♦ Colour production was with TMB (see Section 2.1.7.4.).
The initial condition varied was the insulin incubation time. The short period of 15 
minutes was impractical because it could take 5-10 mins to add the standards and 
PBSGT to all the wells on a plate, therefore the wells that were coated first would 
have been in contact with the standard for nearly twice as long as those coated last. 
Various other optimisation procedures were also investigated including dilution of 
C5/1 and Mab 64-HRP, but little colour was produced, indicating that one of the 
reagents had deteriorated. Different batches of each were tried with no success. A new 
label was produced by conjugating Mab 64 to HRP. This improved the colour 
(absorbance up to 3.5) and manipulation of the assay conditions in an attempt to 
increase specificity and sensitivity continued. These included:
48
♦ Insulin standard incubation time
♦ C5/1 antiserum dilution
♦ Mab 64-HRP dilution
♦ Polyvinylchloride / polystyrene plates
♦ Blocking stage - PBSGT or BSA
♦ Vary amount standard / PBSGT / CSS
♦ Overnight C5/1 antiserum coat
Although some improvements were achieved, these different conditions did not 
improve the assay sensitivity adequately, so a biotinylated label was produced. Mab 
64 was conjugated to sulfo-NHS-biotin instead of HRP. This was used in conjunction 
with streptavidin biotinylated HRP complex.
Biotin is a relatively small molecule, so it can be conjugated to many proteins without 
altering their biological activity. Biotin binds with high affinity to avidin and 
streptavidin and the avidin—biotin interaction is the strongest known non-covalent 
biological recognition. This amplification technique has been shown to increase assay 
sensitivity (Guesdon et al.9 1979; Husby et al.9 1986). The biotinylation protocol used 
was:
a) Purification o f  Mab 64 antiserum
Mab 64 antiserum (1.3 ml) was purified on a protein A column (Harlow and Lane,
1988). The eluate from the column was the dialysed against 50 mM  
carbonate/bicarbonate buffer, pH 9, overnight. The Mab 64 antibody concentration in
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the eluate was 6 mg/ml. This was calculated by measuring the absorbance of the 
eluate at 280 rnn and dividing this answer by 1.4 (an absorbance of 1.4 at 280 nm is 
approximately equivalent to 1 mg/ml).
b) Biotinylation o f  Mab 64 antiserum
Two milligrams (i.e. 330 pi) of the purified antibody was dissolved in 660 pi of 50 
mM carbonate/bicarbonate buffer pH 9. Sulfo-NHS-biotin (74 pi of 1 mg/ml in R.O. 
water) was added to the antibody solution and incubated at room temperature for 45 
minutes. This was then dialysed overnight at 4°C against 50 mM 
carbonate/bicarbonate buffer to remove unreacted biotin.
Concentrations of the biotinylated label and streptavidin biotinylated HRP complex 
were varied until the most suitable combination was obtained. Figure 2.1 compares 
the standard curves obtained with Mab 64-HRP and biotinylated Mab 64 (Mab 64-B). 
Figure 2.1b which enlarges the first part of the graph (12-188 pmol/L) emphasises the 
greater sensitivity obtained with Mab 64-B compared to Mab 64-HRP (20 pmol/L vs 
29 pmol/L). Normal fasting values have been quoted as 6-61 pmol/L (median 18 
pmol/L) in a group of 30 healthy individuals (Andersen et a l, 1993) and 20 ± 0.3 
pmol/L (mean ± S.E.M.) in a group of eight healthy young men (Sobey et a l, 1989), 
so whilst the new label made the assay more sensitive, it was not sensitive enough to 
measure some fasting levels._______________________ _____
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Figure 2.1. Graph comparing standard curves obtained with different Mab 64 labels
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Cross-reactivity was the major problem with this antibody system (see Fig 2.2), nearly 
100 % with des-31,32 proinsulin and < 0.15 % with intact proinsulin and des-64,65 
proinsulin. Des-31,32 proinsulin has been shown to be the major circulating 
proinsulin fragment in healthy subjects (Sobey et a l, 1989) and is raised 
disproportionately to the levels of insulin in subjects with NIDDM (Temple et a l,
1989), so we required an assay that did not cross-react to such an extent with this
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fragment. This, in combination with the insufficient sensitivity, led to the purchase of 
two commercially available antibodies.
Figure 2.2. Graph o f cross-reactivity o f C5/1 /M ab 64 insulin ELISA
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2.2.3. C om m er cial  M ono c lo n al  A n tibo dies  0X1-005 a nd  HUI-018
Two monoclonal antibodies, 0X1-005 (OXI) and HUI-018 (HUI) were purchased 
from Novo Nordisk, Denmark. These IgGi class antibodies had been developed by 
hybridoma technology from mice immunized with bovine and human insulin 
respectively. The epitope for OXI is near the C-terminal end of the B-chain, but its 
exact size is not known. The epitope for HUI is centred around the A-loop (Andersen 
et a i, 1993). They have been used successfully in both fluoroimmunoassay and 
ELISA (Andersen et al., 1993; Wood and Donovan, 1993), and do not cross-react 
with des-31,32 proinsulin (Andersen et al., 1993). The system does cross-react 63 % 
with des-64,65 proinsulin, but this is not considered a problem, because this fragment 
circulates at very low levels (Sobey et al., 1989).
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It was hoped to use one of these antibodies in combination with either C5/1 or Mab 
64, but little absorbance was obtained when different combinations were run in the 
ELISA system, so this was not possible.
The literature published on HUI and OXI was reviewed and a combination of the 
assay conditions used were chosen, which included using biotinylated OXI. A scaled 
down version of the protocol used for Mab 64 (see Section 2.2.2 ), was used for the 
biotinylation because only 0.5 mg antibody was available. To find the optimal dilution 
of biotinylated OXI (OXI-B), the chequerboard procedure outlined below was used:
♦ HUI diluted 10 pg/ml in 0.1 M  carbonate/bicarbonate buffer pH 9.6 (200 
pl/well, polystyrene plate). Incubated overnight at 4°C. Plate was emptied.
♦ Blocking stage - BSA, 5 g/L diluted in PBS (200 pl/well). Incubated 1 hr, 37°C 
on a plate shaker. Plate was washed with PBST.
♦ Standards of 0 and 94 pmol/L insulin diluted in CSS (100 pl/well) were added 
to appropriate wells. PBST containing 1% normal mouse serum (PBST/NMS), 
100 pl/well, was added to all wells and the plate was incubated for 2 hr at 37°C 
on a shaker. Plate was washed with PBST.
♦ OXI-B at dilutions of 1:250, 1:500 and 1:1000 in PBST/NMS was added to the 
plate (200 pl/well) and incubated for 2 hr, 37°C on a shaker. Plate was washed 
with PBST.
♦ Streptavidin biotinylated horseradish peroxidase complex diluted 1:1000 in 
PBST/NMS was added to all wells (200 pl/well) and incubated for 1 hr at 37°C 
on a shaker. Plate was washed with PBST.
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♦ Colour development was with TMB.
Little colour was produced in all wells (absorbance < 0.15), so the process was 
repeated with OXI-B at increased concentrations of 1:50, 1:100 and 1:200. There was 
still little colour, so a chemiluminescent end-point instead of colorimetric was 
assessed. This technique can be extremely sensitive (Whitehead et al.f 1979; Whiting, 
1987).
The chemiluminescent assay procedure was the same as with colorimetry, except for 
the type of ELISA plate used and the detection stage. The chemiluminescent reagent 
Amerlite™ was used in the final stage. The reactions involved are complex. In 
summary, after addition to the plate, hydrogen peroxide in the signal reagent is 
reduced to water by the catalytic action of horseradish peroxidase in the bound 
streptavidin biotinylated horseradish peroxidase complex. The oxygen radicals 
generated oxidise luminol in the reagent to aminophthalic acid. Light is produced at 
this stage and the signal is prolonged and amplified by the enhancer in the reagent. 
The light signal produced can be read on a chemiluminescent plate reader after 2 
minutes and is stable for at least 20 minutes. The enhancement is specific to 
horseradish peroxidase, so the amplified signal resulting from the enzymatic reaction 
will not be affected by high background signals, leading to greater sensitivity 
(Amersham product information).
The results from a chemiluminsecent system were not as good as expected. This was 
thought to be due to poor biotinylation of OXI. The conditions that produced a 
reasonable incorporation of biotin into Mab 64 were not necessarily the same as those
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required for OXI. A different biotinylation protocol of OXI was attempted with the 
aim of obtaining greater incorporation of biotin than was achieved with the previous 
protocol. The procedure used was a modification of that of Berger et a l (1982) as 
described below:
♦ OXI (1 ml of 0.5 mg/ml) was dialysed against 0.1 M  carbonate/bicarbonate 
buffer pH 9 overnight at 4°C.
♦ Sulfo-NHS-biotin (30pl of 3.4 mg/ml) was added to the dialysed OXI and 
incubated at room temperature for 4 hr.
♦ The biotinylated OXI was then dialysed against 0.1 M  carbonate/bicarbonate 
buffer overnight at 4°C.
This new protocol reacted 102 pg biotin with 0.5 mg OXI for 4 hours compared with 
only 16 pg biotin per 0.5 mg OXI for 45 minutes in the previous protocol, therefore it 
would be expected to increase incorporation. Results in the ELISA were improved 
and development continued with the HUI/OXI system.
Due to the high cost of these commercial antisera the aim was to produce a sensitive 
assay whilst using as little antisera as possible. Even though greater signal was 
achieved when HUI was used at 10 pg/ml as other workers have used, we continued 
with 5 pg/ml as the coating concentration.
The protocol that produced the most sensitive standard curve was:
♦ Dynatech Microlite II plate was coated with HUI diluted in 
carbonate/bicarbonate buffer pH 9.6 (200 pl/well of 5 pg/ml) and incubated
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overnight at 4°C. The plate was then emptied.
♦ Standards (0, 12, 23, 47, 94, 188, 375, 750, 1500 pmol/L) diluted in CSS were 
then added in duplicate to the plate (lOOjal/well). Samples and quality controls 
(lOOpl/well) would be added at this stage, if being measured. Biotinylated OXI 
diluted 1:1000 in PBST/NMS (100 pl/well) was added to all wells and the plate 
was incubated for 1 hour at 37°C on a plate shaker. The plate was then washed 
with PBST.
♦ Streptavidin biotinylated horseradish peroxidase complex diluted 1:1000 in 
PBST/NMS was added to all wells (200 pl/well) and incubated for 30 minutes 
at 37°C on a plate shaker. The plate was then washed with PBST.
♦ The chemiluminescent detection reagent Amerlite was added to all wells (145 
pl/well) and incubated at 37°C on a plate shaker for three minutes. The light 
signal produced was read on a chemiluminescent plate reader.
A typical standard curve with HUI and OXI-B is shown in Figure 2.3.
Figure 2.3. Insulin standard curve
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Cross-reactivity, sensitivity and reproducibility experiments were undertaken at this 
stage. The cross-reactivity was as expected (see Figure 2.4) - 66% with des-64,65 
proinsulin and negligible with proinsulin, des-31,32 proinsulin and C-peptide, 
compared to negligible with proinsulin, des-64,65 proinsulin and C-peptide and 100% 
with des-31,32 proinsulin in the C5/1 / Mab 64 system. The limit of detection of the 
assay (mean of 12 zero values + 2 standard deviations from the mean) was 10 pmol/L 
and intra-assay coefficient of variation (CV) was 17.5% (n=12) at 10 pmol/L.
Figure 2.4. Graph o f cross-reactivity o f HUI and OXI-B insulin ELISA
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Recovery and parallelism experiments were also undertaken. The results were not as 
expected. Recoveries using fresh human plasma, spiked across the standard curve 
range, were very poor, varying from 19-45%. Parallelism, using a serially diluted 
known high insulin sample did not produce a curve that was superimposable on the 
standard curve.
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It was obvious from these experiments that the assay needed further development 
before it could be used. The aim then was to increase the background signal which 
was very low for a chemiluminescent system. In an attempt to improve the assay 
CV's, recovery and parallelism, the next protocol used was:
♦ Plate coated with HUI diluted in bicarbonate/carbonate buffer (200 pl/well of 5 
pg/ml) and incubated overnight at 4°C. The plate was then washed with 
PBSGT.
♦ A block of BSA in PBS, (200pl/well of 5 g/L) was added to the plate and 
incubated for 1 hour at 37°C on a plate shaker. The plate was then washed with 
PBSGT.
♦ Standards/samples and biotinylated OXI were added and incubated as in the 
previous protocol. The plate was then washed with PBSGT.
♦ Streptavidin biotinylated horseradish peroxidase complex diluted 1:500 in 
PBST/NMS was added to all wells (200pl/well) and incubated for 45 minutes 
at 37°C on a plate shaker. The plate was then washed with PBSGT.
♦ Amerlite (145 pl/well) was added to the plate and incubated for 3 minutes at 
37°C on a plate shaker. The light signal was then read as before.
A typical standard curve is shown in Figure 2.5a. This new protocol increased the 
background signal by 3-4 fold. However the light signal produced by the 12pmol/L 
insulin standard was lower than the zero standard signal (see Figure 2.5b) and when 
samples were read, fasting plasma signals were much lower than the standard curve 
zero signal.
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Figure 2.5. Insulin standard curve
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It was thought that a component of the CSS could be interfering in the assay. An 
experiment was undertaken comparing recoveries obtained against a curve prepared in 
CSS to one prepared in normal fasting plasma (see Figure 2.6 for standard curves). 
With the CSS curve, recoveries ranged from 37-72% i.e. better than the previous 
recovery experiment. When compared to the unstripped plasma curve, recoveries 
were 96-108%, indicating that the problem was with the current batch of CSS, 
possibly contaminants in the CSS cross-reacting in the assay.
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Figure 2.6 Graph comparing insulin standard curves prepared in CSS and normal 
human plasma
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A standard curve produced using a different batch of CSS gave an improved standard 
curve, without the dip at 12 pmol/L (see Figure 2.7) and fasting plasma values 
between 12 and 23 pmol/L.
A new batch of CSS was produced and validation experiments undertaken using this. 
Recoveries were optimised using the antibody-detecting buffer described by Andersen 
et al. (1993), to dilute the biotinylated 0X1-005 (see Section 2.1 for recipe). The assay 
assessment and validation experiments were repeated and found to be acceptable (see 
Sections 2.2.4 - 2.2.8).
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Figure 2.7 Graph comparing beginning o f standard curves obtained with different 
batches o f CSS
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The final protocol was:
♦ A Dynatech Microlite II plate was coated with HUI-018 diluted in 
carbonate/bicarbonate buffer pH 9.6 (200 pl/well of 5 pg/ml) and incubated 
overnight at 4°C. The plate was then washed with PBSGT.
♦ A block of BSA in PBS, (200pl/well of 5 g/L) was added to the plate and 
incubated for 1 hour at 37°C on a plate shaker. The plate was then washed with 
PBSGT.
♦ Standards (diluted in CSS), samples and quality controls (100 pl/well) were 
added in duplicate to the plate. Biotinylated 0X1-005 diluted 1:1000 in 
antibody-detecting buffer was added to all wells (100 pl/well) and the plate 
incubated for 1 hour at 37°C on a plate shaker. The plate was then washed with 
PBSGT.
♦ Streptavidin biotinylated horseradish peroxidase complex diluted 1:500 in
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PBST/NMS was added to all wells (200 ^1/well )and incubated for 45 minutes 
at 37°C on a plate shaker. The plate was then washed with PBSGT.
♦ Amerlite was added to all wells (145pl/wells) and incubated for 3 minutes at 
37°C on a plate shaker. The light signal produced was then read on a 
chemiluminescent plate reader.
2.2.4. A ssa y  V a lid a tio n
2.2.4.1. Assay sensitivity
The limit of detection of the assay was determined by running a standard curve 
together with 12 zero points (CSS only). The mean and standard deviation of the zero 
signals was calculated. The assay limit of detection was taken as the mean zero signal 
plus two standard deviations of the mean. The insulin concentration corresponding to 
this was read from the standard curve. The value obtained was 10.8 pmol/L.
2.2.4.2. Assay cross-reactivity
The assay cross-reactivity was assessed in two different ways. The first method was 
as illustrated in Figure 2.4. A normal standard curve and curves for proinsulin, des- 
31,32 proinsulin, des-64,65 proinsulin and C-peptide were run on a plate. The amount 
of cross-reactivity was defined as the concentration of insulin that produced 50% of 
maximum insulin binding in the assay divided by the concentration of the cross­
reactant that produced the same effect.
The second method was to look at the recovery of various amounts of insulin when a 
high concentration of cross-reactant was present. This was achieved by making
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solutions of CSS with each of the cross-reactants at concentrations specified in the 
table below. Each of the CS S/cross-reactant solutions was then used to dilute a vial of 
insulin standard to 1500, 150 and 15 pmol/L. These were run in the assay, together 
with a zero of the CSS/cross-reactant solution alone. The concentration of “insulin” 
measured in each preparation was determined from a standard curve.
Table 2.1. Cross-reactivity in insulin ELISA
Cross-reactant Insulin concentration measured (pmol/L)
Proinsulin, 1000 pmol/L 
des-31,32 proinsulin, 1000 pmol/L 
des-64,65 proinsulin, 1000 pmol/L 
C-peptide, 3000 pmol/L
6 27 154 1320
15 27 150 1276
644 681 819 2016
3 22 168 1492
Actual insulin concentration in 
sample
15 150 1500
This data correlated with the previous cross-reactivity experiment indicating that 
when high levels of cross-reactants were present, there was little cross-reactivity with 
proinsulin, des-31,32 proinsulin or C-peptide. Des-64,65 proinsulin cross-reacted 
approximately 64% in the assay as indicated by the detection of 644 pmol/L of 
“insulin” when there was no actual insulin present in the sample, only 1000 pmol/L of 
des-64,65 proinsulin instead. This proportion remained similar as the insulin 
concentration increased - when 1500 pmol/L insulin was present in the sample, 2016 
pmol/L was detected. The difference would be accounted for by the proportion of des- 
64,65 proinsulin cross-reacting. This is unlikely to be of importance because the 
proinsulin fragment has only been found circulating at very low levels (< 1 pmol/L) in 
healthy subjects (Sobey et al., 1989).
63
2.2.43. Assay precision and reproducibility
To investigate precision over the standard curve range (intra-assay variation), 6 
singlicates were run at each standard curve concentration. The coefficients of 
variation (CV) ranged from 1.8-7.6% (see Fig 2.8).
The inter-assay CVs for quality controls with mean values of 38 pmol/L (n = 29), 92 
pmol/L (n = 23) and 825 pmol/L (n = 29) were 9.9%, 6.1% and 4.8% respectively.
Figure 2.8. Insulin standard curve. Error bars denote mean +S.D. (n = 6)
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2.2.4.4. Assay recovery
Recovery was assessed by spiking aliquots of a fasting plasma sample with known 
amounts of insulin across the standard curve range. These samples were then run in 
the assay as usual and the insulin concentration detected in the assay determined from 
a standard curve. The measured concentration was expressed as a percentage of the 
expected insulin concentration. Values ranged from 98-104%, as shown in Fig. 2.9.
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Figure 2.9. Graph showing recovery for insulin ELISA
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2.2.4.S. Parallelism
An aliquot of a human plasma sample known to contain a high concentration of 
insulin (approximately 1500 pmol/L as measured by RIA) was serially diluted with 
CSS a total of seven times to produce an expected range of insulin concentrations 
from approximately 12-1500 pmol/L. These and the original undiluted sample were 
assayed for insulin in the ELISA. The results are shown in Fig 2.10 and compared 
with a normal standard curve. The dilution curve obtained was essentially 
superimposable on the standard curve.
65
Figure 2.10. Parallelism o f insulin ELISA 
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2.2.5. Co m pariso n  o f  Fa sting  In su lin  V a lues  a s M e asured  by  ELISA and  
Ra dio im m u no assa y
Table 2.2. below compares fasting insulin values measured by both the ELISA 
method already described and by radioimmunoassay (see Section 2.3 for method), in 
normal and hyperinsulinaemic subjects. Data is expressed as mean ± S.E.M. with the 
data range in brackets.
Table 2.2. Comparison o f  fasting ELISA and radioimmunoassay insulin values in 
normal and hyperinsulinaemic subjects, mean ± S.E.M. (range).
ELISA (pmol/L) RIA (pmol/L)
Normal, n = 26 38 ± 2  (20-73) 42 ± 4  (18-109)
Non-insulin-dependent diabetic, n = 4 101 ± 18(57-140) 126 ±32 (59-186
Impaired glucose tolerance, n = 4 92 ± 8  (71-108) 103 ± 12(84-137)
Obese, n = 19 104 ± 13 (35-239) 136 ± 18 (36-250)
Hypertriglyceridaemic, n = 15 87 ± 8 (28-135) 127 ±21 (18-338)
Mean insulin values as measured by ELISA were less than those measured by RIA, 
but the differences were not significant and the group numbers were small, 
particularly for the non-insulin-dependent diabetic and impaired glucose tolerance
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groups. Greater differences between the ELISA and RIA measurements, which reflect 
proinsulin and des-31,32 proinsulin levels may be seen postprandially.
2.3. PANCREATIC HORMONE RADIOIMMUNOASSAYS
Radioimmunoassays (RIAs) for insulin, proinsulin and C-peptide were those 
developed in the School of Biological Sciences by Dr S.M. Hampton (Hampton, 
1983; Hampton et a l, 1988).
The 125Iodine radiolabels for each of the assays were produced in-house. The 
procedures are described below. The insulin iodination involved separation of the 
iodinated peptide by gel filtration, whereas the proinsulin and C-peptide iodinations 
utilised anion exchange chromatography.
2.3.1. Io d in a tio n  o f  in sulin
G-15 Sephadex was swollen overnight in 0.04 M  phosphate buffer pH 7.4 containing 
0.5 % BSA, at room temperature. This was then de-gassed and poured into a 1 cm 
diameter disposable plastic column to a bed height of approximately 7 cm. The 
column was then equilibrated with phosphate/BSA buffer by allowing 10 ml to drip 
through.
Insulin (5 pg) was dissolved in 0.4 M  phosphate buffer pH 7.4 (10 pi) in an 
autoanalyser cup. To this was added 125I sodium iodide (5 pi containing 18.5 MBq) 
and chloramine T (5pi of 4 mg/ml in 0.04 M  phosphate buffer pH 7.4). The reaction
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was allowed to proceed for 20 seconds, whilst mixing the contents of the cup by 
repeatedly filling and emptying the pipette tip used to add the chloramine T. The 
reaction was stopped by the addition of sodium metabisulphite solution (200 pi of 
0.25 mg/ml solution in 0.04 M phosphate buffer pH 7.4). Potassium iodide (50 pi of 2 
mg/ml in 0.04 M phosphate buffer pH 7.4) to mop up the free iodine.
The contents of the cup were then transferred to the top of the Sephadex column with 
a plastic pipette. Twenty fractions containing 20 drips per tube were collected. A 10 
pi aliquot was taken from each fraction and the radioactivity counted on a gamma 
counter. An elution profile is shown in Fig 2.11. Iodinated insulin was the first peak, 
followed by free iodine.
Aliquots of iodinated insulin were stored at -20°C until use when they were diluted to 
10000 cpm/100 pi in assay buffer.
Figure 2.11. Elution profile o f iodinated insulin
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2.3.2. Io d in a tio n  o f  Pro in sulin
QAE A25 Sephadex was swollen overnight in Tris buffer. This was then de-gassed 
and poured into a 1 cm diameter glass column to a bed height of 15 cm. The column 
was then equilibrated with Tris buffer by allowing 10 ml to drip through.
Proinsulin (5 jug) was dissolved in 0.4 M  sodium acetate buffer, pH 5.6 (25 pi) in an 
autoanalyser cup. To this was added 125I sodium iodide (5 pi containing 18.5 MBq), 
hydrogen peroxide (10 pi of 0.003 % solution in 0.04 M  sodium acetate) and 
lactoperoxidase (20 pi of 0.2 mg/ml solution in 0.04 M  sodium acetate). The reaction 
was allowed to proceed for two minutes, whilst mixing the contents of the cup by 
repeatedly filling and emptying the pipette tip used to add the lactoperoxidase. The 
reaction was stopped by the addition of 200 pi of Tris buffer.
The contents of the cup were transferred to the top of the ion exchange Sephadex 
column with a plastic pipette and allowed to sink into the column bed before more 
Tris buffer was added to elute the iodinated proinsulin. Thirty tubes containing 20 
drips per tube were collected. A 10 pi aliquot was taken from each fraction and the 
radioactivity counted on a gamma counter. An elution profile is shown in Fig 2.12.
Aliquots of iodinated proinsulin were stored at -20°C until use when they were diluted 
to 10000 cpm/100 pi in assay buffer.
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Figure 2.13. Elution profile o f a proinsulin iodination
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2.3.3. I o d i n a t i o n  o f  C - p e p t i d e
Human C-peptide contains no histidine or tyrosine residues that are necessary for 
iodination, therefore a tyrosylated analogue was used.
QAE A25 Sephadex was swollen overnight in 0.1 M Histidine buffer, pH 6.1. This 
was then de-gassed, poured into a 1 cm diameter disposable plastic column to a bed 
height of 7 cm. The column was then equilibrated with Histidine buffer.
Tyrosylated C-peptide (5 jag) was dissolved in 0.4 M sodium acetate buffer, pH 5.6 
(50 pi) in an autoanalyser cup. To this was added 0.04 M sodium acetate buffer, pH 
5.6 (50 pi), 125I sodium iodide (5 pi containing 18.5 MBq), hydrogen peroxide (10 pi
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of 0.003 % solution in 0.04 M sodium acetate) and lactoperoxidase solution (10 pi of 
0.2 mg/ml solution in 0.04 M sodium acetate). The reaction was allowed to proceed 
for 15 seconds, whilst mixing the contents of the cup. The reaction was stopped by the 
addition o f200 pi of 0.1 M Histidine buffer.
The contents of the cup were transferred to the top of the ion exchange Sephadex 
column with a plastic pipette and allowed to sink into the column bed before more 
Histidine buffer was added. Forty tubes containing 80 drips per tube were collected. A 
10 pi aliquot was taken from each tube and the radioactivity counted on a gamma 
counter. There were two peaks. After the second peak had eluted, 0.02 M HC1 
containing 1 % HSA was applied to the column. Fraction collection of 20 drips/tube 
continued until the third peak eluted. An elution profile is shown in Fig 2.13. The first 
peak was iodinated lactoperoxidase, followed by free iodine and finally iodinated C- 
peptide after the buffer change.
Aliquots of iodinated C-peptide were stored at -20°C until use when they were diluted 
to 10000 cpm/100 pi in assay buffer.
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Figure 2.14. Elution profile o f a C-peptide iodination
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2.3.4. A ssay  m eth o d s
The procedures are outlined in Figs 2.14 - 2.16, with reagents added in the order 
shown. All the assays were carried out on an ice tray. The assay buffer was 0.04 M 
phosphate buffer pH 7.4 containing 0.5 % BSA. The assays were conducted in 
polystyrene LP3 tubes and all standards, samples and blanks were run in duplicate. 
Tubes containing the bound radioactivity were counted on a Wallac Wizard gamma 
counter and a standard curve constructed automatically using the in-built software. 
Sample concentrations were calculated from this.
The cross-reactivity and sensitivity of the assays are shown in the Table 2.3.
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Table 2.3 Cross-reactivity, _____   and sensitivity o f  proinsulin, insulin and
C-peptide radioimmunoassays
ASSAY
Insulin Proinsulin C-peptide
Cross-reactant 
Insulin 
Proinsulin 
C-peptide 
Des-64,65 proinsulin 
Des-31,32 proinsulin
100 % 
42%  
<0.16%  
76%  
61 %
< 0.001 % 
100 %
< 0.001 % 
128 % 
0.7 %
< 0.001 % 
12% 
100 % 
24%  
26%
Assay sensitivity 19 pmol/L 6.7 pmol/L 12 pmol/L
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Figure 2.14. INSULIN RADIOIMMUNOASSAY PROTOCOL
Standards of 23, 47, 94, 188, 375, 750 and 1500 pmol/L were prepared in assay 
buffer.
Reagents Tubes
M
Total NSB Zero Standard Sample/ Sample/
______Standard Standard____________  QC NSB QC
DAY 1 
Buffer — 350 250 200 350 250
Insulin
Standard
— 50 — --------
CSS 50 50 50 — --------
Sample/
QC
plasma
—  —  — — 50 50
Antiserum — — 100 100 -------- 100
Reagents were added in the order shown. Tubes were then vortexed and 
incubated for 24 hours at 4°C.
DAY 2 
Label 100 100 100 100 100 100
Tubes were vortexed and incubated for 24 hours at 4°C.
DAY 3 
Normal 
Guinea Pig 
Serum
— 100 100 100 100 100
Donkey 
anti 
Guinea Pig 
Serum
100 100 100 100 100
4% PEG 700 700 700 700 700
Tubes were vortexed and incubated for 2 hours at 4°C. They were then 
centrifuged at 1300 g  for 30 minutes at 4°C. The supernatant was then 
_________________________ aspirated.
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Figure 2.15. PROINSULIN RADIOIMMUNOASSAY PROTOCOL
Standards of 6.7, 13,26, 53,107, 213 and 425 pmol/L were prepared in CSS.
Reagents
M
Total
Tubes
NSB Zero Standard 
Standard Standard
Sample/ 
QC NSB
Sample/
QC
DAY 1 
Buffer --- 300 200 200 300 200
Proinsulin
Standard
--- — 200 — ---
CSS --- 200 200 —
Sample/
QC
plasma
— - —  — 200 200
Antiserum --- — 100 100 — 100
Reagents were added in the order shown. Tubes were then vortexed and 
incubated for 24 hours at 4°C.
DAY 2 
Label 100 100 100 100 100 100
Tubes were vortexed and incubated for 24 hours at 4°C.
DAY 3 
Normal 
Sheep 
Serum
--- 100 100 100 100 100
Donkey 
anti sheep 
Serum
■ — 100 100 100 100 100
4% PEG 800 800 800 800 800
Tubes were vortexed and incubated for 2 hours at 4°C. They were then 
centrifuged at 1300 g  for 30 minutes at 4°C. The supernatant was then
aspirated.
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Figure 2.16. C-PEPTIDE RADIOIMMUNOASSAY PROTOCOL
Standards of 39, 77, 154, 307, 615, 1230 and 2460 pmol/L were prepared in CSS.
Reagents
M>
Total
Tubes
NSB Zero Standard 
Standard Standard
Sample/ 
QC NSB
Sample/
QC
DAY 1 
Buffer 100 — — 100 —
C-peptide
Standard
--- — — 100 --- ---
CSS --- 100 100 --- ---------
Sample/
QC
plasma
■ — —  —  —— 100 100
Antiserum -------- — 100 100 --------- 100
Reagents were added in the order shown. Tubes were then vortexed and 
incubated for 48 hours at 4°C.
DAY 3 
Label 100 100 100 100 100 100
Tubes were vortexed and incubated for 24 hours at 4°C.
DAY 4 
Normal 
Sheep 
Serum
-------- 100 100 100 100 100
Donkey 
anti sheep 
Serum
-------- 100 100 100 100 100
4% PEG 500 500 500 500 500
Tubes were vortexed and incubated for 2 hours at 4°C. They were then 
centrifuged at 1300 g  for 30 minutes at 4°C. The supernatant was then 
_________________________ aspirated.
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2.4. GUT HORMONE RADIOIMMUNOASSAYS
Radioimmunoassays (RIAs) for GIP and GLP-1 (y.g^amide were performed essentially 
as described by Morgan et al, 1978 and Elliott et al, 1993, respectively.
The 125Iodine radiolabels for each of the assays were produced in-house. The 
procedures are described below. Both labels were produced using the same method.
2.4.1. I o d in a t io n  o f  GIP a n d  GLP-1(7-36)AMide
G-15 Sephadex was swollen overnight in 0.1 M acetate buffer pH 5.0. This was then 
de-gassed and poured into a plastic disposable column to give a bed height of 
approximately 10 cm. The column was then equilibrated with protein elution buffer 
(0.1 M acetate buffer pH 5.0 containing 0.5 % HSA and 500 KIU/ml aprotinin), by 
allowing 15 ml to drip through.
GIP (3 jig) or GLP-l(7-3 6 )amide (5 pg) was dissolved in 10 pi 0.4 M phosphate buffer 
pH 6.5. To this was added 125I sodium iodide (10 pi containing 37 MBq) and 
chloramine T (10 pi of 1.5 mg/ml in 0.4 M phosphate buffer pH 6.5). The reaction 
proceeded for 15 seconds whilst mixing the contents of the cup. The reaction was 
stopped by the addition of sodium metabisulphite (20 pi of 2 mg/ml in 0.4 M 
phosphate buffer pH 6.5). Approximately 200 pi of protein elution buffer was then 
added to the cup and the mixture transferred to the top of the Sephadex gel filtration 
column. Twenty tubes containing 10 drips per fraction were collected. A 10 pi aliquot 
of each fraction was counted on the gamma counter. A typical elution profile is shown
77
in Fig. 2.17. The first peak corresponds to the radiolabelled peptide and the second to 
free iodine.
Aliquots (20 pi) of iodinated GIP and GTP-l^.^amide were stored at -20°C until use.
Figure 2.17. Elution profile o f a G LP-lp^am ide iodination 
Iodinated GLP-l(7-36)amide
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2.4.2. A f f i n i t y  p u r i f i c a t i o n  o f  GIP a n d  G L P -1(7 .36)A M Ide
GIP and GTP-1 ^ .^am ide iodinated labels had to be purified before use in an assay by
the procedure described below. The method was the same for both radiolabels.
An affinity purification column containing rabbit anti-GIP antibodies (or rabbit anti- 
GLP-l(7-3 6)amide antibodies) coupled to silica beads had been previously prepared in 
the School of Biological Sciences (see Elliott, 1992) and stored at 4°C.
The bicarbonate buffer that the column was stored under was allowed to drain off and 
then the column was washed with 10 ml of 0.3 % HC1. The column was then
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equilibrated with assay buffer by allowing 20 ml to drip through. The radiolabelled 
GIP or GLP-l(7 .3 6 )amide was reconstituted with 3 ml of assay buffer (between one and 
three 20 pi aliquots of label could be purified at one time) and this was layered onto 
the stoppered column. The column was capped and roller-mixed for 30 minutes at 
room temperature. The buffer was then allowed to dnp out and the column washed 
with 20 ml of R.O. water. The purified label was eluted with 5 ml of 0.3 % HC1. The 
column was then washed with 10 ml of R.O. water and 10 ml of bicarbonate/ 
carbonate buffer before being stored again under bicarbonate buffer for subsequent 
use.
The purified label was then diluted to approximately 5000 cpm/lOOpl for use.
2.4.3. A ssay  m eth o d s
The procedures are outlined in Figs 2.19. - 2.20., with reagents added in the order 
shown. All the assays were carried out on an ice tray. The assay buffer was 0.04 M 
phosphate buffer pH 6.5 containing 0.5 % HSA and 500 KIU/ml aprotinin. The assays 
were conducted in polythene LP3 tubes and all standards, samples and blanks were 
run in duplicate. Tubes containing the bound radioactivity were counted and sample 
concentrations calculated as in Section 2.3.4.
The GIP RIA exhibited negligable cross-reactivity with cholecystokinin, insulin, 
pancreatic polypeptide, glucagon, secretin and vasoactive intestinal polypeptide 
(Morgan et al., 1978). The limit of detection (assay sensitivity) was 16 pmol/L. Inter­
assay CVs (n = 7) at 37, 163 and 363 pmol/L were 21, 8 and 4 % respectively. Intra­
assay CVs (n = 12) at 24, 212 and 327 pmol/L were 14.5, 2.4 and 4.8 % respectively.
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The GLP-l(7 .36)amide assay exhibited negligible crossreactivity with human GIP, 
porcine GIP, GLP-2, glucagon, vasoactive intestinal polypeptide somatostatin, 
secretin and motilin. It was specific for the C-terminal amidated form of GLP-1, 
crossreacting 1 0 0 % with GLP-l(i.3 6 )amide, but less than 0 . 2  % with G L P - l ^  and 
GLP-1 (i.3 7 ).(Elliott et al, 1993). The limit of detection (assay sensitivity) was 8  
pmol/L. Inter-assay CVs (n = 16) at 15, 30 and 34 pmol/L were 17, 14 and 13 % 
respectively. Intra-assay CVs at 10, 19 and 24 pmol/L were 13, 10 and 9 % 
respectively.
2.4.4. GLP-17_36AMIDE a ssa y  sepa r atio n
One major change from the published method was to the separation technique for the 
GLP-l(7_3 6 )amide assay.
Previously, the separation involved a dextran coated charcoal (DCC) method. Due to 
poor duplicate results, high non-specific binding (NSB) and relative technical 
difficulty, it was decided to look for another method. Different methods were assessed 
and compared to results obtained with the DCC technique. Improved duplicates and a 
higher zero standard binding (see Figure 2.18) were achieved with a commercially 
available solid phase donkey anti-rabbit second antibody coated cellulose suspension - 
Sac-Cel (IDS, Washington, England) and this method was used in later assays.
On the final day of the assay, lOOpl Sac-Cel was added to all tubes (except ’totals'). 
The tubes were then vortexed and incubated at 4°C for 1 hour with intermittent
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mixing. The tubes were then centrifuged at 1500 g, 4°C for 10 minutes and then 
aspirated.
Figure 2.18. Graph comparing GLP-1 (j^am ide 1 standard curves with different 
separation methods
Dextran coated charcoal
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Figure 2.19. GIP RADIOIMMUNOASSAY PROTOCOL
Standards of 25, 50, 100, 200, 400 and 800 pmol/L were prepared in assay buffer.
Reagents
M
Total NSB
Standard
Tubes
Zero Standard 
Standard
Sample/
QCNSB
Sample/
QC
DAY 1 
Buffer --- 300 200 100 300 200
GIP
Standard
--- — 100 ---
CSS 100 100 100 --------- ■ —
Sample/
QC
plasma
--- — - --------- --------- 100 100
Antiserum --------- --------- 100 100 --------- 100
Reagents were added in the order shown. All tubes were vortexed and 
incubated for 24 hours at 4°C.
DAY 2 
Label 100 100 100 100 100 100
All tubes were vortexed and incubated for 48 hours at 4°C.
DAY 4 
Normal 
Rabbit 
Serum
--- 50 50 50 50 50
Donkey
anti
Rabbit
Serum
50 50 50 50 50
14% PEG --------- 100 100 100 100 100
All tubes were vortexed and incubated for 4 hours at 4°C. Tubes were 
then centrifuged at 1400 g  for 20 minutes at 4°C. The supernatant was 
_______________________then aspirated.
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Figure 2.20 GLP-1 RADIOIMMUNOASSAY PROTOCOL 
Standards of 5, 10, 20, 40, 80 and 160 pmol/L were prepared in CSS.
Reagents Tubes
M
Total NSB Zero Standard Sample/ Sample/ 
Standard Standard QC NSB QC
PAY 1
Buffer — 200 100 100 200 100
GLP-1 — — — 200 — —
Standard
CSS — 200 200
Sample/ — — — — 200 200
QC 
plasma
Antiserum — — 100 100 — 100
Reagents were added in the order shown. All tubes were then vortexed 
and incubated for 24 hours at 4°C.
DAY 2
Label 100 100 100 100 100 100
All tubes were vortexed and incubated for 48 hours at 4°C.
DAY 4
Donkey — 100 100 100 100 100
anti 
Rabbit Sac 
Cel
All tubes were vortexed and incubated for Ihour at 4°C with 
intermittent mixing. Tubes were then centrifuged at 1500 g  for 10 
____________________ minutes at 4°C. The supernatant was then aspirated.
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2.5. PLASMA GLUCOSE, NON-ESTERIFIED FATTY ACID, 
TRIACYLGLYCEROL AND PARACETAMOL DETERMINATION
Plasma glucose, non-esterified fatty acid (NEFA) and triacylglycerol (TAG) 
concentrations were determined on a Cobas Mira Plus analyser by automated, 
enzymatic, spectrophotometric techniques, using appropriate test kits and calibrators. 
Samples were analysed in singlicate because of the low intra-assay variation. Quality 
controls were used to measure inter-assay variation.
Each test was based on a series of reactions, as described below, which result in the 
formation of a complex. The light absorbance of this complex was then measured at a 
particular wavelength.
2.5.1 P la s m a  G lu c o s e  D e te r m in a t io n
The reactions involved in the determination of plasma glucose are described below: 
hexokinase
D-glucose + ATP ----------- ►- D-glucose-6-phosphate + ADP
glucose-6-phosphate dehydrogenase 
D-glucose-6-phosphate + NAD+ --------- ►  D-gluconate-6-phosphate + NADH + H*
The amount of NADH formed was measured at 340 nm and was proportional to the 
concentration of glucose in the sample. Inter-assay CV (n = 11) was 2.86 % at 4.04 
mmol/L.
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2.5.2 Pl a sm a  NEFA D eter m in atio n
The reactions involved in the determination of plasma NEFA are described below:
acyl-CoA synthetase 
RCOOH + ATP + C o A ----------- ► Acyl-CoA + AMP + PPi
acyl-CoA oxidase 
Acyl CoA + O2 ------ —►2,3-trans-Enoyl-CoA + H2 O2
2 H2 O2  + 3-methyl-N-ethyl-N-(B-hydroxyethyl)-aniline + 4-ammoantipyrine
peroxidase
 ► purple-coloured adduct + 4 H2 O
The absorbance of this adduct was measured at 550 nm and was proportional to the 
amount of NEFA in the sample. Inter-assay CVs at 0.72 and 2.49 mmol/L were 2.46 
and 1.07 % respectively.
2.5.3 P l a sm a  TAG d eterm ina tio n
The reactions involved in the determination of plasma I TAG are described below.
lipoprotein lipase 
TAG----------- ► Glycerol + Fatty acids
glycerol kinase 
Glycerol + ATP ----------- ► Glycerol-3-phosphate + ADP
glycerol phosphate oxidase 
Glycerol-3-phosphate + O2  ------------- ► Dihydroxyacetone phosphate + H2 O2
In the presence of peroxidase, the hydrogen peroxide formed affects the oxidative 
coupling of 4-chlorophenol and 4-aminophenazone to from a red coloured 
quinoneimine derivative. The light absorbance was read at 500 nm and was 
proportional to the TAG concentration in the sample. Inter-assay CV was 4.11 % at 
2.21 mmol/L.
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2.5.4. Plasm a  Pa r a c eta m o l  D eter m in atio n
This was another enzymatic spectrophotometric method. Acetaminophen was 
hydrolysed to 4-aminophenol by a bacterial aryl acylamidase. The 4-aminophenol 
released was then coupled to o-cresol in the presence of ammoniacal cupric sulphate 
to yield a blue indophenol dye. The production of the blue colour was measured at 
615 nm and was directly related to the concentration of paracetamol in the plasma 
sample. The inter-assay C.V. was 0.9 % at 2 mg/L.
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CHAPTER 3.
E n t e r o - P a n c r e a t ic  H o r m o n e  
R e sp o n se s  t o  A c u t e  C ir c u la t in g  
NEFA M o d u la t io n  in  O b e se  a n d  
L e a n  S u b je c ts .
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3.1. INTRODUCTION
Ranganath et al. (1996) have shown that postprandial GLP-l(7 _3 6 )amide secretion was 
attenuated in obese women following an oral carbohydrate load compared with 
matched lean subjects. The same study also demonstrated that GLP-l(7„3 6 )amide levels 
declined following intravenous heparin administration in both obese and lean 
subjects. The authors postulated that this was due to increased circulating NEFA 
levels, following heparin, and in obesity suppressing G E P-l^^am ide levels.
Hydrolysis of stored lipid in adipose tissue results in release of NEFA into the 
circulation (Frayn, 1996). Several hormones have been shown to influence lipolysis 
including GEP-l^.3 ^amide and GIP which have been reported to increase the 
hydrolysis of TAG and insulin (Hauner et a l, 1988; Ruiz-Grande et a l, 1992) which 
reduces lipolysis by inhibition of hormone-sensitive lipase (Miles and Jensen, 1993).
Studies on the effects of NEFA on insulin secretion have shown conflicting results. 
Some have demonstrated an inhibitory effect of NEFA on insulin secretion (Zhou and 
Grill, 1994), whilst others have indicated that NEFA inhibit the binding and 
degradation of insulin by hepatocytes, leading to an increase in circulating insulin 
(Svedberg et a l, 1991).
GLP-l(7.3 6 )amide has been suggested as an important physiological incretin hormone
(0rskov et a l, 1993) (see Chapter 1.3.1). Other important metabolic and endocrine
effects of GLP-l(7 -3 6 )amide include increasing glucose disposal, reducing glucagon
secretion and its subsequent effects on hepatic gluconeogenesis and somewhat
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contradictory effects on fat metabolism, where GLP-l(7 .3 6 )amide has been shown to 
increase both fatty acid synthesis and lipolysis (see Chapter 1.3.3).
A characteristic feature of obesity is insulin resistance. Insulin normally suppresses 
adipose tissue lipolysis by inhibiting hormone-sensitive lipase, thus resistance to the 
effects of insulin may lead to an elevation of NEFA, as has been found (Kashwagi et 
al., 1983). Obese subjects also have impaired postprandial suppression of NEFA 
levels (Golay et al., 1986).
Circulating NEFA can affect glucose levels by competition for the glucose-fatty acid 
cycle (see Chapter 1.6.1.). This may be of relatively greater importance in obese 
subjects then lean, because the former have elevated NEFA levels, possibly 
contributing to the peripheral insulin resistance seen in this group (Girard, 1995). 
Higher circulating NEFA levels in the obese may also drive the liver to increased lipid 
oxidation and subsequent gluconeogenesis (Ferrannini and Groop, 1989). This does 
not appear to apply in the fasting state, where Fery et al. (1996) have suggested that 
NEFA and ketone bodies suppress gluconeogenesis.
As stated in the first paragraph of this chapter, it is thought that circulating NEFA 
levels may have a role in regulating GEF-l^.^amide levels. Modulation of NEFA 
levels has been undertaken by other workers using heparin or acipimox, to increase 
and decrease respectively, circulating NEFA.
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Heparin is widely used in clinical practice as an anticoagulant (Hirsch, 1991). Heparin 
strips the enzyme lipoprotein lipase from the capillary endothelium, making it more 
readily available to hydrolyse circulating triacylglycerol, resulting in elevation of 
NEFA levels (Rubegni et ah, 1974).
Acipimox is a nicotinic acid derivative used in the treatment of hyperlipidaemias to 
lower both TAG and cholesterol levels. It has been shown to improve glucose 
tolerance, glucose oxidation and non-oxidative glycolysis in lean non-insulin- 
dependent diabetics (Piatti et al., 1996).
Acipimox acts mainly by inhibiting adipose tissue lipolysis, reducing the availability 
of NEFA to the liver for production of very low density lipoproteins (VLDL). Unlike 
nicotinic acid itself, it does not appear to induce lipoprotein lipase (source: British 
National Formulary, 1996). Christie et al. (1996) showed in isolated rat adipocytes 
that the anti-lipolytic action of acipimox is mediated through suppression of 
intracellular cyclic AMP, with subsequent decrease in cyclic AMP-dependent protein 
kinase activity. This leads to a reduced association of hormone-sensitive lipase with 
TAG. Acipimox has also been shown to increase VLDL-TAG clearance in 
hypertriglyceridaemic monkeys (Hannah et ah, 1995).
The aims of this study were two-fold:
♦ To investigate whether circulating NEFA levels modulate glucose-stimulated 
GLP-l(7 -3 6 )amide concentrations and to examine any consequent effects on plasma 
glucose and insulin levels.
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♦ To investigate whether obese and lean subjects respond differently to NEFA 
modulation, in view of the previously shown attenuated ClEF-l^.^amide response 
to carbohydrate in the obese.
This was accomplished by comparing the responses to a standard 100 g oral glucose 
tolerance test (GTT) with i) the responses to intravenous administration of heparin 
simultaneously with oral carbohydrate to acutely increase circulating NEFA levels 
and ii) acipimox prior to oral carbohydrate to decrease circulating NEFA levels. 
Heparin and acipimox were given at different times relative to the oral carbohydrate 
because of their different rates of action. Heparin is administered directly into the 
circulation, having an immediate effect and being cleared rapidly (t% = 60 mins), 
whereas peak concentrations of acipimox following oral administration are not 
reached until about two hours post-dose.
3.2. STUDY DESIGN
This study was conducted in collaboration with Dr L. Ranganath at Epsom General 
Hospital, Epsom, Surrey. Ethical committee approval was obtained from the Epsom 
Health Care District Medical Ethics Committee. All subjects gave written consent 
before participating in the study.
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3.2.1. S ubjec ts
Women over the age of 18 were recruited were recruited from the Chemical 
Pathology Outpatient clinics and staff at Epsom General Hospital. They were divided 
into two groups on the basis of their BMI:
Group 1: Obese women: BMI > 30 kg/m2 (n = 7).
Group 2: Lean control women: BMI < 25 kg/m2 (n = 7).
The mean ± S.E.M. (and range) age of the obese and control subjects was 40 ± 2.0 (25 
- 53) years and 40 ± 3.3 (28 - 55) years respectively. The mean ± S.E.M. (and range) 
BMI of the obese and control groups was 39.6 ± 2.0 (31.5 - 48) kg/m2 and 22.5 ± 0.2 
(21.7 - 23.3) kg/m2 respectively.
Exclusion criteria for the study included thyroid disease, renal impairment, hepatic 
dysfunction, personal or family history (first-degree relative) of diabetes mellitus, 
alcohol consumption > 20 units per week, and subjects receiving medication. Subjects 
had not altered their diet or changed weight in the previous month.
3.2.2. M eth o d s
Subjects each attended the hospital on three occasions, separated by at least seven 
days, for the three different treatments, in random order. The three treatments were:
♦ 100g oral glucose tolerance test, henceforth known as “GTT”
♦ 100g oral glucose tolerance test and an intravenous heparin bolus, henceforth 
known as “heparin”
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♦ 100g oral glucose tolerance test preceded by an oral dose of acipimox, henceforth 
known as “acipimox”.
On each of the treatment days, following an overnight fast, an indwelling cannula was 
inserted into an antecubital vein in the forearm and two baseline blood samples were 
collected before a 100 g glucose load was given orally. The glucose load consisted of 
155 ml Hycal™ diluted to 300 ml with water. Blood samples were then taken every 15 
minutes until 120 minutes following the carbohydrate administration. For the heparin 
treatment, an intravenous bolus of 10,000 units of heparin in 10 ml saline was 
administered at t = 0 mins, just prior to the Hycal™ administration. For the acipimox 
treatment, 500 mg of acipimox was given orally two hours before the Hycal™ 
administration.
Each blood collection consisted of 2 ml for glucose (into a fluoride oxalate tube), 3ml 
for NEFA and TAG (into a plain glass tube with no additives) and 10 ml for GLP-1(7. 
3 6 )amide, GIF, insulin, proinsulin and C-peptide (into a lithium heparin tube with 
100KIU/ml blood of Aprotinin). Blood for glucose and hormones was centrifuged at 
1850 g for 10 minutes immediately after collection and the plasma separated, 
aliquoted and frozen at -20°C until analysis. TAG and NEFA levels were measured on 
serum samples, in which the blood had been allowed to clot, the serum removed and 
then centrifuged and stored as for the plasma.
Glucose, TAG and NEFA measurements were conducted by the Department of 
Clinical Biochemistry at Epsom General Hospital as described in Chapter 2. Plasma
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hormones were measured by radioimmunoassay using the methods described in 
Chapter 2.
3.2.3. S ta t ist ic a l  A nalysis
The data is expressed as mean ± standard error of the mean (mean ± S.E.M.) unless 
otherwise stated, in both tables and graphs. P values of < 0.05 were taken as 
statistically significant. To facilitate statistical analysis, hormone levels below the 
sensitivity of the assay were assigned a value equal to the limit of detection of the 
assay.
Total integrated and incremental responses (area under the curve), TAUC and IAUC 
respectively were calculated using the trapezoidal rule. Integrated responses were also 
calculated on each hour of the study (0-60 and 60-120 mins). Incremental responses 
were calculated as total integrated response minus the zero value multiplied by the 
duration of the study period.
Differences between the three treatments were calculated using a repeated measures 
analysis of variance (ANOVA) with one within and no between factors, followed by a 
Bonferroni Multiple Comparisons Test if significant differences were found. If the 
matching was not effective (F -  test) between columns (treatments), a one-way 
ANOVA was performed on the data followed by a Bonferroni Multiple Comparisons 
Test if appropriate. Obese and control subjects were analysed separately.
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Comparisons between obese and control subjects for each treatment were made using 
a one-way ANOVA followed by a Bonferroni Multiple Comparisons Test if 
significant differences were found. Bartlett’s test was used to determine whether the 
data exhibited homogeneity of variance. Appropriate transformation of the data was 
performed if necessary (log, reciprocal or square root) to satisfy the assumptions of 
analysis of variance.
3.3. RESULTS
3.3.1. S u bje c t  D em o g ra ph ic s
There was no significant difference between the obese and control groups for age. 
BMI was significantly greater in the obese than in the control group (P < 0.0001).
3.3.2. NEFA
The NEFA responses of the obese and control subject groups to the GTT, heparin and 
acipimox treatments are shown in Table 3.1. and illustrated graphically in Figs. 3.1a. 
and 3.1b. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 3.1. NEFA responses of obese and control subjects to GTT, heparin and
acipimox treatments, n = 7 (mean ±S.E.M.)
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting NEFA 
(mmol/L)
0.58 ±  0.02* 0.46 ±  0.09b 0.04 ±  0.03a,b 0.72 ±  0.05e 0.62 ±  0.08f 0.09 ±  0.06ef
Integrated 
NEFA (TAUC) 
(mmol/L.min)
23 ± 5 .7 63 ±  18e'1 3.3 ±  3.0e 42 ± 5 .5 144 ±  32g,i 8.8 ± 6.4s
Incremental 
NEFA (IAUC) 
(mmol/L.min)
-36 ± 11 8.0 ±  23J -1.2 ± 0 .70 -44 ±  6.3h 69 ±  26hj -2.2 ± 1 .7
Integrated 
NEFA (0-60) 
(mmol/L.min)
17 ± 3 .5 46 ±  12d 1.9 ±  1.8d 33 ±  3.2 100 ±  20k 4.8 ±  3.4"
Integrated 
NEFA (60-120) 
(mmol/L.min)
6.2 ± 3 .0 16 ± 7 .0 1.4 ± 1 .3 9.9 ± 4 .0 44 ±  131 4.0 ±3.1'
D’c P < 0.05
a,c,h,i,l p <  o .O l
d,e,f,g,k p <  0.001
Obese subjects had significantly elevated fasting NEFA levels compared with control 
subjects (P < 0.0001), but the post-hoc test could not detect which particular 
treatments) this applied to. Fasting NEFA levels were significantly depressed 
following acipimox treatment compared with fasting levels pre-GTT and pre-heparin 
in both the obese (P < 0.001) and control (acipimox vs GTT: P < 0.01; acipimox vs 
heparin P < 0.05).
Following the GTT, NEFA levels declined in both obese and control subjects to a 
nadir at approximately 60 mins. Following heparin treatment, NEFA levels rose 
sharply in both groups to a peak at 15 mins, before returning to fasting levels by the 
end of the test period. The total integrated NEFA response was significantly greater in 
the obese group compared with the control subjects (P < 0.01). Acipimox was 
administered to both groups and had taken effect, before blood sampling began.
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Figure 3.1a. NEFA responses in obese subjects, n=7
(mean ± S.E.M.)
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Figure 3.1b. NEFA responses in control subjects, n = 7 
(mean ± S.E.M.)
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Consequently, NEFA levels in both subject groups remained suppressed below 
normal fasting concentrations throughout the test period.
A comparison of the three treatments showed that heparin administration produced an 
increase in circulating NEFA levels (integrated and incremental) compared to the 
response following a GTT, in both obese and control subjects, however the 
differences between GTT and heparin treatments were not significant. NEFA 
responses following acipimox were suppressed in both obese and control groups 
relative to the responses following a GTT, but were not significantly different from 
the GTT. The total integrated NEFA responses following heparin were significantly 
greater than following acipimox in both obese and control subjects (obese: P < 0.001; 
control: P < 0.01). When the test period was divided into two hour-long intervals, the 
NEFA response was significantly greater, following heparin than acipimox, in both 
subject groups for the first hour (P < 0.001), but only in the obese group for the 
second hour (P < 0.01).
3.3.3. TAG
The TAG responses of the obese and control subject groups to the GTT, heparin and 
acipimox treatments are shown in Table 3.2. and illustrated graphically in Figs. 3.2a. 
and 3.2b. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 3.2. TAG responses of obese and control subjects to GTT, heparin and
acipimox treatments, n = 7 (mean ± S.E.M.)
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting TAG 
(mmol/L)
1.0 ±0 .26 1.1 ±0.19 0.69 ±  0.09* 2.0 ± 0 .50 1.8 ± 0 .39 1.8 ±0.4*
Integrated TAG 
(TAUC) 
(mmol/L.min)
114 ±  31» 64 ±  12a,J 85 ±  14k 235 ±  59d 147 ±  34d,e’j 219 ±  50ek
Incremental 
TAG (IAUC) 
(mmol/L.min)
-9.0 ± 3 .8 -45 ± 1 7 1.7 ± 3 .8 -3.8 ± 2 .7 -69 ±  14 6.7 ± 9 .8
Integrated TAG 
(0-60) 
(mmol/L.min)
59 ±  15b 39 ± 7 b 4 3 ± 7 1 117 ±  29f 81 ±  19f 104 ±  231
Integrated TAG 
(60-120) 
(mmol/L.min)
55 ±  16c'm 26 ±  5c,n 42 ± 7° 1 1 9 ± 3 0 8’m 65 ±  158’h,n 115 ±  28h’°
a,b,c,e,f.h,i,j,k,l,m,n,o p
dg p  < o.oi
Mean fasting TAG levels were higher in the obese group than in the lean control 
subjects, but the only significant difference between groups was following acipimox 
treatment (P < 0.05).
TAG levels remained fairly constant during the GTT in both obese and control 
subjects. Following acipimox, in obese subjects, TAG levels decreased to a nadir at 
30 mins and then returned to fasting levels by the end of the test period. In control 
subjects, TAG levels decreased slightly to a nadir at 15 mins, returned to fasting 
levels, remaining less than the response following the GTT alone and then decreased 
again at the end of the study. Following heparin, the TAG response decreased in both 
subject groups and stayed less than both other treatments for the remainder of the 
study.
99
Figure 3.2a. TAG responses in obese subjects, n = 7
(mean ± S.E.M.)
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Figure 3.2b. TAG responses in control subjects, n = 7 
(mean ± S.E.M.)
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The integrated TAG response was greater in obese than in control subjects for all 
three treatments, but was only significantly different following acipimox and heparin 
treatments (P < 0.05).
Comparison of the three treatments in the obese subject group, showed a significantly 
reduced total integrated TAG response following both heparin (P < 0.01) and 
acipimox (P < 0.05) compared to the response following the GTT alone. The pattern 
was similar in the control subjects, although only the TAG response to heparin 
treatment was significantly less than the GTT (P < 0.05). Division of the test period 
into two hour-long intervals again reflected these differences with the integrated 
responses being significantly less following heparin than the GTT in both the obese 
and control subjects for the first (P < 0.05) and second hours (obese: P  < 0.01; control 
P  < 0.05) of the study. Heparin treatment also produced a significantly reduced 
response compared with acipimox in the obese subjects for the second hour of the 
study (P < 0.05).
3.3.4. GLP-1(7.36)AMIDE
The GLP-1 responses of the obese and control subject groups to the GTT, heparin and 
acipimox treatments are shown in Table 3.3. and illustrated graphically in Figs. 3.3a. 
and 3.3b. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 3.3. GLP-1 (j^amide responses of obese and control subjects to GTT, heparin
and acipimox treatments, n = 7 (mean ± S.E.M.)
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting GLP-1 
(pmol/L)
12 ± 3 11 ± 2 .5 11 + 1.0 9.4 ± 1 .0 10 ± 1 .5 8.4 ± 0 .4
Integrated 
GLP-1 (TAUC) 
(pmol/L.min)
2212 + 372» 2004± 3 3 6 b 3356 ±  373a’b,i 2031 ±228 1349 ±  233 2201 ±299'
Incremental 
GLP-1 (IAUC) 
(pmol/L.min)
763 ± 3 5 3 c 7 1 0 ± 3 6 5 d 2079±  316c,d 908 ± 162 149 ±  330s 1189± 2 9 0 s
Integrated 
GLP-1 (0-60) 
(pmol/L.min)
1167 + 225 9 0 8 ± 201 1608 ±  258 1179 ± 198 765 ±217 1249 ± 248
Integrated 
GLP-1 (60-120) 
(pmol/L.min)
1044 ±  194* 1096 ± 204% 1747 + 256e,f’k 8 5 2 ± 125 583 ±  63hJ 951 ±  162h,k
a,b,e,f,g,h,i,j p  < q
c'dk p  <  o . o i
Fasting GLP-1 (7 .3 6)amide levels were similar between subject groups and treatments.
Following each of the three treatments, in both obese and control subjects, mean 
GLP-1 (7 -3 6 )amide levels rose to a peak at 30 mins in each group/treatment except the 
control group following heparin treatment, which peaked at 45 mins. G L P-l^^am ide 
levels then returned to near fasting in the obese group, but in the control group, 
following acipimox treatment, GLP-1 (7_36)amide levels remained significantly raised.
Total integrated G L P-l^^am ide responses to each of the treatments were greater in 
control subjects than in the obese group. There was a significant difference between 
obese and control subjects following acipimox treatment (P < 0.05). When the test 
period was divided into two hour-long intervals, there was a trend for the control 
subjects to show a greater GLP-1 (7 .36 )amide response than ^bese subjects in the first
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Figure 3.3a. GLP-1 responses in obese subjects, n = 7
(mean ± S.E.M.)
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Figure 3.3b. GLP-1 responses in control subjects, n = 7 
(mean ± S.E.M.)
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hour (P < 0.1) and significant differences in the second hour (control vs obese: 
heparin treatment, P  < 0.05; acipimox treatment: P < 0.01).
Comparison of the three treatments in the obese group showed them exhibiting a 
similar GLP-1 (7 -3 6 )amide response to the GTT and acipimox treatments, with a 
relatively suppressed response following heparin treatment (incremental GLP-1 (7. 
3 6 )amide: heparin vs acipimox: P  < 0.05).
The pattern of GLP-l^.^amide response was different in control subjects, with the 
acipimox treatment clearly eliciting the greatest GLP-l^.^am ide response compared 
to the other two treatments (integrated and incremental responses: P  < 0.05) and a 
trend for heparin to produce the least response, although not significantly less than the 
GTT alone. The main differences were in the latter half of the study, with the 
integrated area for 60-120 mins being significantly greater following acipimox than 
the other two treatments (P < 0.05), but not significant from 0-60 mins, although there 
was a trend.
3.3.5. GIP
The GIP responses of the obese and control subject groups to the GTT, heparin and 
acipimox treatments are shown in Table 3.4. and illustrated graphically in Figs. 3.4a. 
and 3.4b. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 3.4. GIP responses of obese and control subjects to GTT, heparin and acipimox
treatments, n = 7 (mean ±S.E.M.)
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting GIP 
(pmol/L)
26 ±11 26 ±11 27 ±12 < i5 ; ; < i5  ! < 15
Integrated 
GIP (TAUC) 
(pmol/L.min)
11509 ±1993 12552 ±2016 12351 ±2360 13616 ±1447 14817 ±1320 12456 ±1497
Incremental 
GIP (IAUC) 
(pmol/L.min)
8355 ± 1770 9449 ± 1589 9085 ±1825 11816 ±1447 13017 ±1320 10656 ± 1497
Integrated 
GIP (0-60) 
(pmol/L.min)
5071± 1063 5392 ±1191 5332 ±1292 6110±818 6859 ± 888" 5288 ±821"
Integrated 
GIP (60-120) 
(pmol/L.min)
6434 ±1077 7159 ±972 7019 ±1182 7505 ±754 7958 ±650 7169 ±785
a P < 0.05
Fasting GIP concentrations were below the limit of detection of the assay for all the 
obese subjects and all but one of the control subjects.
Following each of the three treatments, GIP levels rose sharply in the first 15 - 30 
mins and then more slowly in both subject groups. GIP levels in the obese group 
appeared to be declining at the end of the study, and plateauing in the control group, 
but were still much greater than basal levels. There was a trend for increased total
integrated and incremental responses in the obese group compared with the lean 
group, but none were significantly different.
Comparison of the three treatments in the obese group showed the heparin treatment 
eliciting the sharpest rise and highest peak of GIP and acipimox the least. However, 
the GIP levels following all three treatments were similar towards the end of the 
study. This was reflected in a trend rather than significant differences in the total
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Figure 3.4a. GIP responses in obese subjects, n -  7
(mean ± S.E.M.)
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Figure 3.4b. GIP responses in control subjects, n = 7 
(mean ± S.E.M.)
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integrated and incremental GIP responses. The total integrated response for the first 
hour of the study was significantly greater following heparin than acipimox (P < 
0.05).
The responses to all three treatments in the control group were very similar to each 
other.
3.3.6. Glu c o se
The glucose responses of the obese and control subject groups to the GTT, heparin 
and acipimox treatments are shown in Table 3.5. and illustrated graphically in Figs. 
3.5a. and 3.5b. Values in the table with the same superscript small case letter are 
significantly different from each other.
Table 3.5. Glucose responses o f obese and control subjects to GTT, heparin and 
acipimox treatments, n = 7 (mean ±  S.E.M.) ____________
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting glucose 
(mmol/L)
5.3 ± 0 .22 5.1 ±0.24 5.1 ±0.17 5.6 ±  0.26 5.6 ± 0 .18 5.6 ± 0 .22
Integrated glucose 
(TAUC) 
(mmol/L.min)
717 ± 4 9 d 706 ±  38e 680 ± 4 7 964 ±  60d 1060 ± 9 1 e 874 ± 7 3
Incremental glucose 
(IAUC) 
(mmol/L.min)
81 + 31 182 ± 8 3 70 ± 3 5 286 ±  64 382 ± 8 6 202 ±  64
Integrated glucose 
(0-60) 
(mmol/L.min)
390 ± 2 9 387 ±  27f 375 ± 2 6 477 ± 1 5 508 ±  32^ 444 ±  29a
Integrated glucose 
(60-120) 
(mmol/L.min)
3 2 6 ± 23g 318 ±  l l h 305 ±21* 473 ±  48b,s 552 ±  65b,c’h 429 ±  49c,i
a.b.ig.i P < 0.05 
cfP<0.01 
ehP <  0.001
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Fasting glucose levels were slightly higher in obese subjects than controls, but not 
significantly different. There was no difference in fasting glucose levels between 
treatments.
In the obese subjects, glucose levels reached a peak at 45 mins following GTT and 
acipimox treatments and at 60 mins following heparin before decreasing. They had 
not returned to fasting levels by the end of the study period. The peak in control 
subjects was less distinct, occurring earlier than the obese subjects at 15 - 45 mins and 
the excursion in glucose levels from fasting was less. Obese subjects had a 
significantly greater total integrated response to the GTT (P < 0.05) and heparin (P < 
0.01) treatments than control subjects. This was also shown when the test period was 
divided into two hour long intervals. In the first hour, the obese group had a 
significantly greater total integrated glucose response following heparin than control 
subjects (P < 0.01). In the second hour, the obese group had significantly greater total 
integrated glucose responses for all three treatments compared with control subjects 
(heparin: P < 0.01; GTT and acipimox: P < 0.05).
Comparison of the three treatments in obese subjects showed a trend for the greatest 
total integrated glucose response following heparin and the least following acipimox, 
with the GTT response in-between. The differences were not significant. When the 
responses curves were divided into two hour-long periods, heparin produced a 
significantly greater response than acipimox in both the first (P < 0.05) and second (P 
< 0.01) hours in obese subjects. The heparin response was also significantly greater 
than the GTT response in the second hour (P < 0.05).
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Figure 3.5a. Glucose responses in obese subjects, n = 7
(mean ± S.E.M.)
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Figure 3.5b. Glucose responses in control subjects, n = 7 
(mean ± S.E.M.)
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The glucose responses to the three treatments in the control group were almost super­
imposable on each other.
3.3.7. In su l in
The insulin responses of the obese and control subject groups to the GTT, heparin and 
acipimox treatments are shown in Table 3.6. and illustrated graphically in Figs. 3.6a. 
and 3.6b. Values in the table with the same superscript small case letter are 
significantly different from each other
Table 3.6. Insulin responses o f obese and control subjects to GTT, heparin and 
acipimox treatments, n = 7 (mean ±  S.E.M.)___________________________________
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting insulin 
(pmol/L)
43 ± 8.2b 41+4.8= 38 ±6.2" 151 ±32" 163 ±33= 125 ±22"
Integrated 
insulin (TAUC) 
(pmol/L.min)
29930± 2565e 33329 ±4641f 28830 ±3408g 81211 ±14826= 81083 ± 15599' 62373± 8386*
Incremental 
insulin (IAUC) 
(pmol/L.min)
24788± 1909" 28439 ± 4364' 24301 ± 3061J 63133 ±11191" 61558 ± 12544' 47390± 653P
Integrated 
insulin (0-60) 
(pmol/L.min)
15518 + 2258" 15336+ 24251 15655 ±2456 31040±4819a,k 29780 ±59621 25843 ±4663"
Integrated 
insulin (60-120) 
(pmol/L.min)
14413 + 2459"' 17993 ±3435" 13176 ±2175° 50171 ±11728 51303 ± 11733" 36530 ±6256°
a’J>i P < 0.05
b,g,h,i,k,o p  < 0.01
c,d,e,f,m,n p <  Q QQl
Fasting insulin levels were significantly greater in the obese group than in control 
subjects (P < 0.001).
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Following each of the three treatments, insulin levels rose to a higher peak in obese 
subjects than controls. The peak also occurred later in obese subjects than controls (at 
t = 75 - 90 minutes and 30 - 45 mins respectively). Insulin levels had not returned to 
fasting by the end of the study period. Obese subjects exhibited statistically 
significant greater total integrated and incremental insulin responses to the three 
treatments compared with the control subjects (integrated: GTT and heparin 
treatments P < 0.001, acipimox P < 0.01; incremental: GTT and heparin treatments P 
< 0.01, acipimox P < 0.05). Obese subjects did not produce significantly more insulin 
than control subjects in the first hour of the study, but there was a trend for this. 
Obese subjects did have significantly greater total integrated responses than control 
subjects following both the GTT {P < 0.01) and heparin (P < 0.05) treatments in the 
first hour and more for all three treatments in the second hour (GTT and heparin 
treatments P < 0.001; acipimox treatment P < 0.01).
Comparison of the three treatments on the obese subjects showed a trend for acipimox 
to produce a lesser insulin response than the other two treatments, but this was only 
significantly different in the first hour of the study for the GTT vs acipimox 
treatments (P < 0.05).
There were no significant differences between the three treatments for the control 
group, although there was a trend for a more sustained rise in insulin following the 
heparin treatment.
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Figure 3.6a. Insulin responses in obese subjects, n = 7
(mean ± S.E.M.)
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Figure 3.6b. Insulin responses in control subjects, n = 7 
(mean ± S.E.M.)
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3.3.8. Pr o in su l in
The proinsulin responses of the obese and control subject groups to the GTT, heparin 
and acipimox treatments are shown in Table 3.7. and illustrated graphically in Figs. 
3.7a. and 3.7b. Values in the table with the same superscript small case letter are 
significantly different from each other.
Table 3.7. Proinsulin responses o f obese and control subjects to GTT, heparin and 
acipimox treatments, n = 7 (mean ±S.E.M.)_____ _____________________
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting proinsulin 
(pmol/L)
18 ±3.9 14 ±4.6 13 ±1.9 18 ±3.6 22 ±3.3 24 ±2.3
Integrated 
proinsulin (TAUC) 
(pmol/L.min)
2810 ±460b 2722 ±434= 2118 ±285d 4784 ±568" 5472 ±736= 4360 ± 325d
Incremental 
proinsulin (IAUC) 
(pmol/L.min)
668 ±190e 1085 ±330» 566 ±171» 2599 ±406= 2798 ± 664 1531 ±302
Integrated 
proinsulin (0-60) 
(pmol/L.min)
1299 ±285 975 ± 214f 944 ±134 1718 ±223 2041 ±314f 1755 ±203
Integrated 
proinsulin (60-120) 
(pmol/L.min)
1562 ±2322 1748 ±298h 1173 ±177' 3271 ± 5 19s 3431 ±510" 2706 ± 349'
a,b,e P < 0.05
c,d,f,g,h,i p  <  0 .0 1
Fasting proinsulin levels were similar between obese and control subjects and for each 
treatment.
In obese subjects, following all three treatments, proinsulin levels rose gradually and 
peaked near the end of the study. In control subjects, proinsulin levels remained 
relatively constant following the GTT and acipimox treatments, although heparin 
appeared to produce a gradual rise and late peak, but with only half the amplitude 
seen in obese subjects. Obese subjects produced a significantly greater total integrated 
response than control subjects following all three treatments (GTT: P < 0.05; heparin
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Figure 3.7a. Proinsulin responses in obese subjects, n = 7
(mean ± S.E.M.)
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Figure 3.7b. Proinsulin responses in control subjects, n = 7 
(mean ± S.E.M.)
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and acipimox: P < 0.01). The only significant difference in the first hour of the study 
between obese and control subjects was following heparin treatment (P < 0.01). All 
three treatments produced a significantly greater proinsulin response in obese subjects 
in the second hour of the study (P < 0.01).
Comparison of the three treatments on obese subjects showed a non-significant trend 
for heparin to induce the greatest proinsulin response and acipimox the least. In 
control subjects, the total integrated proinsulin response was similar following the 
GTT and heparin treatments, but there was a significant difference between heparin 
and acipimox treatments for the integrated proinsulin response in the second hour of 
the study.
3.3.9. C-PEPTIDE
The C-peptide responses of the obese and control subject groups to the GTT, heparin 
and acipimox treatments are shown in Table 3.8. and illustrated graphically in Figs. 
3.8a. and 3.8b.
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Table 3.8. C-peptide responses o f obese and control subjects to GTT, heparin and
acipimox treatments, n = 7 (mean +S.E.M.)
CONTROL OBESE
GTT HEPARIN ACIPIMOX GTT HEPARIN ACIPIMOX
Fasting C-peptide 
(pmol/L)
327 ±65 286 ±52 293 ±50 415 ±67 410±91 362 ±97
Integrated 
C-peptide (TAUC) 
(pmol/L.min)
106218 ± 22521 106548 ± 23032 98547 ±16182 125334 ±30256 103639 ± 30758 91701 ±24834
Incremental 
C-peptide (IAUC) 
(pmol/L.min)
66978 ± 15842 72202 ±18790 63413 ± 12440 75500 ±25420 54456 ±23625 48296 ±17621
Integrated 
C-peptide (0-60) 
(pmol/L.min)
50470 ±12135 42546 ±10144 46526 ±8484 48353 ±12671 36902 ±10282 37268 ±10179
Integrated 
C-peptide (60-120) 
(pmol/L.min)
55747 ±12807 64000 ±13920 52021 ±9803 76981 ±21487 66737 ±21240 54432 ±16195
Fasting C-peptide levels were similar between obese and control subjects, although 
there was a trend for obese subjects to be higher.
Following each treatment, C-peptide levels rose to a peak at 60 - 90 mins and had not 
returned to fasting by the end of the study. There were no significant differences 
between obese and control subjects following any of the treatments.
Comparison of the three treatments on the obese subjects showed a trend for the GTT 
to induce the greatest C-peptide response and acipimox the least, but the differences 
were not significant. The control group did not exhibit any differences between each 
of the three treatments.
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Figure 3.8a. C-peptide responses in obese subjects, n = 7
(mean ±S.E.M.)
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Figure 3.8b. C-peptide responses in control subjects, n = 7 
(mean ± S. E.M.)
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3.4. DISCUSSION
This study confirms previous reports (Golay et al., 1986). that obese subjects have 
higher fasting and postprandial NEFA levels than lean subjects. These higher levels 
could be due to increased adipose tissue lipolysis caused by resistance of the 
adipocytes to the inhibitory effects of insulin on hormone-sensitive lipase. However, 
some investigators have suggested that the rate of lipolysis is normal (Jansson et a l, 
1992) or reduced (Campbell et ah, 1994) in obese subjects and that the increased 
NEFA levels seen are simply due to an increased fat mass.
The use of heparin and acipimox had the predicted effects on modulation of NEFA 
levels in both obese and control subjects, permitting analysis of the remainder of the 
results with respect to the effects of NEFA modulation. There was a significant 
difference between the elevated integrated NEFA levels produced by heparin and the 
suppressed integrated NEFA levels produced by acipimox in both the obese and 
control subjects. Neither the heparin nor the acipimox treatments produced a NEFA 
response that was significantly different from that elicited by a GTT alone.
The integrated NEFA response following the heparin treatment was significantly 
greater in obese subjects than in controls. This may be due to the obese subjects 
having higher concentrations of circulating TAG levels for the heparin-releasable LPL 
to act upon, thus producing greater NEFA levels in the circulation.
The acipimox treatment caused almost total suppression of NEFA levels in both obese
and control subjects. This was due to a combination of reduced adipose tissue
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lipolysis by the acipimox and the effects of increased levels of insulin following oral 
carbohydrate.
This study confirmed the earlier study by Ranganath et al. (1996), that obese subjects 
have an attenuated GEP-l^.^am ide response to oral carbohydrate compared with 
lean control subjects. The total integrated response was only significantly different 
following acipimox, but there was a trend with the other two treatments to follow the 
same pattern. The difference appeared more pronounced in the latter half of the study, 
when a significant difference was found between obese and control subjects for both 
the heparin and acipimox treatments.
This study clearly demonstrated that modulation of circulating NEFA levels by 
heparin and acipimox produces differences in GEF-l^.^amide levels in both obese 
and control subjects.
Circulating insulin responses did not reflect alterations in GEF-l^.^am ide in both 
obese and control subjects, which might have been expected given the incretin role of 
GLP-l(7 -3 6 )amide. Fukase et al. (1993) suggested that high insulin levels may have a 
negative feedback effect on GEP-l^.^amide, as has also been shown with GIP 
(Creutzfeldt et al., 1978 ; Fukase et al., 1993). The obese subjects in this study
exhibited hyperinsulinaemia and there was a suggestion of lower insulin levels 
following acipimox with higher GEP-l^.^amide and the converse following heparin, 
but no significant differences. The insulin response following the GTT in obese 
subjects was similar to that following heparin, but the G EP-l^.^am ide response was
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doser to that following acipimox, giving no clear evidence for a negative feedback 
action of hyperinsulinaemia. The control group, who exhibited greater differences in 
GLP-l(7 -3 6 )amide than obese subjects, had significantly lower insulin levels than the 
obese, again not supporting the theory of feedback inhibition of insulin on GLP-1(7. 
3 6 )amide.
Acipimox appeared to suppress NEFA levels to a similar level in both obese and 
control subjects, however GEP-l^.3 ^amide levels remained lower in the obese group, 
suggesting that the reduced G E P-l^^am ide is an intrinsic defect of obesity rather 
than purely due to the increased NEFA levels seen in this group. Another possibility 
is that NEFA levels were not suppressed for a long enough period to allow GLP-1(7. 
3 6 )amide levels to increase to that seen in control subjects.
There was a trend for GDP levels to be higher in obese subjects than in controls (P < 
0.1). This was consistent with increased GIP levels reported in obesity by some, but 
not all investigators (Service et a l, 1984; Sirinek et a l, 1986). The obese subjects 
were also hyperinsulinaemic, and so these data do not support the theory of a negative 
feedback of insulin on glucose-stimulated GIP secretion (Fukase et a l,  1993). GIP 
secretion was significantly lower following acipimox than heparin, in the first hour of 
the study, in obese subjects. The converse was true for GLP-l(7_3 6)amide secretion 
(although not significant). This does not support the theory of an enteroendocrine loop 
and GIP stimulating GLP-l(7.3 6)amide secretion (Roberge and Brubaker, 1993), where 
one would expect GIP and GLP-l(7.36)amide to increase together. Nauck et a l  (1993),
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however, found that GLP-l(7 .3 6 )amide levels did not increase when GIP was infused at 
physiological concentrations.
Obese subjects had slightly higher fasting glucose levels and significantly higher 
integrated responses following both the GTT and heparin treatments than control 
subjects. Heparin increases NEFA levels providing more fuel to act as substrate for 
the glucose-fatty acid cycle and enhancing resistance to insulin-stimulated glucose 
uptake. GLP-l(7.3 6 )amide levels were also reduced following heparin, lessening its 
glucose-lowering effects. Acipimox reduces circulating NEFA levels, having an 
opposite effect on the glucose-fatty acid cycle. This in combination with increased 
GLP-l(7 _3 6 )amide could help explain why glucose levels were not significantly raised 
in obese subjects compared with controls following acipimox.
Glucose tolerance was improved in obese subjects following the acipimox treatment 
to the extent that there was no significant difference in total integrated responses 
between the obese and control subjects. This may be due to increased GLP-1(7. 
3 6 )amide secretion, reduced NEFA concentrations, or a combination of both.
Glucose levels did not differ between treatments in control subjects. This could be 
because the increase in circulating NEFA levels following heparin was not of 
sufficient magnitude or duration to induce insulin resistance and thus affect glucose 
metabolism (Persson et ah, 1990; Boden et al., 1991).
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Integrated insulin and proinsulin responses were significantly greater in obese 
subjects, whereas there were no significant differences between groups for C-peptide. 
This is suggestive of both increased insulin secretion and decreased insulin clearance 
in obese subjects.
In summary, modulation of circulating NEFA levels by heparin and acipimox altered 
circulating CEF-l^.^am ide in a group of insulin-resistant, hyperinsulinaemic obese 
subjects and healthy controls. The obese subjects exhibited attenuated glucose- 
stimulated GLP-l(7 -3 6 )amide levels relative to control subjects (significant difference 
following acipimox), even when circulating NEFA levels were suppressed to a similar 
degree suggesting an intrinsic defect of CEF-l^.^am ide secretion in obese subjects. 
There was a trend for obese subjects to exhibit GIP hypersecretion; as these subjects 
were also hyperinsulinaemic, this does not fit with the theory on a negative feedback 
of insulin on glucose-stimulated GIP secretion. Neither does the data support the 
theory of an enteroendocrine loop, because when GIP was increased in the obese, 
GLP-l(7 -3 6 )amide was attenuated.
122
CHAPTER 4.
E n t e r o -P a n c r e a t ic  H o r m o n e  
R e s p o n s e s  t o  a  M ix e d  M e a l  i n  
O b e s e  a n d  L e a n  S u b je c t s
U s e  o f  a  Sp e c if ic  In s u l in  ELISA.
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4.1. INTRODUCTION
Obesity is a known risk factor in many diseases, including non-insulin-dependent 
diabetes mellitus (NIDDM) and cardiovascular disease (CVD) (Larsson et al., 1981; 
Donahue et al., 1987; Kissebah and Peiris, 1989), see Section 1.4.3. Obesity is often 
linked with insulin resistance and hyperinsulinaemia (Bjomtorp, 1987; Moller and 
Flier, 1991; Kohrt et al., 1993), see Section 1.4.6. Increasing amounts of insulin must 
be secreted to have the same blood glucose lowering effect. This in turn causes other 
metabolic complications that may lead to the development of diseases such as 
NIDDM and CVD (Reaven, 1988; Moller and Flier, 1991).
Hyperinsulinaemia has not been clearly demonstrated in all studies (Hampton and 
Withey, 1993). A reason for this is that hyperinsulinaemia has often been defined 
using insulin assays in which partially processed products of the insulin-secreting 
pancreatic B-cell cross-react, leading to spurious conclusions (Temple et al, 1992), 
see Section 1.2.8. The disproportionate hyperproinsulinaemia seen in patients with 
NIDDM (Temple et al., 1989) may also be a feature of obesity (Haffner et ah, 1993). 
It has been shown here in a pilot study (Hampton and Withey, 1993) that obese 
subjects have a tendency towards raised proinsulin and proinsulin fragment levels, 
which varies depending on their body fat distribution.
Body fat distribution appears to be an important and possibly independent 
determinant when considering the potential risk of obesity (Kissebah et a l, 1982; 
Ohlson et a l, 1985). Abdominally located adipose tissue (android distribution), 
especially the deep-seated visceral type has been significantly linked with several
124
metabolic disturbances including increased levels of insulin and triacylglycerol and 
decreased levels of HDL-cholesterol (Evans et a l, 1984, Despres et a l, 1989; 
Despres 1993).
To investigate the effects of fat distribution on hormonal and metabolic profiles it is 
necessary to categorise subjects in some way. The ‘gold standard’ method of direct 
measurement of abdominal tissue, is cadaver analysis, but obviously, this is not an 
option for normal research purposes. Methods such as computerised tomography (CT) 
and magnetic resonance imaging (MRI), would be the next methods of choice, but are 
very expensive and not suited to routine use in the field. Dual-energy X-ray 
absorbitometry (DEXA) is a cheaper option, but is less accurate and necessitates 
exposing the subjects to X-rays of the whole body (Seidell et a l,  1987).
Anthropometric measurements e.g. weight, height, circumferences, diameters and 
skinfold thickness are cheap and easy to perform and therefore more suitable for 
many studies. The most commonly used measure of body fat distribution is waist-to- 
hip circumference ratio (WHR), which does correlate with visceral fat measurements 
made by other methods, but is far less accurate. Waist circumference alone, waist-to- 
height ratio and other measurements are also used and have varying correlations with 
visceral fat. The major disadvantage of measurements involving circumferences is 
that they do not differentiate quantitatively between visceral and subcutaneous fat, 
however they are useful as a guide to body fat distribution.
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The site at which circumference measurements, particularly for waist, are made vary 
widely in the literature and some are not stated at all. Small differences may give 
different results in the calculation of ratios of WHR and the subsequent classification 
of a subject as being android or gynoid (van der Kooy and Seidell, 1993).
GIP and GHP-l^.^amide both have a direct anabolic action on adipose tissue 
stimulating de novo lipogenesis (Oben et ah, 1991) suggesting a possible direct role in 
obesity (Marks et a l, 1991). Some previous workers have found that GIP response to 
nutrient stimulation in obesity is increased compared to normal weight subjects 
(Sirinek et a l, 1986), but results vary according to experimental design (Service et a l, 
1984). GLP-l(7 -3 6 )amide secretion in obesity is less well characterised, mainly due to 
the lack of availability of analytical procedures to measure the low circulating levels 
of the hormone. Previous work here has found that GHP-l^.^amide levels are 
attenuated in obesity following a glucose load, but not after a fat load (Ranganath et 
ah, 1996). This contrasts with other workers who have found GHP-l^.^amide and 
GIP hypersecretion in obese diabetic subjects (Fukase et a l, 1993). Hormone 
responses to a mixed meal have not been investigated.
The aims of this study were:
♦ to clarify results from a pilot study in obese subjects carried out in this department 
(Hampton and Withey, 1993) that showed a trend towards higher proinsulin 
secretion in obese subjects, who appeared to have different patterns of body fat 
distribution, by using a specific ELISA for insulin and making measurements of 
body fat distribution
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♦ to investigate GLP-l(7 -3 6 )amide and GIP production in obese subjects following a 
mixed test meal and ascertain whether body fat distribution influences their 
secretion
♦ to investigate whether measurement of waist circumference at different sites 
affects the designation of subjects as android and gynoid obese, modifying 
subsequent mean hormone and metabolite profiles.
4.2. STUDY DESIGN
Ethical committee approval for this study was obtained from South West Surrey 
District Ethics Committee and the University of Surrey Advisory Committee on 
Ethics. The study was conducted at the Clinical Investigation Unit, Royal Surrey 
County Hospital, Guildford. All subjects gave written consent to participate in the 
study.
4.2.1 Subjec ts
Two subject groups were recruited, 12 subjects per group, through advertisements and 
word of mouth. They consisted of healthy men and women aged 18-50 years. 
Exclusion criteria for this study included family history (first degree relative) of 
diabetes mellitus, medication (apart from the contraceptive pill), allergies, excess 
exercise (>30 mins, 3 times per week) and alcohol consumption > 20 units per week. 
The subject groups were:
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Obese group: Men and women defined as obese by a Body Mass Index (BMI) 
[Weight (kg) / Height2 (m2)] > 30. These were subsequently divided into two groups 
on the basis of their waist:hip ratio (WHR):
obi: Gynoid obese.
ob2: Android obese.
Further details of the division are given in Section 4.3.
Control group: Men and women, defined as normal weight by a BMI of 20-25. 
Subjects in the control group were sex and age matched to subjects in the obese 
group.
4.2.2. M eth o d s
Subjects arrived fasted in the Investigation Unit at 9 am, having consumed only water 
or decaffeinated drinks since 8 pm the previous evening. They had been asked to 
regulate their last meal to one low in fat and moderate-high in carbohydrate. Meal 
suggestions were provided e.g. ham salad, boiled potatoes and a piece of fruit. The 
subjects had also been requested to refrain from alcohol or exercise for 24 hours 
preceding the study.
Weight and height measurements were made on calibrated balance scales and a fixed 
stadiometer respectively. Waist circumference was measured at two sites - the 
umbilicus (waist 1) and the minimal circumference (waist 2). Hips were measured at 
the site of the greatest circumference.
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An indwelling cannula was inserted into an antecubital vein of the forearm by a 
medically qualified person and two baseline blood samples were collected before a 
test breakfast (see Table 4.1 for nutritional analysis) was given. Venous blood 
samples were collected every 15 minutes up to 90 minutes and then every 30 minutes 
up to 240 minutes after the test meal. Each collection consisted of 1 ml for glucose 
(into fluoride oxalate tubes), 15 ml for insulin, ELISA insulin, proinsulin, C-peptide, 
TAG and NEFA (into lithium heparin tubes), 5 ml for GIP and GLP-l^.^am ide (into 
lithium heparin tubes containing 200 KIU/ml blood Aprotinin) and 1 ml into EDTA 
tubes for TAG and NEFA, for comparison with the lithium heparinised plasma TAG 
and NEFA measurements. A total of 273 ml blood was collected per subject. The 
blood was centrifuged at 1850 g for  10 minutes immediately after collection and the 
plasma separated, aliquoted and frozen at -20°C until analysis. Samples were analysed 
using the methods in Chapter 2.
Table 4.1. Nutritional analysis o f test meal.
FOOD WEIGHT
(g)
ENE
(kcal)
RGY
(kJ)
CHO
(g)
FAT
(g)
PROTEIN
(g)
Rice Krispies 40 148 629 33.9 0.3 2.4
Milk (whole) 200 132 550 9.6 7.7 6.4
Sugar 21 83 353 22 0 0
Croissants 100 360 1535 38.3 18.2 8.3
Butter 30 221 910 0 25 0.1
Marmalade 50 131 557 33 0 0.1
Orange Juice 150 54 230 12.2 0.2 0.8
TOTAL 1129 4764 149 51.4 18.2
PERCENT 53% 41% 6%
OF TOTAL
ENERGY
129
4.2.3 S t a t i s t i c s
The data is expressed as mean ± standard error of the mean (mean ± S.E.M.), unless 
otherwise stated, in both tables and graphs. Significance was taken at P < 0.05.
Integrated responses (total area under the curve [TAUC]), incremental responses 
([IAUC] calculated as TAUC minus the baseline value multiplied by the total study 
length) and integrated responses for each hour of the study (area under the curve 
[AUC 0-60, AUC 60-120, AUC 120-180 and AUC 180-240]) were calculated using 
the trapezoidal rule.
The results were tested for approximation to normality using Bartlett’s test for 
homogeneity of variances which examines whether the data originates from 
populations with equal standard deviations. If the data approximated to the normal 
distribution, appropriate parametric tests were performed (see below). If it was not, 
then the data was appropriately transformed (log, square root or reciprocally). If the 
data did still not approximate to a normal distribution, then non-parametric tests were 
used.
Differences between two groups (obese and control) were analysed using the two- 
tailed unpaired Student’s f-test (parametric) or the two-tailed unpaired Mann-Whitney 
U test (non-parametric). Differences between three groups (obi, ob2 and control) 
were analysed using a one-way Analysis of Variance (ANOVA) followed by a 
Scheffé’s S post-hoc test (suitable for uneven group sizes) if significant differences
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were found. If the data did not approximate to a normal distribution, a Kruskall- 
Wallis non-parametric ANOVA was performed.
Repeated measures ANOVA was performed on each of hormone and metabolite data 
to see if there was a difference between the groups with respect to time.
Correlation analysis was performed on the data to examine if there was any 
significance of association between variables. Correlation was examined separately 
for the obese and control groups and then the data combined and correlation analysis 
performed on data from all the subjects together. Only statistically significant 
correlations are stated. The Pearson product-moment correlation coefficient (r) was 
calculated for data approximating to a normal distribution. The Kendall rank- 
correlation coefficient is the corresponding non-parametric test.
4.3. RESULTS
The data was initially analysed as two groups, obese (ob) and control (co). The obese 
group was subsequently divided into two groups in an attempt to differentiate between 
android and gynoid obesity. Several different anthropometric variables were used to 
divide the obese group into two. These included waist circumference measured at the 
umbilicus (Wl); waist circumference measured at the minimal circumference (W2); 
waist:hip ratio, using W l (WHR1); waist:hip ratio using W2 (WHR2) and 
waist:height ratio using W l and W2 (W1HTR and W2HTR respectively). Data
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obtained from groupings produced using WHR1 is shown for all parameters and for 
some parameters using W2 as a comparison.
The median value for WHR1 of 0.915 was used to differentiate the obese subjects into 
those who were more gynoid (obi: WHR1 < 0.915) and those with a more android 
body fat distribution (ob2: WHR1 > 0.915). When W2 was used as the divisor, the 
median value of a minimal waist circumference of 102.5 cm was used to separate the 
obese subjects into two groups (ob3 [gynoid]: W2 < 102.5 cm; ob4 [android]: W2 > 
102.5 cm).
4.3.1. D e m o g r a ph ic  a nd  A n th r o po m e tr ic  R e sults
Table 4.2. shows demographic and anthropometric data for the subjects. Results are 
expressed as mean ± standard deviation of the mean (S.D.). Values with the same 
superscript small case letter are significantly different from each other.
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Table 4.2. Demographic and anthropometric data for control and obese subjects and 
obese subjects divided using WHR1 (mean ± S.D.).
CONTROL 
(n = 12)
OBESE 
(n = 12)
OBI 
(n = 6)
OB2 
(n = 6)
Sex 4M:8F 4M:8F 1M:5F 3M:3F
Age 34 ±10 35 ±10 32 ± 9.4 37 ±11
Weight (kg) 65 ± 9.2a,b 113 ±38" 96.2 ±11 130 ± 49b
Height (m) 1.68 ±0.02 1.68 ±0.07 1.66 ± 0.06 1.70 ±0.07
BMI (kg/m2) 23± 0.43c,d’e 39. 5 ± IF 34.8 ± 4.0d 44.2 ± 14e
Waist 1 (cm) 80 ± 6.5f,g’h 122 ± 21f 108± 4.1g,i 138 ± 23h,i
Waist 2 (cm) 76 ± 6AiM 108 ± 18j 99 ± 5.6k 116 ± 231
Hips (cm) 102 ± 5m’n’° 131±18m 123.3 ± 6.9" 138.8 ± 23°
WHR1 0.77 ± 0.06p’q,r 0.93 ± 0.06p 0.89 ± 0.02qs 0.98 ± 0.06r s
WHR2 0.74 ± 0.05''" 0.82 ± 0.05' 0.80 ± 0.05 0.84 ± 0.06"
W1HTR 0.46 ± 0.04v’w,x 0.72 ± 0.1v 0.65 ± 0.03w,y 0.80 ±0.12x,y
i,k,q,t,u,y
b,c,e,g,h,l,m,o,r,w,x
a,f,j,p,v
P < 0.05 
f  <0.01 
P < 0.001 
P < 0.0001
When the whole obese group was compared with the control group, age and height 
were not significantly different between the groups, but weight, BMI, Waist 1, Waist2, 
Hips, WHR1, WHR2 and W1HTR were significantly different. Following division of 
the obese group into two and comparing these with the control group, the three groups 
were not significantly different for age or height. Obi and ob2 were not significantly 
different for weight, however, neither was obi compared with control. Both obese 
groups had a significantly greater BMI than the control group, but obi and ob2 were 
not significantly different. Both obese groups had a significantly greater waist 
circumference as measured at the umbilicus (waist 1) than the control, and ob2 was 
also significantly greater than obi, as expected, as this was the criteria used to divide 
the obese group into two. Waist 2 measurements were significantly greater in both 
obese groups than control, but obi compared with ob2 was not significantly different.
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The same applied to hip circumference. WHR1 was significantly different between 
both obese groups and the control group and also between the obese groups 
themselves. WHR2 was significantly greater in ob2 than control, but not between obi 
and control or obi and ob2. W1HTR was significantly different between all groups.
BMI correlated with WHR1 in control subjects (r = 0.60, P = 0.05) and all subjects (r 
= 0.69, P = 0.0003). BMI correlated with WHR2 in control subjects (r = 0.74, P = 
0.009) and all subjects (r = 0.62, P = 0.002). WHR1 correlated with WHR2 in control 
subjects (r = 0.65, P = 0.03) and all subjects (r = 0.77, P < 0.0001).
4.3.2. Glu c o se
Table 4.3. shows the data and statistical results for glucose. The data is illustrated 
graphically in Figs 4.1.a and b. Values with the same superscript small case letter are 
significantly different from each other.
Repeated measures ANOVA of the three groups (obi, ob2, co) showed that there was 
a significant difference between groups {P = 0.03).
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Table 4.3. Glucose responses of control and obese subjects and obese subjects
divided using WHR1 to a mixed test meal (mean ± S.E.M. ).
CONTROL
(n = 12)
OBESE
(n = 12)
OBI
(n = 6)
OB2
(n = 6)
Fasting glucose 
(mmol/L)
4.67 ±0.10" 4.96 ±0.17 4.59 ±0.16" 5.32 ± 0.23*'"
Integrated glucose 
(TAUC) 
(mmoI/L.min)
1196 ± 6 2 ^ 1464 ±47" 1396 ±44 1532 ± 76d
Incremental 
glucose (IAUC) 
(mmol/L.min)
76 ± 64e 233 ± 39e 212 ±55 255 ± 60
Integrated glucose 
0-60 mins 
(mmol/L.min)
352 ± 18*': 417 ± 16* 402 ±18 432 ± 26:
Integrated glucose 
60-120 mins 
(mmol/L.min)
288 ± 20h,1,J 391±17h 374 ± 20' 407 ± 29"
Integrated glucose 
120-180 mins 
(mmol/L.min)
288 ±19k 342±16k 318 ±16 366 ± 24
Integrated glucose 
180-240 mins 
(mmol/L.min)
267 ± 121,m 314 ±9' 301 ± 12 327 ±13m
P < 0.05 
P < 0.01
Comparison of the whole obese group with the control group found no significant 
difference between fasting glucose values, but the total AUC, incremental AUC and 
hourly AUC’s were all significantly greater in the obese group. Ob2 was significantly 
greater than both obi and control for fasting glucose, but there was no significant 
difference between obi and control. Ob2 had a significantly greater total AUC than 
the control group, but there was no difference between obi and control or obi and 
ob2. Incremental AUC and AUC 120-180 were not significantly different between the 
3 groups. AUC 0-60 was significantly greater in ob2 than control, as was AUC 60- 
120 and AUC 180-240. AUC 60-120 was also significantly different for obi 
compared with ob2. There were no other significant differences between the groups.
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Figure 4.1a. Glucose responses to a test meal in lean and obese subjects
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Figure 4.1b. Glucose responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
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Fasting glucose correlated with BMI in the obese group (r = 0.68, P = 0.02) and all 
subjects (r = 0.60, P = 0.002). Fasting glucose correlated with Waist 1 in obese 
subjects (r = 0.67, P = 0.02) and all subjects (r = 0.57, P = 0.005). Fasting glucose 
correlated with WHR1 in all subjects (r = 0.43, P = 0.04). Fasting glucose correlated 
with W1HTR in obese subjects (r = 0.69, P = 0.01) and all subjects (r = 0.54, P = 
0.008). Fasting glucose correlated with Waist2 in all subjects (r = 0.42, P = 0.04).
Total AUC correlated with BMI for all subjects (r = 0.54, P = 0.006). Total AUC 
correlated with Waist 1 in all subjects (r = 0.57, P = 0.005). Total AUC correlated with 
WHR1 for all subjects (r = 0.48, P = 0.02). Total AUC correlated with W1HTR in all 
subjects (r = 0.57, P = 0.004).
4.3.3. I n s u lin
Table 4.4. shows the data and statistical results for insulin as measured by RIA. The 
data is illustrated graphically in Figs 4.2.a and b. Values with the same superscript 
small case letter are significantly different from each other.
Repeated measures ANOVA showed that there was a significant difference between 
groups (P = 0.0001).
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Table 4.4. Insulin responses of control and obese subjects and obese subjects divided
using WHR1 to a mixed test meal (mean ± S.E.M.)._____________________________
CONTROL
(n = 12)
OBESE
(n = 12)
OBI
(n = 6)
OB2
(n = 6)
Fasting insulin 
(pmol/L)
45 ± 4a,b 128 ± 22a 94 ±16 162 ± 37"
Integrated insulin 
(TAUC) 
(pmol/L.min)
81937 ± 9556c’d,e 168882 ± 16570° 157600 ± 16789e1 180100 ± 29591°
Incremental insulin 
(IAUC) 
(pmol/L.min)
71236 ± 9270t,g’h 138242 ± 14483' 135100±15027g 141400± 26329"
Integrated insulin 
0-60 mins 
(pmol/L.min)
24835 ± 26241’J,lc 46052 ±4465' 46059 ± 6147J 46045 ± 7067"
Integrated insulin 
60-120 mins 
(pmol/L.min)
24132 ±2915Un’n 54784 ±6153' 50951 ±4321m 58618± 11918"
Integrated insulin 
120-180 
mins(pmol/L.min)
20784 ± 3208o,p 40451 ±4397° 35290 ±4981 45612± 7042p
Integrated insulin 
180-240 mins 
(pmol/L.min)
12185 ± 1873q,r’s 27595± 2880q 25332 ±3522' 29858 ± 4694s
c,e,i,n,o,p,s P  <  0  0 1
a,b,f,l,q f  < 0 . 0 0 1
Comparison of the whole obese group with the control group found the obese group to 
be significantly greater for fasting and all AUC insulin values. Ob2 was also 
significantly greater than the control group for all insulin parameters. Obi was 
significantly greater than the control group for everything apart from fasting and AUC 
120-180. Obi compared with ob2 showed no significant differences.
Fasting insulin correlated with BMI in obese subjects (r = 0.91, P < 0.0001) and all 
subjects (r = 0.93, P < 0.0001). Fasting insulin correlated with Waist 1 in obese 
subjects (r = 0.90, P < 0.0001) and all subjects (r = 0.88, P < 0.0001). Fasting insulin 
correlated with WHR1 in all subjects (r = 0.59, P = 0.003). Fasting insulin correlated
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Figure 4.2a. RIA insulin responses to a test meal in lean and obese subjects
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Figure 4.2b. RIA insulin responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
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with W1HTR in obese subjects (r = 0.85, P = 0.0004) and all subjects (r = 0.84, P = 
0.0001).
Total insulin AUC correlated with BMI in all subjects (r = 0.68, P = 0.0002). Total 
AUC correlated with Waist 1 in all subjects (r = 0.74, P < 0.0001). Total AUC 
correlated with WHR1 in all subjects (r = 0.65, P = 0.0008). Total AUC correlated 
with W1HTR in all subjects (r = 0.88, P < 0.0001).
Insulin was also measured by ELISA. Table 4.5. shows the data and statistical results 
for ELISA insulin. Values with the same superscript small case letter are significantly 
different from each other. The comparison between RIA and ELISA values is 
illustrated graphically in Figs. 4.3.a and b.
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Figure 4.3a. Comparison o f  RIA and ELISA insulin responses to a test meal in
lean and obese subjects, n -  12 (mean ± S.E.M.)
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Figure 4.3b. Comparision of RIA and ELISA insulin responses to a test meal in lean and android 
and gynoid subjects, n = 12 for lean control subjects and n ~ 6 for obese groups 
(mean ± S.E.M.)
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Table 4.5. ELISA insulin responses of control and obese subjects and obese subjects
divided using WHR1 to a mixed test meal (mean ± S.E.M. ).______________________
CONTROL
(n = 12)
OBESE
(n = 12)
OBI
(n = 6)
OB2
(n = 6)
Fasting ELISA 
insulin (pmol/L)
40 ± 3a,b 104 ± 18a 78 ± 15 131 ± 31b
Integrated ELISA 
insulin (TAUC) 
(pmol/L.min)
71006 ± 9122c,d’e 141297 ± 16538e 143431±21433d 139163 ± 27243e
Incremental ELISA 
insulin (IAUC) 
(pmol/L.min)
61517 ± 8653*': 116217 ±14702* 124611± 196008 107823 ±23211
Integrated ELISA 
insulin 0-60 mins 
(pmol/L.min)
21822 ±2301tM 40291 ±4613h 42672 ±6836' 37909 ± 6681
Integrated ELISA 
insulin 60-120 
mins (pmol/L.min)
21118 ±2982J’k’1 45399 ± 6057J 45771 ±6161k 45026 ±11110'
Integrated ELISA 
insulin 120-180 
mins (pmol/L.min)
18986 ±3143m 33318 ±4052m 33150 ± 6430 33485 ± 5558
Integrated ELISA 
insulin 180-240 
mins (pmol/L.min)
9081 ± 1604n’°’p 22290± 2964" 21838 ±4016° 22743 ±4738p
d,e,g,l,k,l,m,o,p
f  <0.01 
P < 0.001
The correlation between ELISA and RIA values was significant in obese (r = 0.93, P 
< 0.0001), control (r = 0.96, P < 0.0001) and all subjects (r = 0.95, P < 0.0001).
4.3.4. Pr o in su l in
Table 4.6. shows the data and statistical results for proinsulin. The data is illustrated 
graphically in Figs 4.4.a and b. Values with the same superscript small case letter are 
significantly different from each other.
Repeated measures ANOVA of the three groups (obi, ob2, co) showed that there was 
a significant difference between groups (P = 0.03).
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Table 4.6. Proinsulin responses of control and obese subjects and obese subjects
divided using WHR1 to a mixed test meal (mean ±  S.E.M.).
CONTROL
(n = 12)
OBESE
(n = 12)
OBI
(n = 6)
OB2
(n = 6)
Fasting proinsulin 
(pmol/L)
17.7 ± 1.67" 26.3 ±3.27" 24.2 ±4.73 28.2 ±4.8
Integrated
proinsulin
(TAUC)
(pmol/L.min)
8170 ± 716b,c 16762 ± 2226" 19674 ± 3060c 13849 ± 3009
Incremental 
proinsulin (IAUC) 
(pmol/L.min)
3920 ±731d,e 10462±1707d 13854 ±2081"'* 7069 ± 1970*
Integrated 
proinsulin 0-60 
mins (pmol/L.min)
1538 ± 159g,tl 2669 ±308g 2959 ±43 lh 2378 ±444
Integrated 
proinsulin 60-120 
mins (pmol/L.min)
2068 ± 1821J 4869 ± 625' 5685 ±912 4049 ±788
Integrated 
proinsulin 120-180 
mins (pmol/L.min)
2600± 312"' 4914 ±639" 5595 ±781' 4232± 1001
Integrated 
proinsulin 180-240 
mins (pmol/L.min)
1964 ± 224m,n 4312 ±853™ 5435 ± 1416" 3190 ±832
a,b,f,h,k,m,n ~P<~0~05
cAeJJ p  < o OJ
ej P < 0.001
Fasting and all AUC’s were significantly greater in the whole obese group compared 
with the control group. Fasting proinsulin was not significantly different when the 
three groups were compared. All AUC’s were significantly greater in obi than 
control, but not ob2 compared with the control group. The incremental AUC was 
significantly greater in obi compared with ob2. There were no other significant 
differences between groups.
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Figure 4.4a. Proinsulin responses to a test meal in lean and obese subjects
n = 12 (mean ± S.E.M.)
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Figure 4.4b. Proinsulin responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
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4.3.5. C-PEPTIDE
Table 4.7. shows the data and statistical results for C-peptide. The data is illustrated 
graphically in Figs 4.5a and b. Values with the same superscript small case letter are 
significantly different from each other.
Table 4.7. C-peptide responses o f control and obese subjects and obese subjects 
divided using WHR1 to a mixed test meal (mean ±  S.E.M.)._______________________
CONTROL
(n = 12)
OBESE
(n = 12)
O B I
(n = 6)
OB2
(n = 6)
Fasting C-peptide 
(pmol/L)
370 ± 35a,b,c 845 ±91* 730 ± 83b 961 ± 155°
Integrated 
C-peptide (TAUC) 
(pmol/L.min)
284665 ± 38422d’e,t 509163 ±19734d 512071± 26772e 506254 ±31516t
Incremental 
C-peptide (IAUC) 
(pmol/L.min)
195827 ± 32137g,h 306283 ±20553s 336931 ±23110h 275634 ±30803
Integrated 
C-peptide 0-60 
mins (pmol/L.min)
66973 ±7885,’J’k 114417 ± 4363' 116900 ±6320) 111973 ±6435k
Integrated 
C-peptide 60-120 
mins (pmol/L.min)
83163 ± 10795,’m’n 142754 ± 5999' 143811 ±8637m 141696 ±9126"
Integrated 
C-peptide 120-180 
mins (pmol/L.min)
75746 ± 12020°’p'q 132688 ± 6250° 129188 ±8402p 136188 ±9816q
Integrated 
C-peptide 180-240 
mins (pmol/L.min)
62969 ± 10282r,s,t 119305 ± 6407' 122212 ± 8527s 116398 ±10223*
P < 0.05
c>fj»k»ra,nfq,s,t p ^  0  Q1
cor f  <0.001
aAiJ p < 0  0 0 0 1
Fasting and all AUC values were significantly greater in the whole obese group
compared to the control group and also obi vs control. Ob2 was significantly greater
than the control group for all parameters apart from incremental AUC. There were no 
significant differences between obi and ob2.
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Figure 4.5a. C-peptide responses to a test meal in lean and obese subjects
n = 12 (mean ± S.E.M.)
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Figure 4.5b. C-peptide responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n -  6 for obese groups (mean ± S.E.M.)
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4.3.6. GIF
Table 4.8. shows the data and statistical results for GIF. The data is illustrated 
graphically in Figs 4.6a and b. Values with the same superscript small case letter are 
significantly different from each other.
Repeated measures ANOVA showed that there was a significant difference between 
groups (P = 0.0001).
Table 4.8. GIP responses o f control and obese subjects and obese subjects divided 
using WHR1 to a mixed test meal (mean ±  S.E.M.).
CONTROL
(n = 12)
OBESE
(n = 12)
OBI
(n = 6)
OB2
(n = 6)
Fasting GIP 
(pmol/L)
29.5 ±2.98 36.2 ± 5.49 37.7 ± 8.04 34.8 ±8.18
Integrated GIP 
(TAUC) 
(pmol/L.min)
50704 ±3138 61780 ±4797 68061± 6390 55499± 6681
Incremental GIP 
(IAUC) 
(pmol/L.min)
43614 ± 2870 53090 ± 4650 59021± 6329 47159 ± 6405
Integrated GIP 
0-60 mins 
(pmol/L.min)
8166 ±857 8905± 1036 10378 ± 1408 7433± 1369
Integrated GIP 
60-120 mins 
(pmol/L.min)
14092 ± 983 15115 ±1237 17371± 1754 12859 ± 1272
Integrated GIP 
120-180 mins 
(pmol/L.min)
14349 ± 733a,b 18180 ± 1532" 19800 ± 1745b 16560± 2495
Integrated GIP 
180-240 mins 
(pmol/L.min)
14098 ± 852c,d 19580 ± 1563c 20512 ± 1816d 18648 ± 2666
a,b,c,d p <  a ( ) 5
Statistically significant differences for GIP were found in the latter parts of the 
postprandial period. GIP levels were higher in both the whole obese group compared 
with the controls and obi compared with controls for AUC’s 120-180 and 180-240.
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Figure 4.6a. GIP responses to a test meal in lean and obese subjects,
n -  12 (mean ± S.E.M.)
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Figure 4.6b. GIP responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
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4.3.7. GLP-1(7.36)AMIDE
Table 4.9. shows the data for GLP-l(7 _3 6 )amide. This is illustrated graphically in Figs 
4.7a. and b.
Table 4.9. GLP-1 (j^am ide responses o f control and obese subjects and obese 
subjects divided using WHR1 to a mixed test meal (mean ±  S.E.M.).________________
CONTROL
(n = 12)
OBESE
(n = 12)
O B I
(n = 6)
OB2
(n = 6)
Fasting GLP-1 
(pmol/L)
9.4 ±1.21 8.6 ± 0.42 8.7 ± 0.68 8.6 ± 0.58
Integrated GLP- 
1 (TAUC) 
(pmol/L.min)
5709 ±911 5244 ± 829 5764± 1054 4724 ± 1342
Incremental GLP- 
1 (IAUC) 
(pmol/L.min)
3449 ± 878 3174± 769 3684 ± 947 2664 ± 1265
Integrated GLP- 
1 0-60 mins 
(pmol/L.min)
1433 ± 212 1420 ± 282 1659 ±487 1181 ±299
Integrated GLP- 
1 60-120 
mins(pmol/L.min)
1348 ± 222 1219 ±197 1310 ± 269 1129 ±308
Integrated GLP- 
1 120-180 mins 
(pmol/L.min)
1620 ± 290 1312 ±202 1440 ± 228 1185 ±347
Integrated GLP- 
1180-240 mins 
(pmol/L.min)
1309 ±301 1292 ±262 1355 ± 260 1230 ± 482
There were no significant differences between any of the groups for GLP-1 (7.3 6)amide, 
although mean GLP-1 (7.3 6 )amide levels were lower in the ob2 group compared with 
the control group.
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Figure 4.7a. GLP-1 responses to a test meal in lean and obese subjects,
n = 12 (mean ± S.E.M.)
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Figure 4.7b. GLP-1 responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
60 n
I
§
50
40 -
30
z 20
O
10
-30
obi
ob2
control
30 60 90 120
Time (mins)
150 180 210 240
150
4.3.8. TAG
Table 4.10. shows the data and statistical results for TAG I The data is illustrated 
graphically in Figs 4.8a. and b. Values with the same superscript small case letter are 
significantly different from each other.
Repeated measures ANOVA showed that there was a significant difference between 
groups (P = 0.002)
Table 4.10. TAG responses o f control and obese subjects and obese subjects divided
using WHR1 to a mixed test meal fmean ±S.E.M.).
CONTROL
(n = 12)
OBESE
(n = 12)
O B I
(n = 6)
OB2
(n = 6)
Fasting TAG 
(mmoI/L)
0.84 ±0.07*'" 1.50 ±0.29* 1.87 ±0.55" 1.12 ± 0.13
Integrated TAG 
(TAUC) 
(mmol/L.min)
252 ± 25c’d 441± 73° 504± 135" 379 ± 59
Incremental TAG 
(IAUC) 
(mmol/L.min)
49 ±16 82± 18 55 ±15 110 ± 31
Integrated TAG 
0-60 mins 
(mmol/L.min)
53±4.9e't 89 ± 15e 105 ±29' 74 ±9.1
Integrated TAG 
60-120 mins 
(mmol/L.min)
56 ± 5.9g 100 ±18g 113 ±34 86 ±15
Integrated TAG 
120-180 mins 
(mmol/L.min)
67 ±7.7" 116 ±19" 133 ±35 100 ± 16
Integrated TAG 
180-240 mins 
(mmol/L.min)
76 ± 8.01,J 136 ±21' 153 ± 38J 119 ± 21
f  <0.01
Comparison of the whole obese group with the control group showed significantly 
higher TAG values in the obese group for all parameters apart from incremental AUC.
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Figure 4.8a. TAG responses to a test meal in lean and obese subjects
n = 12 (mean ± S.E.M.)
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Figure 4.8b. TAG responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
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Obi was significantly greater than control for fasting, total AUC, AUC 0-60 and 
AUC 180-240. There were no other significant differences between the groups.
4.3.9. NEFA
No significant difference was found between values for NEFA measured in lithium- 
heparinized plasma or EDTA-preserved plasma, therefore the lithium-heparinized 
plasma values were used because this had been collected on all subjects.
Table 4.11. shows the data and statistical results for NEFA. Values with the same 
superscript small case letter are significantly different from each other. The data is 
illustrated graphically in Figs 4.9a. and b.
Table 4.11. NEFA responses o f control and obese subjects and obese subjects divided 
using WHR1 to a mixed test meal (mean ±  S.E.M.)._____________
CONTROL
(n = 11)
OBESE
(n = 12)
OBI
(n = 6)
OB2
(n = 6)
Fasting NEFA 
(mmol/L)
0.62 ±0.04 0.76 ±0.05 0.77 ± 0.08 0.74 ±0.07
Integrated NEFA 
(TAUC) 
(mmol/L.min)
41 ±3.5 49 ± 5.6 55 ±11 43 ±2
Incremental NEFA 
(IAUC) 
(mmol/L.min)
-109 ± 9.2 -132 ±9.3 -131 ±12 -134 ±15
Integrated NEFA 
0-60 mins 
(mmol/L.min)
18 ±1.9" 25 ±1.3" 25 ±2 25 ±1
Integrated NEFA 
60-120 mins 
(mmol/L.min)
6.3 ±1.02 5.8 ±0.77 6.5 ± 1.5 5.1 ±0.4
Integrated NEFA 
120-180 mins 
(mmol/L.min)
7.0 ±1.0 7.0 ± 2.0 9.1 ±4 4.9 ± 0.8
AUC 180-240 
(mmol/L.min)
9.5 ± 1.2 11 ±2.5 14 ±4.7 8.7 ± 1.3
aP< 0.01
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Figure 4.9a. NEFA responses to a test meal in lean and obese subjects
n = 12 (mean ± S.E.M.)
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Figure 4.9b. NEFA responses to a test meal in lean and android and gynoid obese subjects 
n = 12 for lean control subjects and n = 6 for obese groups (mean ± S.E.M.)
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The only statistically significant difference was between the whole obese group and 
control group for the AUC 0-60. One-way ANOVA between the three groups also 
showed a difference for this parameter, but the post-hoc test did not differentiate 
between the groups.
Repeated measures ANOVA showed that there as a significant difference between the 
groups (P = 0.02).
4.3.10. Data analysis of obese groups produced using W2 as divisor
As stated in the introduction to Section 4.3. the data was also analysed using W2 as a 
divisor. The results were similar for insulin, C-peptide, GIP, GUP-l^.^amide and 
NEFA, but differences were seen for glucose, proinsulin and TAG. Differences 
between the android and gynoid subjects for glucose were less clear cut using W2 as a 
divisor compared with WHR1. Mean proinsulin and TAG data were higher in android 
subjects (ob4) following division with W2, whereas following division with WHR1, 
gynoid subjects (obi) had higher mean values. All of the results are expressed 
graphically in Fig. 4.10. a-h.
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Figure 4.10. Metabolite, pancreatic and gut hormone responses to a test meal in obese and control 
subjects (obese subjects grouped using W2 as divisor for ob3 and ob4), n = 12 for control 
and n = 6 for obese groups (mean ± S.E.M.).
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Figure 4.10. cont’d Metabolite, pancreatic and gut hormone responses to a test meal in obese and 
control subjects (obese subjects grouped using W2 as divisor for ob3 and ob4), n = 12 for control 
and n = 6 for obese groups (mean ± S.E.M.).
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4.4. DISCUSSION
WHR1 was chosen as a divisor for the obese group because of the two waist 
measurements made, waist circumference as measured at the umbilicus is the more 
commonly used. Since this study was undertaken, the use of waist circumference 
alone, rather than as part of a ratio has been advocated, as has waistiheight ratio. Both 
methods have been said to have a better correlation with non-anthropometric 
techniques such as CT scanning than WHR, although this is disputed by others 
(Ashwell et al., 1996)
The subjects were matched for age and sex. Although the obese group were 
significantly greater for weight than the control group, further analysis when the 
obese group was split into obi and ob2 showed that the obi group were not 
significantly heavier than the control group, even though there was a mean difference 
of 31 kg.
The obese and control groups had similar fasting glucose levels. However, when the 
obese group was split into two, the more android group had a significantly higher 
glucose than the both the control and obi groups. Postprandially, the obese group 
were hyperglycaemic relative to the control group, with the ob2 subjects exhibiting a 
trend for higher glucose levels than obi, although this was not significant. This 
concurs with several studies looking at both obese and specifically android obese 
subjects, although it does disagree with the pilot study carried out in this department
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(Hampton and Withey, 1993), when differences in glucose levels between obese and 
control groups were not found, apart from at t = 180 mins, following the test meal.
This study showed that obese subjects have both fasting and meal-stimulated 
hyperinsulinaemia, agreeing with many studies, but again disagreeing with our pilot 
study. The android and gynoid groups had similar insulin levels as measured by RIA. 
As expected, insulin as measured by ELISA was less than RIA insulin. The difference 
was significant in android obese subjects, but not gynoid obese.
The obese group also exhibited both fasting and meal-stimulated 
hyperproinsulinaemia, agreeing with our pilot study, which showed a trend towards 
post-prandial hyperproinsulinaemia. The hyperproinsulinaemia would contribute in 
part to the hyperinsulinaemia seen, although this cannot be the only explanation, 
because specific insulin as measured by the ELISA which does not cross-react with 
proinsulin was also raised, as discussed above. When divided using WHR1, the more 
gynoid group had significantly greater proinsulin levels than control subjects. This 
data suggests that in android obese subjects a possible explanation for similar RIA 
insulin levels, but lower ELISA insulin and proinsulin levels than in gynoid obese 
subjects could be increased production of des-31,32 proinsulin. However when 
divided using W2, the more android group was significantly higher than the control 
group and the more gynoid group was not. Therefore, hypotheses as to possible 
different mechanisms affecting insulin production related to differences in body fat 
distribution can only be speculative.
159
The obese subjects in this study had significantly higher C-peptide levels than 
controls, both fasting and postprandially. We did not observe the wide variation in 
C-peptide levels seen in the pilot study (Hampton and Withey, 1993). The android 
and gynoid groups had similar levels of C-peptide, so we did not see the trends for 
differences seen with glucose, insulin and proinsulin.
The obese and control groups had similar circulating amounts of GIP in the first two 
hours of the study, but after this point, the control group plateaued, whereas the obese 
group continued to rise and had significantly greater circulating GIP in the last two 
hours of the study. This agrees with some studies that have found increased GIP 
secretion in obesity (Creutzfeldt et a l, 1978; Elahi et a l, 1984), but differs with 
others that have found unaffected GIP secretion in obesity (Lauritsen et al., 1980; 
Service et al., 1984). The differences may reflect the different nutritional content of 
the meals administered to subjects. Traditionally hormone levels are examined 
following a liquid glucose load. This study was conducted following a mixed test 
meal, with a high fat content as well as carbohydrate and protein.
When divided into obi and ob2, both obese groups had higher levels of GIP than 
controls, but only the more gynoid subjects showed a statistically significant 
difference from the control group in the second two hours of the study. This also 
applied when the groups were divided using W2. This concurs with the role of GIP as 
an incretin, because proinsulin and specific insulin were also higher in the gynoid 
obese.
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GIP production can be used as a marker for gastric emptying, so it is possible that 
the obese subjects and particularly those with a more gynoid fat distribution had 
delayed gastric emptying.
GLP-1 (7 -3 6 )amide levels were similar between obese and control groups, although 
there was a non-significant trend towards lower mean GLP-l^.^am ide values in the 
android obese. We did not see the clear attenuation of postprandial GLP-l^.^am ide 
levels in the obese that were found in Chapter 3. This could be due to a combination 
of different nutritional stimuli and different prevailing NEFA levels which were only 
slightly higher in obese subjects compared with controls in this study and not 
significantly different as in Chapter 3, when the GLP-l^.^am ide attenuation was 
seen.
Obese subjects had significantly higher fasting and integrated levels of TAG. This 
was partly due to one subject having extremely high levels skewing the data. When 
divided into groups by WHR1, the more gynoid group had higher TAG levels than the 
more android group. This was reversed when divided by W2. Again, this was due to 
the subject with high levels being placed in different groups.
Obese and control subjects had similar NEFA concentrations over the test period. The 
only difference was for the area under the curve between 0 and 60 minutes. The obese 
group had higher levels, but this would be partly due to an unexpected increase in 
NEFA concentration between -10 and 0 mins. This phenomenon is seen sometimes 
following cannulation and is caused by stress inducing catecholamine production
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which in turn stimulates hormone sensitive lipase to catalyse the breakdown of stored 
TAG into NEFA which is released into the circulation.
The choice of site at which waist circumference is measured is obviously a very 
important one. This study has demonstrated that use of different sites affects whether 
some subjects are classified as being either more android or gynoid. This alters the 
results when subjects are grouped using a ‘waist’ measurement and thus the 
conclusions that can be drawn from the hormone and metabolite data for android and 
gynoid obese. This also makes direct comparison with other published studies more 
difficult if they have differentiated between obese subjects using different criteria, or 
not stated how they measured waist and hip circumference.
In summary, obese subjects had higher fasting insulin, proinsulin, C-peptide and TAG 
levels than control subjects and higher post-prandial glucose, insulin, proinsulin C- 
peptide and TAG levels following a test meal. GIP levels were raised in the latter part 
of the study, particularly in the gynoid obese suggesting that GIP may have a role in 
the hyperinsulinaemia of obesity, but probably only a minor one. There was no 
evidence of a role for GEP-l^.^amide in the hyperinsulinaemia seen.
The situation when the obese group was divided into those with a more android 
distribution and those more gynoid is less clear. Whilst there was a trend for the more 
android subjects to show greater levels of glucose and pancreatic hormones, this was 
not always true and was not usually significant. The differences would probably be 
more clear cut with a greater sample number, either examining one sex only or being
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more strict with cut-off points when dividing subjects between android and gynoid 
groups and using different cut-off points for men and women.
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CHAPTER 5.
E n t e r o -Pa n c r e a t ic  H o r m o n e  
R e s p o n s e s  t o  a  M ix e d  M e a l  i n  
H y p e r t r ig l y c e r id a e m ia .
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5.1. INTRODUCTION
The metabolism of TAG and NEFA is closely linked with insulin in vivo (see Section 
1.2.2). Hypertriglyceridaemia, a disorder of lipid metabolism, is associated with 
peripheral hyperinsulinaemia and insulin resistance (Olefsky et al., 1974; Reaven et al., 
1983; Gama et al., 1995a), with subjects showing elevated levels of both fasting and oral 
glucose-stimulated insulin concentrations (Crapo et al., 1981; McKane et al., 1990). 
Fasting proinsulin levels in hypertriglyceridaemics do not appear to be elevated (Gama et 
a l, 1995a), but postprandial measurements have not been made.
The gut hormones GBP and GEF-l^.^amide potentiate glucose-induced insulin secretion 
and it has been proposed that they contribute to the increased insulin levels seen in other 
hyperinsulinaemic states such as non-insulin dependent diabetes mellitus and obesity 
(0rskov, 1992; Alam et al., 1993; Fukase et al., 1993). GIF and G EF-l^.^am ide are also 
both stimulated by fat and involved in lipid metabolism in vivo (see Sections 1.3.2. and 
1.3.3.).
The aim of this study was:
♦ to investigate whether abnormalities of GBP and GEF-l^.^am ide contribute to the 
pathogenesis of the hypertriglyceridaemia or hyperinsulinaemia seen in clinically 
hypertriglyceridaemic subjects.
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This was achieved by studying several blood parameters in subjects with varying degrees 
of hypertriglyceridaemia and a normotriglyceridaemic control group following a mixed 
test meal.
5.2. STUDY DESIGN
This study was conducted in collaboration with Dr R. Gama at the Royal Surrey County 
Hospital Guildford. Ethical committee approval was obtained from the South West 
Surrey District Ethics Committee.
5.2.1. Su bjec ts
Two subject groups were recruited:
Group 1: Sixteen hypertriglyceridaemic subjects over the age of 18 were recruited from 
metabolic clinics at the Royal Surrey County Hospital. They were divided into two 
groups (n = 8), on the basis of fasting TAG concentration, one group with moderately 
raised fasting levels and the other with high fasting levels:
Groupla: Fasting plasma TAG 2.5-6 mmol/L henceforth known as “modTAG”
Grouplb: Fasting plasma TAG > 6 mmol/L henceforth known as “highTAG”
Group 2: A control group consisting of eight healthy, age and weight matched 
volunteers, with fasting plasma TAG levels < 2 mmol/L, were recruited through clinics 
and personal contacts.
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The subject groups consisted of five men and three women in the modTAG group, seven 
men and one woman in the highTAG group and six men and two women in the control 
group. The mean ± S.E.M. (and range) age of the subjects were 41.6 ± 3.3 (30 -  54) years 
in the modTAG group, 46.5 ± 3.5 (27 -  57) years in the highTAG group and 42.1 ± 3.5 
(29 -  55) years in the control group. The mean ± S.E.M. (and range) BMI of the subjects 
were 26.2 ± 0.7 (23.3 -  29.5) in the modTAG group, 27.2 ± 0.9 (22.9 -  29.9) in the 
highTAG group and 26.4 ± 0.6 (24.3 -  29.1) in the control group. There were no 
statistically significant differences between the groups for age or BMI.
Exclusion criteria for the study included thyroid disease, renal impairment, hepatic 
dysfunction, personal or family history (first-degree relative) of diabetes mellitus, obesity 
(BMI > 30), alcohol consumption > 20 units per week, and subjects receiving medication. 
Subjects had not altered their diet or changed weight in the previous month.
5.2.2. M eth o d s
Following an overnight fast, an indwelling cannula was inserted into an antecubital vein 
in the forearm and two baseline venous blood samples were collected before a test 
breakfast was given. The breakfast was the same as that used in Chapter 4 (see Table 4.1 
for nutritional analysis). In summary, the meal contained 1129 kcal, 53.7g fat, 154g 
carbohydrate and 18.2g protein. Following the breakfast, blood samples were collected 
every 15 minutes up to 60 minutes and then every 30 minutes up to 240 minutes. Each
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sample collection consisted of 2 ml for glucose (into a fluoride oxalate tube) and 19 ml 
for insulin, proinsulin, GIF (into a lithium heparin tube), GLP-l(7 _3 6 )amide (into a lithium 
heparin tube with 200KIU/ml blood of Aprotinin) and TAG (into a plain glass tube with 
no additives). A total of 273 ml blood was collected from each subject. The blood was 
centrifuged at 1850 g for 10 minutes immediately after collection and the plasma 
separated, aliquoted and frozen at -20°C until analysis. TAG levels were measured on 
serum samples, in which the blood had been allowed to clot, the serum removed and then 
centrifuged and stored as for the plasma.
Glucose and TAG measurements were conducted by the Biochemistry Department at the 
Royal Surrey County Hospital, using the methods described in Chapter 2. Plasma 
hormones were measured by radioimmunoassay using the methods stated in Chapter 2.
5.2.3. S t a tistic a l  A n alysis
Results are expressed in both tabular and graphic form as means with standard error of 
the means (S.E.M.), unless otherwise stated. To facilitate statistical analysis, hormone 
levels below the sensitivity of the assay were assigned the limit of detection value of the 
assay. Total integrated and incremental responses (area under the curve), TAUC and 
IAUC respectively were calculated using the trapezoidal rule. Integrated responses were 
also calculated for each hour of the study (0-60, 60-120, 120-180 and 180-240 mins). 
Differences between groups were investigated using the one-way analysis of variance 
(ANOVA) followed by a Duncans New Multiple Range post hoc test if a significant
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difference (P < 0.05) was found. Repeated measures analysis of variance was calculated 
to examine differences between groups with respect to time.
5.3. RESULTS
5.3.1. T r ia c y lg ly c er o l
The TAG responses of the hypertriglyceridaemic and control subject groups to the test 
meal are shown in Table 5.1 and illustrated graphically in Fig. 5.1. Values in the table 
with the same small case superscript letter are significantly different from each other.
Table 5.1. Triacylglycerol responses to a test meal in hypertriglyceridaemic and control 
subjects, n = 8 (mean ±S.E.M.)
control modTAG highTAG
Fasting TAG (mmol/L) 1.19 ± 0.15a 3.79 ± 0.25b 9 .94+ 1 .59^
Integrated TAG (TAUC) 
(mmol/L. min)
394 ± 84c,d 1181 + 9 4 ^ 2403 ± 338'"
Incremental TAG (IAUC) 
(mmol/L. min)
109 ± 50 270 + 52' 17 + 75'
Integrated TAG 
0-60mins (mmol/L. min)
68 ±10sh 230 ± 158,i 570 ± 90"'
Integrated TAG 
60-120mins (mmol/L. min)
77 ± 14i,k 256 ± 20i’1 565 ± 86kJ
Integrated TAG 
120-180mins (mmol/L.min)
106 + 24"" 310 ±27™'° 600 + 82"°
Integrated TAG 
180-240mins (mmol/L.min)
142 ± 36p,q 384 ± 37p,r 668 ± 82+'
P < 0.05
a,b,c,e,f,h,i,k,l,n,o,p,q,r
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Fasting TAG concentrations were significantly different between the groups, with both 
the control and modTAG groups having significantly lower fasting levels than the 
highTAG group (P < 0.01). Although the fasting TAG levels in the control group 
appeared lower than the modTAG group, the difference was not significant.
The total integrated TAG response to the test meal was significantly different between all 
three groups, with the highTAG group being significantly higher than both the modTAG 
and control groups (P < 0.01) and the modTAG group being significantly higher than the 
control group (P < 0.05).
The incremental integrated response was significantly greater in the modTAG group than 
the highTAG group (P < 0.01). The mean incremental integrated response of the control 
group was greater than the highTAG group and less than the modTAG group, but the 
differences were not significant, because of the wide spread of data.
Repeated measures analysis of variance showed a significant difference between the 
groups (P < 0.0001)
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5.3.2. G lu c o se
The glucose responses of the hypertriglyceridaemic and control subject groups to the test 
meal are shown in Table 5.2 and illustrated graphically in Fig. 5.2. Values in the table 
with the same small case superscript letter are significantly different from each other.
Table 5.2. Glucose responses to a test meal in hypertriglyceridaemic and control 
subjects, n = 8 (mean ±  S.E.M.)
control modTAG highTAG
Fasting glucose (mmol/L) 4.59 ± 0.20a 5.01 ±0.15 5.52 ± 0.21a
Integrated glucose (TAUC) 
(mmol/L. min)
1469 ±71 1587 ± 89 1694 ±58
Incremental glucose (IAUC) 
(mmol/L.min)
366 ± 68 384 ±70 368 ± 56
Integrated glucose 
0-60mins (mmol/L.min)
426 ±19 457 ±27 516 ±30
Integrated glucose 
60-120mins (mmol/L.min)
383 ±33 396 ± 35 463 ± 33
Integrated glucose 
120-180mins (mmol/L.min)
334 ±19 380 ±21 385 ±15
Integrated glucose 
180-240mins (mmol/L.min)
326 ±21 353 ± 14 330 ±11
aP<0.01
Fasting glucose levels were significantly higher in the highTAG group than the control 
group. The modTAG group had higher fasting glucose levels than the control group and 
lower levels than the highTAG group, but these differences were not significant.
The three groups showed a similar postprandial glucose response to the test meal, 
peaking at 30 minutes and then declining, although the highTAG group appeared slower 
to decrease initially than the other two groups. The modTAG group showed a slight rise
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between 90 and 150 minutes that was not exhibited by the other two groups, as did the 
control group between 180 and 210 minutes.
The total integrated glucose response was greatest in the highTAG group, followed by the 
modTAG group and finally least in the control group, however the differences were not 
significant. The incremental response was similar between all three groups.
Repeated measures analysis of variance did not show a difference between the groups.
5.3.3. In su lin
The insulin responses of the hypertriglyceridaemic and control subject groups to the test 
meal are shown in Table 5.3 and illustrated graphically in Fig. 5.3. Values in the table 
with the same small case superscript letter are significantly different from each other.
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Table 5.3. Insulin responses to a test meal in hypertriglyceridaemic and control subjects,
n = 8 (mean ±  S.E.M.).
control modTAG highTAG
Fasting insulin (pmol/L) 45 + 7* 60 ± 10b 314 ± 129"*
Integrated insulin (TAUC) 
(pmol/L. min)
95802± 15493e 107718 ±13913d 237848 ± 50074c,d
Incremental insulin 
(IAUC) (pmol/L. min)
85047± 14739e 93273±12851f 162548 ±31062"'
Integrated insulin 
0-60mins (pmol/L.min)
22827 ± 2338g 31828 ±5801h 64444 ± 11472g,h
Integrated insulin 
60-120mins (pmol/L.min) 28734 ±4584' 30598 ± 4326' 74844 ± 14893ij
Integrated insulin 
120-180mins (pmol/L.min)
25509 ± 5744k 27096 ±3355' 62762 ± 17109*"'
Integrated insulin 
180-240mins (pmol/L.min)
18731 ±4979 18197 ± 2074 35798 ± 9422
a,b,e,t,k,l p <  Q Q^ 
c,d,g,h,i,j p <  q  Q1
Insulin levels rose to a peak between 30 -  60 minutes postprandially in all three groups, 
before declining slowly. None had reached fasting levels by the end of the test period.
The highTAG group had significantly higher fasting insulin levels than both the 
modTAG and control groups (P < 0.05), who were very similar.
The highTAG group had significantly greater total integrated (P < 0.01) and incremental 
(P < 0.05) responses than both the modTAG and control groups. The total area under the 
curve (AUC) for each of the first three hours of the study was also significantly greater in 
the highTAG group than both other groups (AUC 0 -6 0  mins and AUC 6 0 -  120 mins: P  
< 0.01; AUC 120-180 mins P  < 0.05). There was no significant difference in the AUC
Fi
gu
re
 
5.3
. 
In
su
lin
 
re
sp
on
se
s 
to 
a 
tes
t 
me
al
 in
 
hy
pe
rtr
ig
ly
ce
rid
ae
m
ic
 
and
 
co
nt
ro
l 
su
bj
ec
ts,
 n 
= 
8 
(m
ea
n 
± 
S.
E.
M
.) 
18
00
 
-,
i  -a
O
O
fN
O
OO
oun
o(N
O
Os
O
<D
Om
om
ooso
oo ooCN
ooo
oooo
ooso
oo<N
(q/iomd) U04BJ)U3DU03 ui|nsu%
176
Ti
me
 
(m
in
s)
between 180 -  240 mins, although the trend was for a greater response in the highTAG
group.
Repeated measures analysis of variance showed a significant difference between the 
groups (P < 0.001).
5.3.4. PROINSULIN
The proinsulin responses of the hypertriglyceridaemic and control subject groups to the 
test meal are shown in Table 5.4 and illustrated graphically in Fig. 5.4.
Table 5.4. Proinsulin responses to a test meal in hypertriglyceridaemic and control 
subjects, n -  8 (mean ±S.E.M.)
control modTAG highTAG
Fasting proinsulin 
(pmol/L)
15 ±3.2 15 ±1.8 17 ±3.8
Integrated proinsulin 
(TAUC) (pmol/L.min)
10356 ± 2399 11658 ±2320 18698 ±5542
Incremental proinsulin 
(IAUC) (pmol/L.min)
6651± 1776 8133 ±2052 14558 ±4987
Integrated proinsulin 
0-60mins (pmol/L.min)
1500 ±261 1846 ±401 2362 ±510
Integrated proinsulin 
60-120mins (pmol/L.min)
2644 ± 464 3022 ±720 5571± 1700
Integrated proinsulin 
120-180mins (pmol/L.min)
3154 ±822 3591 ±784 6898 ± 2337
Integrated proinsulin 
180-240mins (pmol/L.min)
3058± 937 3199 ±548 3868 ± 1050
Fasting proinsulin concentrations were very similar between all three groups. Levels rose
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more sharply and remained higher postprandially in the highTAG group than the other 
two groups, peaking at 120 minutes, and had not returned to fasting levels by the end of 
the study period. However, there was a large standard deviation within this group. The 
proinsulin response was slightly higher in the modTAG group than the control group, but 
both followed a similar pattern, increasing slowly, with no clear peak. There were no 
statistically significant different results for proinsulin between the groups.
5.3.5. GIF
The GIF responses of the hypertriglyceridaemic and control subject groups to the test 
meal are shown in Table 5.5 and illustrated graphically in Fig. 5.5. Values in the table 
with the same small case superscript letter are significantly different from each other.
Table 5.5. GIP responses to a test meal in hypertriglyceridaemic and control subjects, n 
= 8 (mean ±  S.E.M.)
control modTAG highTAG
Fasting GIP (pmol/L) <15 <15 < 15
Integrated GIP (TAUC) 
(pmol/L.min)
47270 ±5153a,b 67718 ±5191b 63089± 5226a
Incremental GIP (IAUC) 
(pmol/L.min)
43670 ±5153c,d 64118 ±5191d 59489 ± 5226°
Integrated GIP 
0-60mins (pmol/L.min)
3481 ±161° 6535± 987 9466± 2018e
Integrated GIP 
60-120mins (pmol/L.min)
11327 ± 2407 17741± 1749 16629 ±1401
Integrated GIP 
120-180mins (pmol/L.min)
16033±1472f 22468±1672f 18504± 1416
Integrated GIP 
180-240mins (pmol/L.min)
16429± 1657 20974± 2375 18489± 1191
a,b,c,d,t p <  0  0 5  5 f  < 0 . 0 1
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Fasting GIP levels were below the level of detection of the assay for all three subject 
groups. Postprandial GIP levels initially rose most sharply in the highTAG group, but had 
begun to plateau at 60 minutes, whilst both other groups continued to rise. The control 
group GIP levels remained less than the highTAG group for the study period, but the 
modTAG group plateaued at a higher GBP concentration than the highTAG group, before 
beginning to decrease at 180 minutes. None of the groups had returned to fasting GIP 
levels by the end of the study period.
The total integrated and incremental GIP responses to the test meal were significantly 
less in the control group than in both the modTAG and highTAG groups (P < 0.05). 
When the total integrated response was examined by each hour of the study, the 
highTAG group was significantly greater than the control group in the first hour (P < 
0.01) and the modTAG group GIP response was significantly greater than the control 
group between 120 -  180 minutes (P < 0.05). There were no statistically significant 
differences between 6 0 -1 2 0  and 180 -  240 minutes.
Repeated measures analysis of variance showed a significant difference between the 
groups (P = 0.04).
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5.3.6. GLP-1(7.36)AMIDE
The GLP-l(7.3 6 )amide responses of the hypertriglyceridaemic and control subject groups 
to the test meal are shown in Table 5.6 and illustrated graphically in Fig. 5.6.
Table 5.6. GLP-l(7 .3 6 )amide responses to a test meal in hypertriglyceridaemic and 
control subjects n = 8 (mean ±  S.E.M.).
control modTAG highTAG
Fasting GLP-1 (pmol/L) 14 ±2.0 17 ±4.1 13 ±2.6
Integrated GLP-1 
(TAUC) (pmol/L.min)
6251 ±816 7611 ±1204 5190 ±1098
Incremental GLP-1 
(IAUC) (pmol/L.min)
2951 ±673 3592 ±1317 2100 ±793
Integrated GLP-1 
0-60mins (pmol/L.min)
1699 ± 240 1915 ±348 1421± 353
Integrated GLP-1 
60-120mins (pmol/L.min)
1361 ±224 1869 ±367 1209 ±261
Integrated GLP-1 
120-180mins (pmol/L.min)
1592 ±262 2092± 342 1279 ± 282
Integrated GLP-1 
180-240mins (pmol/L.min)
1599 ±230 1734 ± 369 1281 ±268
Fasting GFF-l^.^am ide levels were similar between the three subject groups. They rose 
to a peak at 30 minutes postprandially, with the highTAG group mean level appearing 
lower than the other two groups, but there were large standard deviations at each time 
point. Lower GLF-l^.^amide in the highTAG group persisted throughout the study, 
with the modTAG group having the greatest total integrated and incremental response of 
all three groups, but none of the differences were significant.
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5.4. DISCUSSION
Subject numbers were relatively small in each group (n = 8 per group) and groups were 
not matched for sex, although they were for age and BMI. At the end of the four hour test 
period, Plasma TAG had not reached their peak levels, GIP levels were just past their 
peak and glucose, insulin, proinsulin and GTP-l^.^amide had not quite returned to 
fasting levels. This means that the calculated integrated responses to the test meal 
stimulus were only partial values and were not necessarily indicative of the complete 
response. This is more important when comparing integrated responses of hormones or 
metabolites that are still near their peak at the conclusion of the study, with those that 
have nearly returned to basal. These caveats have to be considered when any 
interpretation of the results is made.
This investigation confirms many previous studies that subjects with marked 
hypertriglyceridaemia (highTAG group: fasting TAG > 6.0 mmol/L) have both fasting 
and meal-stimulated peripheral hyperinsulinaemia (Olefsky et ah, 1974; Reaven et a l, 
1983; Gama et a l, 1995a). It also demonstrates that those subjects with lower fasting 
TAG levels, who are still defined clinically as hypertriglyceridaemic (modTAG group: 
fasting TAG 2.5 - 6 mmol/L), are similar to normal subjects in both their fasting insulin 
concentrations and response to insulinotropic stimuli.
Fasting glucose levels were greater in the highTAG group than the modTAG group and 
significantly elevated in the highTAG group compared with the control group. There was
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also a trend for glucose levels to be higher throughout most of the test period in the 
highTAG group than both other groups.
This suggests that while plasma TAG levels are not too elevated, hypertriglyceridaemic 
subjects can maintain near normal insulin and glucose levels. However, as fasting TAG 
concentrations increase, circulating insulin concentrations and the degree of insulin 
resistance also rise to a level where the compensatory hyperinsulinaemia is no longer 
sufficient to adequately suppress plasma glucose. This concurs with a study by Coppack 
et ah, (1989) who demonstrated in normoglycaemic subjects that the degree of insulin 
resistance is correlated with plasma TAG levels.
Fasting proinsulin levels are similar between groups, but the highTAG group show a non­
significant trend towards an increased response to a mixed test meal. This concurs with 
the increased insulin levels seen in this group.
There were no significant differences between groups for either fasting or postprandial 
GLP-1 (7 -3 6 )amide levels. There was a trend for lowest integrated and incremental GLP-1 (7 . 
3 6 )amide in the highTAG group, greatest in modTAG group and the control group 
inbetween. Low GLP-l^.3 ^amide levels in the highTAG group could be due to increased 
circulating NEFA levels as was seen in obese subjects in Chapter 3 when heparin was 
administered, increasing circulating NEFA levels and causing a decrease in GLP-1 (7 . 
3 6 )amide levels. NEFA concentrations were not measured in this study, so we do not
know if they were increased in the highTAG group, however, the study in Chapter 6 
showed that hypertriglyceridaemic subjects had higher fasting and post-sucrose NEFA 
levels.
Fasting GIP levels were below the level of detection of the assay, so comparisons cannot 
be made between the groups. Both the highTAG and modTAG groups had significantly 
greater integrated and incremental responses to the test meal than the control group. 
There were no statistically significant differences between the highTAG and modTAG 
groups, but there was a trend for a faster rise, but earlier plateau in the highTAG group 
than modTAG group, leading to a greater total integrated and incremental GIP response 
in the modTAG group than either the highTAG or control group.
The modTAG group exhibited a near normal insulin response to the test meal, but a 
significantly raised GIP response, whereas the highTAG group were hyperinsulinaemic 
with a lower GIP response than in the modTAG group. This supports the theory of 
negative feedback of high levels of insulin on fat-stimulated GIP secretion in the 
highTAG group (Creutzfeldt et al., 1978). Whilst GIP may have a small role as an 
incretin in hypertriglyceridaemia, high insulin levels feed back in an attempt to suppress 
this effect in severely hypertriglyceridaemic subjects. There was no evidence that GLP- 
l(7 _3 6 )amide was playing a part in the hyperinsulinaemia of hypertriglyceridaemia.
GIP and GEP-l^.^am ide are known to have a direct effect on glucose uptake and
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metabolism (see Sections 1.3.2. and 1.3.3.) e.g. suppression of hepatic glucose production 
(Hartmann et al., 1986) and facilitation of glucose transport into tissues (D’Alessio et ah, 
1994). This could help explain why the modTAG group does not exhibit the same degree 
of hyperglycaemia as the highTAG group, because of the controlling effects of the 
enteroinsular axis on circulating glucose levels. The modTAG group may also be less 
resistant to the glucose-lowering effects of insulin than the highTAG group.
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CHAPTER 6.
E f f e c t s  o f  A c a r b o s e  o n  S u c r o s e - 
In d u c e d  E n t e r o -Pa n c r e a t ic  
H o r m o n e  Se c r e t io n  i n  
H y p e r t r ig l y c e r id a e m ia .
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6.1. INTRODUCTION
The hormones GIP and GLP-1 (7 -3 6 )amide are released into the circulation by cells in 
the gastrointestinal tract in response to nutrient ingestion (see Section 1.3.). They have 
been demonstrated to have an insulinotropic effect and it is postulated that they have a 
physiological role in maintaining glucose and lipid homeostasis. Postprandial GIP 
release is dependent on the absorption of nutrients from the gut. Less is known about 
the mechanisms underlying GLP-l^.^am ide release. An indirect neuro-humoral 
signal from the proximal small intestine has been suggested due to the observation 
that GLP-1 (7 -3 6 )amide is secreted rapidly in response to nutrient ingestion, before the 
nutrients come into direct contact with the G L P-l^^am ide secreting L-cells in the 
distal ileum and colon (see Section 1.3.3).
Acarbose is an inhibitor of a-glucosidase enzymes that are situated in the brush- 
border of the gastrointestinal tract mucosa and also of pancreatic oc-amylase (Jenkins 
et al., 1981; Hiele et al., 1992). Inhibition of these enzymes prevents the hydrolysis of 
sucrose and larger carbohydrate molecules into their constituent monosaccharides, 
which is a prerequisite for their absorption. This leads to the attenuation of 
postprandial blood glucose and insulin levels (Fôlsch et a l, 1981), making acarbose 
useful in the treatment of non-insulin dependent diabetes (Fôlsch et a l, 1987).
Administration of sucrose together with acarbose causes a suppression of GIP 
secretion (Fukase et a l, 1992; Qualmann et a l, 1995), as might be expected because 
the sucrose is not broken down into its monomers glucose and fructose, thus 
preventing the active absorption of glucose, the latter of which has been shown to be
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necessary for sucrose-stimulated GIF secretion.
In contrast to the suppressed GDP secretion, exaggerated and prolonged GLP-1(7. 
3 6 )amide secretion has been demonstrated following combined sucrose and acarbose 
administration (Fukase et al., 1992; Qualmann et al., 1995). Gôke and co-workers 
(1995) utilising another ot-glucosidase inhibitor, voglibose, which has little effect on 
oc-amylase activity, suggested that the inhibition of intestinal disaccharidases leading 
to delayed glucose absorption mobilised the endogenous pool of GFF-l^.^am ide.
The rate of nutrient absorption following meal ingestion and subsequent stimulation 
of hormone production is influenced by the rate of gastric emptying delivering 
nutrients to the small intestine. Increased GTF-l^.^amide levels have been shown to 
inhibit gastric emptying (Fehmann et a l, 1995). The effect of acarbose on gastric 
emptying is not known, but as acarbose administration appears to increase GFF-l^. 
3 6 >amide levels, gastric emptying may be inhibited and this may be another 
mechanism whereby acarbose attenuates glucose, insulin and GIF secretion.
Mouth to caecum transit times, as monitored by breath hydrogen measurements have 
been shown to be reduced following acarbose (Ladas et a l, 1992). It was suggested 
that reduced carbohydrate absorption causes an increase in intestinal motility. Gastric 
emptying rates were not measured.
Gastric emptying rates can be measured using isotopically labelled markers, but this is
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not used routinely because of the exposure of the subjects to ionising radiation. A 
simple non-invasive technique is to use an oral paracetamol bolus, where the 
appearance of paracetamol in the circulation has been shown to be mainly determined 
by the rate of gastric emptying, rather than paracetamol absorption (Heading et a l, 
1973; Gainsborough et al., 1993).
The study in Chapter 5 demonstrated raised GIF levels in hypertriglyceridaemic 
subjects in response to a test meal. Altered gastric emptying could have contributed to 
this. Whilst a mixed test meal is a more physiological situation, it can introduce 
confounding variables when attempting to assess hormone and metabolite production 
in different disease states. Single nutrient administration can overcome this.
The aims of the study were:
♦ to examine sucrose-mediated entero-pancreatic hormone secretion and the effects 
of acarbose on this in hyper- and normotriglyceridaemic subjects
♦ to investigate whether gastric emptying, as interpreted from paracetamol 
measurements, is altered in hypertriglyceridaemia and the effects of acarbose on 
gastric emptying in hyper- and normotriglyceridaemic subjects.
6.2. STUDY DESIGN
This study was conducted in collaboration with Dr L. Ranganath at Epsom General 
Hospital, Epsom, Surrey. Ethical committee approval was obtained from the Epsom
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Health Care District Medical Ethics Committee. All subjects gave written consent 
before participating in the study.
6.2.1. Su bjec ts
Six hypertriglyceridaemic men (age: 47.8 ± 8.6 years; BMI: 26.5 ± 1.4; fasting TAG: 
4.8 ±1 .9  mmol/L [mean ± S.D.]) were recruited from the metabolic clinic at Epsom 
General Hospital. Six male normotriglyceridaemic age-matched control subjects (age: 
47.4 ± 7.6 years; BMI: 24.1 ± 2.5; fasting TAG: 1.2 ± 0.8 mmol/L [mean ± S.D.]) 
were recruited from hospital staff.
6.2.2. M eth o d s
Subjects attended the hospital on two occasions separated by at least a week in 
random order. On each of the treatment days, following an overnight fast, an 
indwelling cannula was inserted into an antecubital vein in the forearm and two 
baseline blood samples were collected before 100 g sucrose dissolved in 500 ml water 
was administered orally. The solution also contained 4 g of finely powdered 
paracetamol (Pameton™, paracetamol with a methionine group provider) and was 
ingested over 15 minutes. Blood samples were collected at 15 and 30 minutes and 
then every 30 minutes until 210 minutes post-sucrose. On one of their two visits, 
subjects were given 100 mg acarbose (Glucobay™) orally 3 minutes before 
consuming the sucrose/paracetamol solution.
Each blood collection consisted of 2 ml for glucose (into a fluoride oxalate tube), 3ml
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for paracetamol, NEFA and TAG (into a plain glass tube with no additives) and 10 
ml for insulin, GEF-l^.^am ide and GIF (into a lithium heparin tube containing 
1000KIU/ml blood of Aprotinin). Blood for glucose and hormones was centrifuged at 
1850 g for 10 minutes immediately after collection and the plasma separated, 
aliquoted and frozen at -20°C until analysis. Paracetamol, TAG and NEFA levels 
were measured on serum samples, in which the blood had been allowed to clot, the 
serum removed and then centrifuged and stored as for the plasma.
Glucose, TAG, NEFA and paracetamol measurements were conducted by the 
Department of Clinical Biochemistry at Epsom General Hospital using the methods 
described in Chapter 2. Insulin was measured by Dr L. Ranganath at the University 
using the radioimmunoassay method in Chapter 2. Plasma gut hormones were 
measured by radioimmunoassay using the methods described in Chapter 2.
The different treatments will henceforth be called “sucrose” for sucrose alone and 
“acarbose” for sucrose and acarbose together.
6.2.3. S ta tistic a l  A nalysis
The data is expressed as mean ± standard error of the mean (mean ± S.E.M.) unless 
otherwise stated, in both tables and graphs. P values of < 0.05 were taken as 
statistically significant. To facilitate statistical analysis, hormone levels below the 
sensitivity of the assay were assigned the limit of detection of the assay.
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Total integrated and incremental responses (area under the curve 0 - 1 2 0  mins), 
TAUC and IAUC respectively, were calculated using the trapezoidal rule. The time- 
period was also divided into three intervals (0-60, 60-120 and 120-210 mins) and 
integrated responses calculated on these.
Differences between treatments for each subject group i.e. responses following 
sucrose compared with responses following acarbose for hypertriglyceridaemic 
subjects (and the same for control subjects) were compared using a paired Student’s 
‘t’ test. If the pairing was ineffective, an unpaired test was used. Differences between 
subject groups for each treatment i.e. responses following sucrose in the 
hypertriglyceridaemic subjects compared with responses following sucrose in the 
control subjects (and the same for the acarbose treatment) were compared using an 
unpaired Student’s ‘t’ test. Appropriate transformations (log, reciprocal or square 
root) were used if necessary to satisfy the assumptions of t-test. The non- 
parametric Mann-Whitney U test was used if the data did not fit the criteria necessary 
for parametric testing.
6.3. RESULTS
6.3.1. Glu c o se
The glucose responses of the hypertriglyceridaemic and control subject groups to the 
sucrose and acarbose treatments are shown in Table 6.1. and illustrated graphically in 
Fig. 6.1.
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Table 6.1. Glucose responses of hypertriglyceridaemic and control subjects to
sucrose and acarbose treatments, n = 6 (mean ± S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Fasting glucose 
(mmol/L)
5.6 +  0.18 5.4 ±  0.20 5.8 ± 0 .39 5.8 ±0.41
Integrated glucose 
(TAUC) 
(mmol/L.min)
1252±111 1175 ± 6 5 1327 ±101 1312 ± 7 9
Incremental 
glucose (IAUC) 
(mmol/L.min)
86 + 89 39 ± 2 9 104 ±  34 94 ± 3 0
Integrated glucose 
0-60 mins 
(mmol/L.min)
460 ± 4 3 384 ±  26 462 ± 41 395 ±  24
Integrated glucose 
60-120 mins 
(mmol/L.min)
370 + 53 327 ±  25 403 ±  34 377 ±  26
Integrated glucose 
120-210mins 
(mmol/L.min)
421 ± 2 9 464 ±  19 462 ±  26 540 ±  30
Fasting glucose levels were slightly, but not significantly, higher in the 
hypertriglyceridaemic group compared with the control group for both treatments.
Following the sucrose alone treatment, glucose levels rose sharply in both groups, 
peaking at 30 mins and declining to sub-basal levels, between 120 and 210 minutes. 
Following the acarbose treatment, glucose levels again peaked at 30 mins, but at a 
significantly reduced concentration in both groups (P < 0.05). Glucose levels returned 
to basal by 90 minutes in the control group, but remained elevated throughout the 
study in the hypertriglyceridaemic subjects.
There was a trend for the hypertriglyceridaemic group to have a higher integrated 
glucose response than the control subjects following acarbose between 120-210 mins 
(P < 0.1) and also for the hypertriglyceridaemic group to have a higher integrated
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response between 120-210 mins following sucrose alone compared with acarbose (P 
< 0.1).
6.3.2. TAG
The TAG responses of the hypertriglyceridaemic and control subject groups to the 
sucrose and acarbose treatments are shown in Table 6.2. and illustrated graphically in 
Fig. 6.2. Values in the table with the same superscript small case letter are 
significantly different from each other.
Table 6.2. TAG responses o f hypertriglyceridaemic and control subjects to sucrose 
and acarbose treatments, n = 6 (mean ±  S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Fasting TAG 
(mmol/L)
1.1+0.31* 1.2 + 0.3C 4.9 ±0.69* 5.4 ±  l . l c
Integrated TAG 
(TAUC) 
(mmol/L.min)
233 ± 6 6 b 251 + 74d 954 ± 113b 1024 ±  208d
Incremental TAG 
(IAUC) 
(mmol/L.min)
-5 + 4 -4 ± 1 2 -68 ±  39 -109 ± 4 0
Integrated TAG 
0-60 mins 
(mmol/L.min)
65 ± 1 8 72 ± 1 9 276 ±  38 307 ±  64
Integrated TAG 
60-120 mins 
(mmol/L.min)
66 + 19 72 ± 2 2 269 ±  33 293 ±  62
Integrated TAG 
120-210mins 
(mmol/L.min)
102 ±  30 107 ±  33 409 ± 4 4 424 ±  82
a,b,c,d p  <  o , 0 0 1
As expected, because of the groupings chosen, the hypertriglyceridaemic subjects had 
higher fasting and postprandial integrated TAG levels following both sucrose and 
acarbose treatments (P < 0.001). TAG levels decreased slightly, initially, in both
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groups, following both treatments and then remained constant for the remainder of the 
study. There was no difference in incremental response between subject groups for 
each treatment.
There were no differences between treatments for either of the subject groups.
6.3.3. NEFA
The NEFA responses of the hypertriglyceridaemic and control subject groups to the 
sucrose and acarbose treatments are shown in Table 6.3. and illustrated graphically in 
Fig. 6.3. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 6.3. NEFA responses of hypertriglyceridaemic and control subjects to sucrose
and acarbose treatments, n -  6 (mean ± S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Fasting NEFA 
(mmol/L)
0.43 ±0.11" 0.45 ± 0.07 0.74 ±0.07" 0.67 ±0.10
Integrated NEFA 
(TAUC) 
(mmol/L.min)
51 ±13 45 ± 12b 78 ±14 96 ± 18b
Incremental 
NEFA (IAUC) 
(mmol/L.min)
-40 ± 14d -49 ± 9 -79 ± 12c,d -44 ±6'
Integrated NEFA 
0-60 mins 
(mmol/L.min)
21 ± 6 19 ± 4e 35 ±4 38 ± 6e
Integrated NEFA 
60-120 mins 
(mmol/L.min)
11 ± 3 o 1+ 20 ± 4 28 ± 6 f
Integrated NEFA 
120-210mins 
(mmol/L.min)
19 ±7 16±6 23 ±7 29 ±8
a>b’c’e>t P < 0.05 
d f  <0.1
Fasting NEFA levels were higher in the hypertriglyceridaemic subjects than controls, 
but were only statistically significantly different following the sucrose alone treatment 
(P < 0.05). There were no significant differences in fasting NEFA levels between 
treatments for either of the subject groups.
NEFA levels decreased postprandially in both groups following each treatment and in 
all except the hypertriglyceridaemic group following acarbose treatment had begun to 
rise towards the end of the study period. The rate of NEFA decline appeared slower 
following acarbose in the obese group compared with sucrose.
The hypertriglyceridaemic group had higher mean integrated and incremental
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postprandial NEFA responses than control subjects for both treatments. However, the 
only significant differences between subject groups were following acarbose (total 
integrated, integrated 0 - 6 0  and 60 -  120: P < 0.05). There was also a trend (P < 0.1) 
following sucrose for greater incremental and integrated 0 - 6 0  mins NEFA response 
in the hypertriglyceridaemic subjects.
The NEFA responses between treatments for each group were quite similar, although 
the acarbose treatment did appear to produce a less rapid decline in the 
hypertriglyceridaemic subjects than sucrose alone and NEFA concentrations remained 
at a higher level. This produced the only statistically significant difference between 
treatments for either subject group (greater incremental response following sucrose 
alone than acarbose in the hypertriglyceridaemic subjects, P  < 0.05).
6.3.4. In su l in
The insulin responses of the hypertriglyceridaemic and control subject groups to the 
sucrose and acarbose treatments are shown in Table 6.4. and illustrated graphically in 
Fig. 6.4. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 6.4. Insulin responses o f hypertriglyceridaemic and control subjects to sucrose
and acarbose treatments, n = 6 (mean ± S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Fasting insulin 
(pmol/L)
109 ± 39 153 ±43 268 ± 85 198 ± 67
Integrated insulin 
(TAUC) 
(pmol/L.min)
104104 ± 2441 Ie 68292± 13553e 116925 ±29635" 70729 ±28418"
Incremental 
insulin (IAUC) 
(pmol/L.min)
81214 ±18420d 36074± 6673d 60610 ±12417b 29219 ±15687b
Integrated insulin 
0-60 mins 
(pmol/L.min)
31054 ±6519 21279 ±3834 43598 ± 10774e 23339± 8081e
Integrated insulin 
60-120 mins 
(pmol/L.min)
44995 ± 10752g 23808 ± 5453s 40830 ±9960f 22372± 9369f
Integrated insulin 
120-210mins 
(pmol/L.min)
28055 ±8281 23205 ±5033 32498 ± 10476 25018 ±11190
a,b,c,d,e,t,g p KQ Q5
Mean fasting insulin levels were greater in the hypertriglyceridaemic subjects than in 
controls, but the differences were not statistically significant.
Insulin levels rose promptly in both groups following both treatments to peak at 30 
mins in the hypertriglyceridaemic subjects following both treatments and between 60 
-  90 mins in the control subjects. Insulin levels had returned to basal by the end of the 
study period. There were no differences between hypertriglyceridaemic and control 
subjects for either treatment.
Comparison of the two treatments for each subject group showed that the acarbose 
treatment produced significantly reduced insulin responses in both
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hypertriglyceridaemic and control subjects (integrated, incremental and integrated 60 
-  120 mins responses, P < 0.05 for both subject groups; integrated 0 - 6 0  mins 
response, P < 0.05 for hypertriglyceridaemic subjects only). There were no 
differences in the last 90 mins of the study as insulin concentrations returned to basal.
6.3.5. GLP-l(7.36)AMiDE
The GLP-l(7 _3 6 )amide responses of the hypertriglyceridaemic and control subject 
groups to the sucrose and acarbose treatments are shown in Table 6.5. and illustrated 
graphically in Fig. 6.5. Values in the table with the same superscript small case letter 
are significantly different from each other.
Table 6.5. GLP-1 (j^am ide responses o f hypertriglyceridaemic and control subjects 
to sucrose and acarbose treatments, n = 6 (mean ±  S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Fasting GLP-1 
(pmol/L)
10 ±1.3 8.5 ±0.5 9.5 ±1.0 12 ± 2
Integrated GLP-1 
(TAUC) (pmol/L.min)
2246 + 153c 6291± 1005° 2926 ±880" 7001± 1745"
Incremental GLP-1 
(IAUC) (pmol/L.min)
93 ±241d 4506 ± 974d 931 ±672b 4551±1415b
Integrated GLP-1 
0-60 mins 
(pmol/L.min)
1021±137g 1569 ± 247s 1469 ±709 1966 ±582
Integrated GLP-1 
60-120 mins 
(pmol/L.min)
485 ± 5 h 2265±385h 688 ±135e 2288 ± 591e
Integrated GLP-1 
120-210mins 
(pmol/L.min)
740 + 20' 2458 ± 414' 770±47f 2748 ± 595f
a,b,e,t,g p <  0  0 5  
c,d,h,i p < 0 . 0 1
Fasting GFF-l^.^am ide levels were similar between hypertriglyceridaemic and 
control subjects.
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GLP-1 (7 -3 6 )amide increased rapidly postprandially, peaking at 30 mins in the 
hypertriglyceridaemic group following both treatments and the control group 
following sucrose alone. The control group following acarbose treatment peaked later, 
between 60 -  90 mins. There was no difference in responses between 
hypertriglyceridaemic and control subject groups for either treatment.
Comparison of the two treatments showed that acarbose produced a sustained 
elevated GLP-l^.^am ide response in both subject groups relative to sucrose alone. 
GLP-1 (7 _3 6 )amide concentrations had not returned to basal following acarbose in either 
subject group by the end of the study period, whereas following sucrose alone GLP- 
l(7 _3 6 )amide levels returned to basal approximately 60 mins postprandially 
(hypertriglyceridaemic, acarbose vs sucrose: integrated, incremental, integrated 60 -  
120 and 120 -  210 responses: P < 0.05; control, acarbose vs sucrose: integrated, 
incremental, integrated 6 0 -1 2 0  and 120-210 responses: P  < 0.01; integrated 0 - 6 0  
response: P < 0.05).
6.3.6. GIP
The GIP responses of the hypertriglyceridaemic and control subject groups to the 
sucrose and acarbose treatments are shown in Table 6.6. and illustrated graphically in 
Fig. 6.6. Values in the table with the same superscript small case letter are 
significantly different from each other.
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Table 6.6. GIP responses of hypertriglyceridaemic and control subjects to sucrose
and acarbose treatments, n = 6 (mean ± S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Fasting GIP 
(pmol/L)
39 + 11 <25 40 ±14 42± 11
Integrated GIP 
(TAUC) 
(pmol/L.min)
18602 ±2874° 6021± 699c 2621o ± 2623" 8251± 1668"
Incremental GIP 
(IAUC) 
(pmol/L.min)
10447 ± 2782 771± 699 16078 ±1392b -362 ± 1261b
Integrated GIP 
0-60 mins 
(pmol/L.min)
5842 + 977s 2119±547s 7653 ±1003d 2845 ± 767d
Integrated GIP 
60-120 mins 
(pmol/L.min)
7260±1273h 1630+ 130h 10085 ±93 Ie 2712±524e
Integrated GIP 
120-210mins 
(pmol/L.min)
5500+754' 2272 + 22' 8472±1132f 2964 ±428'
c,d,g,h,i p  <  o  0 1
a f P < 0.001
b'e P < 0.0001
Fasting GDP levels were similar between hypertriglyceridaemic and control subjects.
GDP levels increased following sucrose alone to peak at 90 mins in both 
hypertriglyceridaemic and control subject groups. The hypertriglyceridaemic subjects 
appeared to have a greater response to sucrose than the control subjects, but there 
were no significant differences. There was a trend for this between 120-210  mins (P 
< 0.1).
The GDP response to sucrose following acarbose treatment was virtually abolished in
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both subject groups, although again, the hypertriglyceridaemic subjects appeared to 
have a higher GIP response than control subjects, particularly between 6 0 -  120 mins 
following acarbose treatment (P < 0.1). In hypertriglyceridaemic subjects, 
significantly greater responses to sucrose alone were found for incremental and 
integrated 6 0 -  120 mins (P < 0.0001); total integrated and integrated 120-210  mins 
(P < 0.001) and integrated 0 - 6 0  mins (P < 0.01). In control subjects, significantly 
greater responses to sucrose alone were found for total integrated (P < 0.0001); and 
integrated 0 -  60, 60 -  120 and 120 -  210 (P < 0. 01).
6.3.7. P a r a c e t a m o l
The paracetamol responses of the hypertriglyceridaemic and control subject groups to 
the sucrose and acarbose treatments are shown in Table 6.7. and illustrated 
graphically in Fig. 6.7. Values in the table with the same superscript small case letter 
are significantly different from each other.
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Table 6.7. Paracetamol responses of hypertriglyceridaemic and control subjects to
sucrose and acarbose treatments n = 6 (mean ±  S.E.M.).
CONTROL HYPERTRIGLYCERIDAEMIC
SUCROSE ACARBOSE SUCROSE ACARBOSE
Integrated paracetamol 
(TAUC)
(mg/L.min)
3499 ±  464a 1923 ±  224a 2838 ± 493 1695 ±395
Incremental
paracetamol
(IAUC) (mg/L.min)
3412 + 4145 1852±275b 2768 ±  543 1695 ±  395
Integrated paracetamol 
0-60 mins
(mg/L.min)
204 ± 5 9 108 ± 4 4 225 ± 7 4 272 ± 7 3
Integrated paracetamol 
60-120 mins 
(mg/L.min)
960 ± 174 508 ±  80 9 3 5 ± 199 552 ±1 8 2
Integrated paracetamol 
120-210mins 
(mg/L.min)
2355 + 292" 1308 ±  162" 1678 ±  284d 870 ±  248d
0 P < 0.05
a b c P < 0.01
Paracetamol levels rose steadily in all groups following administration at t = 0 mins. 
The response was similar between groups and treatments for the first 30 -  60 mins of 
the study, after which the responses were higher following sucrose alone in both 
hypertriglyceridaemic and control subjects, with control subjects having the greatest 
response. Control subjects also showed the greater paracetamol response of the two 
subject groups following acarbose treatment, although this was still less than the 
responses elicited following sucrose alone.
There were no statistically significant differences between hypertriglyceridaemic and 
control subjects for paracetamol response following either treatment. There were 
differences between treatments for each subject group. Control subjects exhibited 
significantly higher total integrated, incremental and integrated 120-210  mins
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paracetamol responses following sucrose alone (P < 0.01) compared with acarbose 
treatment and a trend for a greater response between 60 -  120 mins (P < 0.1). The 
only statistically significant difference in the hypertriglyceridaemic subjects was in 
the last 90 mins of the study, with a greater response following sucrose alone than 
acarbose (P < 0.05).
6.4. DISCUSSION
The administration of acarbose produced significantly reduced insulin and GIP 
responses to sucrose in both hypertriglyceridaemic and control subjects and a trend 
towards reduced glucose concentrations, consistent with its role as an a-glucosidase 
inhibitor, preventing digestion and subsequent absorption of glucose. This confirms 
the findings of other investigators (Fôlsch et a l, 1981; Lembcke et a l, 1990; Gôke et 
al., 1995). Glucose levels were not significantly reduced following acarbose, as has 
been shown by other groups, but this may be due to the doses of acarbose and sucrose 
used.
The hypertriglyceridaemic subjects did not exhibit fasting or postprandial
hyperinsulinaemia as other studies have found (Crapo et ah, 1981; McKane et al.,
1990). This may be due to their degree hypertriglyceridaemia. The study in Chapter 5
showed that subjects with moderate hypertriglyceridaemia (fasting TAG levels, mean
± S.E.M., 3.8 ± 0.25 mmol/L) had insulin levels similar to control subjects both
fasting and postprandially. However, subjects with severe hypertriglyceridaemia
(fasting TAG levels, mean ± S.E.M., 9.9 ±1.6  mmol/L) were hyperinsulinaemic. The
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subjects in this study had fasting TAG levels of 4.9 ± 0.69 mmol/L (mean ± S.E.M.) 
and so would be considered to show moderate hypertriglyceridaemia and we could 
expect a near normal insulin response.
The hypertriglyceridaemic subjects appeared to have a greater GBP response following 
sucrose than the control subjects, but the difference was not significant. A significant 
difference was found with the hypertriglyceridaemic subjects in Chapter 5. However, 
they were responding to a different stimulus (mixed meal), which is also reflected in 
the different pattern of GIP secretion which returns to basal by the end of this study, 
but remains sustained in Chapter 5. As stated earlier, acarbose suppressed GIP 
secretion throughout the study period in both subject groups.
There were no differences in GLP-1 (y^amide between subject groups following 
either treatment. Acarbose induced a prolonged, exaggerated G LP-l^.^am ide 
response to sucrose, in both subject groups, which was sustained to the end of the 
study period. This concurs with other studies (Fukase et al., 1992; Qualmann et al., 
1995). The findings disagree with the theory of an endocrine loop (Roberge and 
Brubaker, 1993) that proposes that GIP secretion in the proximal intestine initiates a 
neuro-humoral stimulus to GLP-l^.^^amide secretion in the distal intestine. This was 
particularly marked following acarbose, when GIP secretion was markedly attenuated, 
yet GLP-1 (7 -3 6 )amide secretion was exaggerated.
There were no significant differences in paracetamol levels between 
hypertriglyceridaemic and control subjects. This suggests that there was no difference
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in gastric emptying between hyper- and normotriglyceridaemic subjects.
Following acarbose treatment there was a trend {P < 0.1) for reduced paracetamol 
levels from 60 - 120 mins in the control group and a significant decrease in both 
subject groups from 120 - 210 mins. This is suggestive of delayed gastric emptying 
following acarbose in the latter part of the study. The lower paracetamol levels could 
be due to other factors such as reduced paracetamol absorption caused by the 
acarbose, but this is unlikely as acarbose does not appear to inhibit absorption of 
drugs including digoxin or propranolol (Hillebrand et a l, 1981), although one group 
reported inhibition of metformin absorption by acarbose (Scheen et al, 1994). A more 
direct measure is needed to confirm whether gastric emptying is altered following 
acarbose treatment. A technique such as epigastrography that is both non-invasive and 
non-isotopic would be suitable.
Paracetamol levels following acarbose treatment did not diverge from those following 
sucrose alone until 60 - 90 mins into the study. dFP-l^ .^am ide levels rise and peak 
earlier than this, possibly indicating a causative role of dFP-l^ .^am ide in the delay 
of gastric emptying as has been suggested by other investigators.
In summary, administration of acarbose slowed glucose absorption by a combination 
of a-glucosidase inhibition and delayed gastric emptying, the latter possibly caused 
by increased GLP-l(7 -3 6 )amide levels. The a-glucosidase inhibition also suppressed 
GIP secretion by preventing active absorption of glucose. The extended presence of 
sucrose in the gut allowed increased and prolonged G FP-l^.^am ide secretion The
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reduced glucose levels entering the circulation decreased insulin requirements
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7.1. INTRODUCTION
Polycystic ovarian syndrome (PCOS) is usually associated with hyperinsulinaemia 
and insulin resistance, however conflicting insulin results have been seen (see Section 
1.7.3). The gut hormone incretins, GIP and GCP-l^.^amide, have not been studied in 
relation to PCOS and may be involved in the pathogenesis of the hyperinsulinaemia 
that is seen. The hyperinsulinaemia and hyperandrogenaemia that are features of 
PCOS are partly reversible by changes to diet or weight loss (Kiddy et a l, 1989; 
Andersen et al., 1995), so it is possible that these changes occur via the enteroinsular 
axis.
This study was designed primarily to investigate the contribution (if any) of the 
enteroinsular axis to the peripheral hyperinsulinaemia that is characteristic of PCOS. 
Measurements were also made of proinsulin and C-peptide to ascertain the 
involvement of altered secretion or hepatic extraction of insulin in the 
hyperinsulinaemia seen in these women. Lean, normoglycaemic women were chosen 
to remove the confounding factors of obesity and impaired glucose tolerance on 
plasma insulin concentrations.
7.2. STUDY DESIGN
This study was conducted in collaboration with Dr R. Gama at the Royal Surrey 
County Hospital, Guildford. Ethical Committee approval was obtained from South 
West Surrey District Ethics Committee.
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7.2.1 Su bje c ts
Seven normal weight Caucasian women with PCOS were recruited from the 
endocrine clinics at the Royal Surrey County Hospital, Guildford. PCOS was defined 
as hirsuitism and oligomenorrhoea (intermenstrual interval > 35 days), or 
amenorrhoea together with raised serum testosterone levels (> 2.5 nmol/L) and/or 
androstenedione (>12 nmol/L). These women had ultrasound features of polycystic 
ovaries and no biochemical or clinical features of adrenal enzymatic defects, 
Cushing's syndrome, acanthosis nigricans, acromegaly or hyperprolactinaemia. The 
control group consisted of 8 Caucasian women with regular menstrual cycles (menses 
every 28-32 days), no biochemical or clinical evidence of hyperandrogenism and no 
ultrasound evidence of PCOS. All subjects had a normal body mass index (BMI < 25 
kg/m2) normal glucose tolerance, as defined by WHO, 1985 and no clinical or 
biochemical evidence of hypertensive, renal, hepatic, thyroid or other somatic disease. 
None were receiving medication, had altered their diet, changed weight in the 
previous month or had a family history of diabetes mellitus.
7.2.2 M eth o d s
After an overnight fast, subjects were given a 75g oral glucose tolerance test (Hycal, 
Smithkline Beecham Consumer Brands, Brentford, UK, diluted to 200 ml with water). 
Blood samples were taken from an indwelling antecubital venous cannula at 0, 30, 60, 
90 and 120 minutes into fluoride oxalate tubes for glucose, lithium-heparinized tubes 
containing 200 KIU aprotinin per ml blood for GLP-U.^amide and into lithium- 
heparinized tubes for the other hormones. Analyses of insulin, C-peptide, proinsulin,
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LH, FSH, testosterone, SHBG and androstenedione were undertaken by the Clinical 
Biochemistry Department of the Royal Surrey County Hospital, Guildford. Samples 
for GIP and GLP-1 measurement were carried out at the University using the assays 
described in Chapter 2. Unfortunately there was only enough sample to measure 4 of 
the controls for GLP-1.
7.2.3 Statistic s
The results were analysed using non-parametric 2-tailed Mann-Whitney U tests and 
are expressed as mean ± standard error of the mean (S.E.M.). Significance is taken at 
p < 0.05. Integrated responses (total area under the curve) were calculated using the 
trapezoid rule. The significance of association between variables was measured using 
Spearman’s rank correlation. The data is expressed graphically as mean values ± 
S.E.M.
7.3. RESULTS
There were no differences between subject groups for either age (PCOS: 28.5 ± 1.4; 
control: 27.5 ±1.4 years) or BMI (23.4 ± 0.4; 22.7 ± 0.5).
7.3.1. Fa st in g  Se x  H o r m o n e  D a ta
Table 7.1. below shows the fasting sex hormone data for the PCOS subjects and 
controls. Values in the table with the same lower case superscript letter are 
significantly different from each other.
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Table 7.1. Fasting sex hormone data in PCOS and control women (mean ± S.E.M.).
Control (n = 8) PCOS (n = 7)
Testosterone (nmol/L) 1.86 ±0.12" 3.3 ±0.11"
SHBG (nmol/L) 84.5 ± 6.8b 57.0 ± 7.7b
Free androgen index 2.2 ±0.1" 6.4 ±0.9"
Androstenedione (nmol/L) 6.9 ± 0.8d 12.0 ± 0.9d
LH (IU/L) 4.9 ±0.9" 14.9 ±2.1"
FSH (IU/L) 6.4 ±0.9 5.9 ± 0.7
P < 0.05 
P < 0.01 
P< 0.001
The PCOS group were hyperandrogenaemic, with both testosterone and 
androstenedione being significantly higher than the control group. LH was also 
significantly higher and FSH lower.
7.3.2. B-CELL H o rm o nes
Table 7.2. shows the glucose and pancreatic hormone responses of the PCOS and 
control women. Values in the table with the same lower case superscript letter are 
significantly different from each other. The results are illustrated graphically in Fig. 
7.1.
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Table 7.2. Glucose and pancreatic hormone responses to a to a 2 hour 75 g oral
glucose tolerance test in PCOS and control women (mean ± S.E.M.).______________
Controls (n = 8) PCOS (n = 7)
Fasting Glucose (mmol/L) 4.9 ± 0.2 5.2 ±0.3
Two-hour glucose (mmol/L) 5.7 ±0.16 5.1 ±0.5
Integrated glucose (mmol/L.min) 824 ±31 780 ± 57
Fasting insulin (pmol/L) 34 ± 3 59 ±15
Integrated insulin (pmol/L.min) 28350 ±2513" 45707 ±4003"
Fasting C-peptide (pmol/L) 303 ±61 448 ±49
Integrated C-peptide (pmol/L.min) 178614 ±12146b 228504 ± 20557b
Fasting proinsulin (pmol/L) 5.4 ±2.7 4.3 ±1.5
Integrated proinsulin (pmol/L.min) 1429 ±425 2636± 592
Fasting glucoserinsulin molar ratio 
(x lO )
0.15 ±0.01 0.12 ±0.02
Integrated glucosednsulin molar ratio 
(x lO )
0.03 ± 0.003" 0.02 ±0.001"
Fasting insulimC-peptide molar ratio 0.13 ±0.06 0.10 ±0.03
Integrated insulimC-peptide molar 
ratio
0.16 ± 0.01d 0.21 ± 0.03d
Fasting proinsuliminsulin molar ratio 0.14 ±0.07 0.06 ±0.01
Integrated proinsuliminsulin molar 
ratio
0.05 ±0.01 0.06 ±0.01
b,d P < 0.05
acP<0.01
Women with PCOS had a trend for higher (P < 0.1) fasting insulin concentrations, but 
similar fasting proinsulin and C-peptide concentrations to control subjects. There was 
a trend (P < 0.1) for the integrated proinsulin response to be higher and it was 
significantly higher for insulin (P < 0.01) and C-peptide (P < 0.05) in women with 
PCOS than control women. The fasting insulin:C-peptide molar ratio was similar 
between subject groups, but the integrated ratio was higher in women with PCOS. 
Both fasting and integrated proinsuliminsulin ratios were similar in each group.
Integrated insulin correlated with testosterone (P< 0.05, r = 0.58), LH (P < 0.05, r = 
0.56), free androgen index (P < 0.05, r = 0.58) and BMI (P< 0.05, r = 0.54). Fasting
C-peptide correlated with testosterone (P < 0.05, r = 0.6), whilst integrated C-peptide 
correlated with BMI (P < 0.05, r = 0.53). Integrated proinsulin correlated with the free 
androgen index (P < 0.05, r = 0.54). There were no other significant correlations.
7.3.3. G u t  H o r m o n es
Table 7.3. shows the GIP responses of the PCOS and control women. Values in the 
table with the same lower case superscript letter are significantly different from each 
other. The results are illustrated graphically in Fig. 7.2.
Table 7.3. GIP responses to a 2 hour 75 g oral glucose tolerance test in PCOS and 
control women (mean ±S.E.M.).
Control (n = 8) PCOS (n = 7)
Fasting GIP (pmol/L)
Integrated GIP 
(pmol/L.min)
43 ± 8  
13755 ± 1726
50 ±18 
16811 ±2231
There were no significant differences between groups for GIP.
GLP-l(7 -3 6 )amide levels were mainly below the level of detection of the assay in both 
PCOS and control subjects. This was not expected and suggested a problem with the 
assay. Unfortunately, there was not enough sample to repeat the assay, so the GLP-1(7. 
3 6 )amide data was not included in further analysis.
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Figure 7.1. Glucose and pancreatic hormone responses to a 75 g oral glucose tolerance 
test in PCOS and control women, n = 7 for PCOS group and 8 for control group 
(mean ± S.E.M.).
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Figure 7.2. GIP responses to a 75 g  oral glucose tolerance test in PCOS
and control women, n = 7 for PCOS group and 8 for control group (mean ± S. E.M.).
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7.4 DISCUSSION
This study shows that peripheral hyperinsulinaemia, which is independent of obesity 
and glucose tolerance, is a feature of PCOS. There was a trend towards fasting 
hyperinsulinaemia, although it did not quite reach significance (P = 0.05), whereas the 
difference in integrated insulin, which is the amount circulating during the test period 
was highly significant.
Integrated proinsulin concentrations in women with PCOS were greater than controls, 
although it did not quite reach significance (P = 0.05), suggesting that proinsulin 
contributes to the glucose-stimulated hyperinsulinaemia, but not fasting levels. The 
stimulated proinsuliminsulin ratio was similar in control and PCOS subjects, 
suggesting that stimulated pancreatic B-cell function is normal and the B-cells are not 
releasing more unprocessed proinsulin into the circulation as is seen in NIDDM 
(Ward et a l, 1987). These results are similar to those of Conway et ah (1993), 
however, this group also reported fasting hyperproinsulinaemia in lean 
hyperinsulinaemic women with PCOS. We did not see this, but we studied a smaller 
number of subjects who were also less hyperinsulinaemic than the subjects of Conway 
et al. (mean fasting insulin: this study, 59 pmol/L; Conway et a l, 89 pmol/L).
The amount of insulin and C-peptide secreted was significantly greater in women with 
PCOS than controls suggesting that greater secretion of insulin from the pancreas was 
contributing to the hyperinsulinaemia seen. The ratio of integrated insulin:C-peptide 
was increased in the PCOS subjects, suggesting that reduced hepatic extraction of 
insulin or possibly increased C-peptide removal was also involved. These results
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agree with those of Mahabeer et al. (1989) and O’Meera et a l  (1993), but differ from 
another (Tropeano et a l, 1994), where only increased C-peptide was seen. The results 
are also consistent with other states of hyperinsulinaemia, e.g. hypertriglyceridaemia 
and obesity, where the peripheral hyperinsulinaemia seen was said to be due to the 
combined effects of increased insulin secretion by the pancreas and decreased 
removal of insulin by the liver (Meistas et a l, 1983; Gama and Marks, 1989; Gama et 
a l, 1995a).
GIP results were similar between PCOS and control subjects, so it appeared that 
increased GIP levels were not involved with the hyperinsulinaemia seen in PCOS. 
This corresponds to some other studies of hyperinsulinaemic states such as obesity 
and pregnancy where attenuated or unchanged GIP concentrations are seen (Homnes, 
1984; Ranganath et al., 1996). G hP-l^.^am ide results were mainly below the 
sensitivity of the assay in both PCOS and control subjects. We expected to see a GLP- 
l(7 -3 6 )amide response to glucose in control subjects, if not those with PCOS. so this 
was indicative of a problem with the assay, the most likely cause being the batch of 
CSS used. Unfortunately there was not enough sample to repeat the assay, so no 
conclusions could be drawn about the role of GUP-l^.^amide in the 
hyperinsulinaemia of PCOS, but there was no evidence for overproduction of GLP-
l(7 _3 6 )amide.
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8.1. INTRODUCTION
Gama et al. (1995b) reported a case of a woman with a proinsulinoma tumour whose 
fasting hypoglycaemia was aggravated by the long-acting somatostatin analogue 
octreotide. Other B-cell stimulation and suppression tests were undertaken at the time, 
but the results were not published and samples saved for further analysis.
Glucagon is a potent stimulus to insulin secretion and as such can be used as a test for 
insulin secretion. Glucagon administration also raises or at least does not decrease 
circulating glucose levels, making it safer to use in the investigation of 
hypoglycaemia than some B-cell stimulation tests (Marks and Rose, 1981).
The long-acting somatostatin analogue octreotide can depress insulin secretion and as 
such has been proposed as a test for insulinoma, however, results have been variable.
Infusion of diazoxide causes blood glucose levels to rise. If plasma insulin levels fall 
and glucose levels return from hypo- to normo-glycaemic following diazoxide 
infusion, it can strengthen the opinion that the plasma insulin level is inappropriately 
high for prevailing blood glucose levels (Fajans et al., 1966)
Most immunoassays for insulin cross-react to varying degrees with other B-cell 
products e.g. proinsulin, des-31,32 proinsulin and des-64,65 proinsulin (see Section 
1.2.6). The relative importance of cross-reactivity depends on circulating levels of 
these peptides compared with insulin.
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The aim of this study was to investigate whether a specific assay for insulin could 
provide a new perspective on pancreatic B-cell production in this patient with a 
proinsulin secreting tumour. In particular, this study addressed the question of 
whether the hormone production that was seen in response to insulinotropic stimuli 
and B-cell suppressants was coming from the tumour itself or from the remaining B- 
cells in the pancreas.
8.2. METHODS
8.1.1. Ca se  H isto r y
A 62-year old woman was admitted to hospital following three convulsions. She had 
been previously fit and healthy. Glucose levels were undetectable on a glucometer. 
Intravenous glucose was administered, leading to a full recovery.
Analysis of a fasting venous plasma sample showed:
♦ Glucose 1.9 mmol/L
♦ RIA insulin 410 pmol/L
♦ C-peptide 1249 pmol/L
♦ Proinsulin 420 pmol/L
♦ 6-hydroxybutyrate < 20 jimol/L
♦ Sulphonylurea negative
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She was hypoglycaemic, with an inappropriately elevated insulin (approximately 10 
fold increase on normal levels) and disproportionately high proinsulin relative to her 
insulin levels (approximately 100-fold increase on normal fasting proinsulin). 13- 
hydroxybutyrate levels were low and she was not self-administering sulphonylureas. 
On the basis of this data, an initial preliminary diagnosis was made of a 
proinsulinoma tumour.
Following a four hour fast, her venous plasma glucose was 2.6 mmol/L and she had a 
normal electroencephalogram (EEG), with an a-rhythm of 10 Hz. By nine hours of 
fasting, with intermittent exercise, her glucose levels had dropped to 1.2 mmol/L, 
accompanied by a slowed a-rhythm of 8 Hz. She exhibited impaired intellectual 
responses to testing, but there were no signs of acute neuroglycopaenia. An 
intravenous infusion of saline had no effect, but one of 25 g glucose restored her 
mental state to normal a-rhythm to 10 Hz.
She underwent further testing including an abdominal CT scan, which showed no 
detectable tumour and investigations for Multiple Endocrine Neoplasia type 1, which 
was also negative.
The investigations that this chapter will focus on are her responses to insulinotropic 
stimuli (75 g oral glucose tolerance test and 1 mg intravenous glucagon) and B-cell 
suppressants (50 jxg subcutaneous octreotide and 600 mg diazoxide infusion).
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Preoperative treatment with diazoxide and chlorothiazide prevented further 
hypoglycaemia. A 1 cm diameter tumour was resected from the anterior aspect of the 
body of the pancreas correcting her hypoglycaemia, however she later died of 
necrotizing pancreatitis.
8.2.2. ANALYTICAL METHODS
Specific insulin levels measured by ELISA (detailed in Chapter 2), were conducted by 
the author. Insulin levels as measured by RIA (see Chapter 2) were repeated by the 
author and compared with original values to check for sample degradation. The 
insulin ELISA cross-reacted 66% with des-64,65 proinsulin and exhibited negligible 
cross-reactivity with proinsulin, des-31,32 proinsulin and C-peptide. The insulin RIA 
cross-reacted 42 % with proinsulin, 61 % with des 31,32-proinsulin, 76 % with des 
64,65-proinsulin and negligible with C-peptide. All other analytical investigations 
were undertaken by the Department of Clinical Biochemistry at the Royal Surrey 
County Hospital, Guildford.
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8.3. RESULTS
8.3.1. O r a l  g l u c o s e  T o l e r a n c e  T e s t
Figure 8.1. shows the patient’s glucose and pancreatic hormone responses to a 75 g 
oral glucose tolerance test.
Her fasting analyte levels were: glucose, 1.4 mmol/L; RIA insulin, 409 pmol/L; 
ELISA insulin, 118 pmol/L; C-peptide 1689 pmol/L; proinsulin, 348 pmol/L.
Glucose was given at t = 0. This was followed by an immediate rise in plasma glucose 
with a corresponding increase in insulin and C-peptide. Proinsulin levels remained 
relatively constant throughout the time period. Peak analyte levels were: glucose, 9.5 
mmol/L; RIA insulin, 677 pmol/L; ELISA insulin, 412 pmol/L; C-peptide 2468 
pmol/L; proinsulin, 360 pmol/L. Insulin levels had returned to basal by the end of the 
period, glucose and C-peptide had not.
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8.3.2. G l u c a g o n  Test
Table 8.1 shows the patient’s fasting and 15 minute glucose and pancreatic hormone 
responses to 1 mg glucagon administered intravenously at t = 0.
Table 8.1. Glucose and pancreatic hormone responses to 1 mg glucagon in a patient 
with a proinsulinoma tumour._______________________________________________
Time (mins)
0 15
Glucose (mmol/L) 1.3 3.6
RIA insulin (pmol/L) 269 471
ELISA insulin (pmol/L) 56 152
C-peptide (pmol/L) 1082 1231
Proinsulin (pmol/L) 342 345
Glucagon ( pmol/L) 20 500
Glucose, insulin (RIA and ELISA) and C-peptide all rose following glucagon 
administration. Proinsulin levels remained unchanged.
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8.3.3. O c tr eo tid e  T est
Figure 8.2. shows the patient’s glucose and pancreatic hormone responses to 50 jug 
octreotide administered subcutaneously at t = 0.
Her fasting analyte levels were: glucose, 2.7 mmol/L; RIA insulin, 308 pmol/L; 
ELISA insulin, 131 pmol/L; C-peptide, 1776 pmol/L; proinsulin: 356 pmol/L.
Octreotide was administered subcutaneously at t = 0. This was followed by a decrease 
in glucose, insulin and C-peptide. Proinsulin levels remained relatively constant 
throughout the time period. Nadir analyte levels were: glucose, 1.3 mmol/L; RIA 
insulin, 258 pmol/L; ELISA insulin, 29 pmol/L; C-peptide, 1096 pmol/L; proinsulin: 
344 pmol/L.
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8.3.4. D ia z o x id e  T est
Figure 8.3. shows the patient’s glucose and pancreatic hormone responses to 600 mg 
diazoxide.
Fasting analyte values were: glucose, 2.1 mmol/L; RIA insulin 348 pmol/L; ELISA 
insulin, 84 pmol/L; C-peptide, 1420 pmol/L; proinsulin 368 pmol/L.
Diazoxide was infused over one hour starting at t = 0. Glucose rose between 30 and 
60 minutes, decreased until 120 minutes and then rose again. There was an initial 
decrease in insulin and C-peptide, but insulin levels rose again. Proinsulin levels 
remained relatively constant.
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8.4. DISCUSSION
The aim of this study was to investigate whether a specific assay for insulin could 
give further insight into the pathogenesis of a particular proinsulinoma tumour. 
Insulin is formed from proinsulin via either of two pathways (see Chapter 1.2.4.). 
Consequently the insulin molecule contains part of the same structure as that of the 
less biologically active intermediate fragments and proinsulin itself. To discover what 
is happening to insulin alone, therefore, it is necessary to have an assay specific to 
insulin. The ELISA used cross-reacts 66 % with des 64,65-proinsulin but as this 
normally only circulates at very low levels it should not cause any interference with 
the specific insulin assay. Des 64,64-proinsulin production in this patient was 
however not known.
The patient’s basal insulin levels were high as measured by both RIA and ELISA 
(although considerably less in the ELISA) The cross-reactivity of proinsulin and des 
31,32-proinsulin was negligible in the ELISA, so these two peptides must account for 
the difference in RIA and ELISA insulin measurements The observation that basal 
insulin levels were high as measured by ELISA suggests that some of the proinsulin 
from the tumour was being partially processed into des 64,65-proinsulin, or fully 
processed into insulin, both of which would be measured in both the ELISA and RIA.
Prior to the OGTT the patient was hypoglycaemic, with inappropriately elevated 
insulin relative to her glucose level and disproportionately high proinsulin relative to 
insulin. Following the OGTT, although the insulin levels were raised, the incremental 
change seen was of a similar magnitude to what might be expected from a healthy
240
person undergoing the same glucose challenge. The patient’s plasma glucose and C- 
peptide levels also responded to the glucose load, but proinsulin levels remained 
constant.
Before the glucagon bolus, the patient was again hypoglycaemic, with inappropriately 
elevated insulin and disproportionately high
proinsulin levels. Her glucose levels rose following glucagon, as did insulin and C- 
peptide, but proinsulin remained unchanged. Insulin as measured by ELISA increased 
approximately three-fold, whereas the rise in RIA insulin was less than two-fold, 
emphasising how the large amount of circulating proinsulin or des-31,32 proinsulin 
that cross-reacts in the RIA could mask changes in insulin levels.
Prior to the octreotide test, the patient had a low glucose level (although not clinically 
hypoglycaemic). Again, she had an inappropriately high insulin level and 
disproportionately high proinsulin. Following the subcutaneous octreotide injection 
ELISA insulin and C-peptide decreased, but not proinsulin. Alterations in RIA insulin 
levels were more difficult to distinguish because of the masking effect of the high 
proinsulin levels. The decrease seen in glucose levels was probably due to a decrease 
in glucagon that was also suppressed by the octreotide. This together with 
unsuppressed proinsulin levels would have a hypoglycaemic effect.
Prior to the diazoxide test, the patient was hypoglycaemic with inappropriately high 
insulin and disproportionately high proinsulin levels. During the diazoxide infusion 
there was an initial decrease in insulin (RIA and ELISA) and C-peptide. Proinsulin
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levels decreased slightly. Glucose levels increased during the diazoxide infusion. This 
may have occurred if glucagon was not being suppressed as it was with octreotide 
(glucagon measurements were not made). Glucose levels decreased again as 
proinsulin and insulin concentrations rose.
In summary, insulin (as clarified by the ELISA), C-peptide and consequently glucose 
concentrations altered appropriately in response to insulinotropic stimuli and B-cell 
suppressants, however the proinsulin response remained fairly constant throughout the 
tests. This is similar to previously published reports of tumours with high levels of 
proinsulin-like component (proinsulin and fragments) being unresponsive to 
diazoxide or somatostatin suppression (Berger et al., 1983).
Use of a specific insulin assay in combination with other radioimmunoassay data 
suggested that tumour production of proinsulin was unresponsive to insulinotropic 
stimuli and B-cell suppressants. The changes seen in ELISA insulin and C-peptide 
levels suggested that the remainder of the B-cells were functioning normally. The 
specific insulin assay provided clarification in a situation where proinsulin levels were 
abnormally elevated, distorting routine RIA insulin measurements and thus masking 
insulin responses to stimuli/suppressants that were relatively small compared with the 
concentration of circulating proinsulin.
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CHAPTER 9.
D is c u s s io n .
243
The aim of this project was to investigate pancreatic B-cell, GDP and GBB.^.^amide 
secretion and function in different hyperinsulinaemic, insulin resistant states. This was 
achieved by examining fasting and postprandial hormone production in obesity, 
hypertriglyceridaemia and polycystic ovarian syndrome. As part of this, a specific 
ELISA for insulin was developed and this was also used to re-examine a case study of 
a patient with a proinsulinoma tumour. The purpose of this chapter is to draw together 
information from the thesis and compare hormone and metabolite production in 
different disease states, which have the common theme of hyperinsulinaemia.
9.1. OBESITY
Two studies of obese subjects were undertaken. In the first study, hormone and 
metabolite responses to oral glucose were studied following modulation of circulating 
NEFA levels with heparin or acipimox. Circulating NEFA levels influenced GLP_i(7. 
3 6 )amide secretion in both lean and obese subjects, with high levels attenuating the 
GLP-l(7 -3 6 )amide response. The implication of this finding in pathological states 
where NEFA levels are raised is discussed later (see Section 9.4).
Obese subjects showed a trend to GIP hypersecretion relative to the control subjects 
following oral glucose, but this did not achieve statistical significance. The obese 
subjects had an attenuated GLP-l^.3 ^amide response to glucose relative to control 
subjects, confirming previous work (Ranganath et a l, 1996), although the differences 
were only significant following the acipimox treatment when NEFA levels were 
suppressed.
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The hormone and metabolite responses of a second group of obese and control 
subjects following a mixed test meal were studied in Chapter 4. The obese group were 
analysed as a whole and then divided into two groups (android and gynoid) on the 
basis of their waistrhip ratio. Waist circumference was measured at two sites and 
different combinations of waist alone, waistrhip ratio and waistrheight ratio were used 
to divide the group prior to analysis of the data. The designation of subjects as either 
android or gynoid obese varied according to the method of anthropometric 
measurement. This in turn affected the mean hormone and metabolite levels observed 
for each group, emphasising the need for a standard set of anthropometric criteria to 
be used when assigning obese subjects as having an android or gynoid body fat 
distribution.
The obese subjects in Chapter 4 exhibited fasting and postprandial hyperinsulinaemia 
using both the specific insulin ELISA and less specific RIA. The obese also 
demonstrated signs of resistance to insulin-stimulated glucose uptake with 
significantly higher fasting glucose in the android obese and a trend for postprandial 
elevated levels. | The gynoid obese subjects had significantly greater proinsulin 
j  (incremental response) than android obese, similar ELISA insulin levels and lower 
(not significant) RIA insulin than android subjects. Postprandial insulin responses as 
i measured by RIA were significantly greater than by ELISA in android obese but not
!
| gynoid obese subjects. In android obese subjects, this data suggests that a possible 
I explanation for raised RIA insulin, similar ELISA insulin and lower proinsulin levels
I
I than in gynoid subjects could be increased levels of des-31,32 proinsulin. This is not 
measured in the proinsulin RIA or insulin ELISA but is in the insulin RIA. However, 
because this proinsulin fragment is less biologically active than insulin, the android
obese were less able to suppress both fasting or postprandial glucose levels, whereas 
the compensatory hyperinsulinaemia seen in the gynoid obese allowed maintenance of 
near normal glucose levels, in spite of insulin resistance. This is similar to studies on 
non-insulin-dependent diabetic individuals who have been shown to have raised des- 
31,32 proinsulin levels (Temple et ah, 1989).
In contrast with the first study, following the mixed meal, obese subjects exhibited 
GIP hypersecretion in the latter part of the study relative to control subjects. Other 
studies have found postprandial GIP secretion in obesity to be increased (Creutzfeldt 
et a l, 1978; Elahi et a l, 1984), or unaffected (Lauritsen et a l, 1980; Amland et a l, 
1984; Service et a l, 1984) relative to control subjects. GIP secretion was higher in the 
gynoid obese, as was proinsulin and insulin as measured by ELISA, as already 
discussed above. This concurs with the role of GIP as an incretin with previous 
studies demonstrating that GIP can stimulate proinsulin gene expression (Fehmann 
and Gôke, 1995). The increased GIP secretion could therefore reduce glycaemic 
excursions via its insulinotropic effect. The android obese subjects also exhibited GIP 
hypersecretion relative to control subjects, but to a lesser degree than gynoid obese 
subjects. The insulin levels in this group were less as measured by ELISA than in 
gynoid subjects (not significant) and proinsulin responses were significantly less; 
however they were still greater than in control subjects. This again supports an 
insulinotropic effect of GIP.
Several factors could contribute to the differences in GIP secretion in obese subjects 
seen in the literature. In particular body fat distribution was not assessed in previously 
reported studies. In Chapter 4, the gynoid obese subjects exhibited the greatest
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postprandial GBP secretion, suggesting that body fat distribution may therefore 
influence GIP secretion.
In contrast with the first study, postprandial GBP-l^.^amide production was similar 
between obese and control subjects following the mixed meal in Chapter 4. As with 
GIP, results from other studies are contradictory. Fukase and co-workers (Fukase et 
fl/., 1993) observed elevated GLP-1 levels in obese diabetic subjects, but similar 
postprandial responses between non-diabetic obese and lean control subjects. 
However attenuated GLP-1 (y^amide responses in non-diabetic obese subjects were 
seen by Ranganath et a l, (1996) following a carbohydrate but not a fat load. The 
studies in this thesis have shown that the nature of the test meal is important in 
eliciting differences in GIP and GLP-l^.^amide secretion between obese and normal 
weight subjects.
Whilst theories have been proposed for the differences in hormone production 
between android and gynoid obese subjects, it must be remembered that the small 
group numbers necessitated that subjects were assigned to groups arbitrarily and there 
was therefore no clear distinction between groups. Subjects were placed in different 
groups when other anthropometric measurements were used as a divisor and 
subsequent mean metabolite and hormone data was affected. This means that 
conclusions can only be speculative and further work with larger group sizes and a 
more direct measure of body fat distribution such as CT scanning are necessary
Some differences were seen between fasting hormone and metabolite levels in the two 
studies of obese subjects in Chapters 3 and 4. When the two studies were compared,
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the obese subject groups had very similar BMIs (Chapter 3, 39.6 ± 2.0; Chapter 4, 
39.5 ±3.1; mean ± S.E.M.), so the degree of obesity could not be contributing to any 
differences seen. Obviously, the subjects in the two studies were responding to 
different stimuli - a glucose load in Chapter 3 and a mixed meal in Chapter 4, but this 
does not explain any fasting differences. Fasting differences between the two studies 
were probably due to small subject group size in both studies, with subjects not 
necessarily being representative of the obese population. We could not obtain 
anthropometric data on the subjects in Chapter 3, so do not know if body fat 
distribution influenced hormone and metabolite secretion. Another contributory factor 
could be sex differences - women only were studied in Chapter 3, whereas the study 
in Chapter 4 used both sexes.
9.2. HYPERTRIGLYCERIDAEMIA
A study comparing subjects with both moderate and severe hypertriglyceridaemia and 
a group of normotriglyceridaemic controls and their hormone and metabolite 
responses to a mixed test meal was described in Chapter 5. Severely 
hypertriglyceridaemic subjects (fasting TAG levels > 6 mmol/L) were
hyperinsulinaemic relative to the control subjects, but the moderately 
hypertriglyceridaemic subjects (fasting TAG 2.5 -  6 mmol/L) had insulin responses 
only slightly greater than controls, indicating an association between elevated 
circulating TAG and insulin resistance. Consistent with this, glucose responses to the 
meal followed a similar pattern with the severely hypertriglyceridaemic showing a 
trend towards a higher glucose response than the moderately hypertriglyceridaemic 
and control subjects.
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The hypertriglyceridaemic subjects showed a greater GIP response to the meal than 
the control subjects. The moderately hypertriglyceridaemic group were higher than 
the severely hypertriglyceridaemic, although the differences between the two 
hypertriglyceridaemic groups were not significant. There were no significant 
differences in G fP-l^ .^am ide levels between the three groups, although the trend 
was for the moderately hypertriglyceridaemic to have a greater postprandial GLP-1 (7 . 
3 6 )amide response than the other two groups.
Chapter 6 described the hormone and metabolite responses of a different group of 
hypertriglyceridaemic and control subjects to a sucrose load with and without the cc- 
glucosidase inhibitor acarbose. This hypertriglyceridaemic group did not exhibit 
fasting or postprandial hyperinsulinaemia. Glucose responses were also similar 
between the two groups. There was a trend for the hypertriglyceridaemic subjects to 
have a greater GIP response to sucrose than the control subjects, but no differences 
were found in GLP-l^.^amide responses.
Comparison of these two studies showed that the hypertriglyceridaemic subjects in 
Chapter 6 had similar TAG levels to the moderately hypertriglyceridaemic in Chapter 
5. Both of these groups showed similar insulin levels to control subjects. This 
suggests that moderately hypertriglyceridaemic subjects can maintain near normal 
insulin levels and glucose tolerance. As the disease becomes more severe and TAG 
levels rise, the degree of insulin resistance worsens, and insulin levels rise eventually 
until this compensatory hyperinsulinaemia is not sufficient to suppress plasma 
glucose.
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Mean GBP levels were higher in the hypertriglyceridaemic subjects in both studies, 
although the differences did not reach statistical significance following oral sucrose in 
the second study. They were higher in the moderately hypertriglyceridaemic than the 
severely hypertriglyceridaemic in Chapter 5. The group with higher insulin levels 
(severely hypertriglyceridaemic) had lower GIP levels than those with lower insulin 
levels (moderately hypertriglyceridaemic), supporting the theory of negative feedback 
of insulin on GBP secretion proposed by Creutzfeldt (Creutzfeldt et al., 1978), which 
is exercised predominantly on fat-stimulated GIP secretion. Consistent with this, the 
differences between normo- and hyper-triglyceridaemic subjects following oral 
sucrose were not as marked.
There were no significant differences in GBP-l^.^amide between 
hypertriglyceridaemic and control subjects in either study.
9.3. POLYCYSTIC OVARIAN SYNDROME
Chapter 7 described a study comparing the hormone responses of women with 
polycystic ovarian syndrome to healthy control subjects. The women with PCOS 
exhibited postprandial hyperinsulinaemia and a trend for fasting hyperinsulinaemia. 
There were no differences in GIP levels between the women with PCOS and the 
control group, suggesting that increased circulating GIP levels are not contributing to 
the hyperinsulinaemia seen in this group. Assay problems prevented firm conclusions 
being drawn from the GLP-1 (7 .3 6 )amide data, but there was no evidence that GLP-1 (7 . 
3 6 )amide levels were elevated in PCOS and played any role in their hyperinsulinaemia.
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9.4. THE ROLE OF THE ENTEROINSULAR AXIS IN DISEASE
The enteroinsular axis has been reported to contribute to 50 % of postprandial insulin 
secretion (Berthoud, 1984). The gut hormones GIP and GLP-l^.^am ide are the most 
potent incretin hormones known.
An important finding in this project was that circulating NEFA levels can modulate 
GLP-1 (7 -3 6 )amide concentrations (Chapter 3). This is potentially relevant in disease 
states such as obesity and hypertriglyceridaemia where NEFA levels are often raised.
GLP-1 (7 -3 6 )amide levels were lower in obese than control subjects even when NEFA 
levels were suppressed to a similar degree following acipimox administration, 
suggesting a defect in GLP-1 (7_3 6 )amide secretion in the obese. The attenuated GLP- 
l(7 -3 6 )amide response previously reported following glucose in obese subjects was not 
seen following a mixed meal, possibly because the other components of the meal were 
over-riding any intrinsic defect of G LP-I^^am ide secretion in response to 
carbohydrate that obese subjects might have. The prevailing fasting NEFA levels of 
the obese and lean subjects may also be a factor; they were similar in the mixed meal 
study, whereas the fasting NEFA levels of the obese subjects in Chapter 3, where 
attenuated GLP-I^.3 ^amide secretion was observed, were significantly elevated 
relative to control subjects.
GLP-1 (7 -3 6 )amide has been postulated as a satiety factor, following observations 
including the discovery of G L P-l^^am ide producing cells and receptors in areas of 
the brain concerned with food intake (0rskov et a l, 1996b) and administration of
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GLP-1 (7 -3 6 )amide to the cerebroventricular region of the brain inhibiting food intake 
and drinking behaviour in rats (Lambert et al., 1993). Deficiency of GLP-1 (y.sejamide, 
as appears to occur in obesity in response to carbohydrate ingestion could therefore 
promote overeating. However, postprandial GLP-l^.^amide levels do not appear to 
be attenuated in the obese following a mixed meal, suggesting that the hormone may 
not be as important in the termination of eating in the normal physiological situation 
of mixed nutrient consumption.
Raised postprandial levels of GIP were seen in both obesity and 
hypertriglyceridaemia. In hypertriglyceridaemia, the subjects with lower insulin levels 
(moderately hypertriglyceridaemic) exhibited this. This group also had lower glucose 
levels than the severely hypertriglyceridaemic subjects. This data supports the 
hypothesis that GIP can directly suppress glucose levels other than via its 
insulinotropic effects. Hartmann and co-workers (1986) proposed that GIP can 
suppress hepatic glycogenolysis, thus lowering glucose levels. The moderately 
hypertriglyceridaemic may also be less insulin resistant than the severely 
hypertriglyceridaemic, which would also lessen their glucose levels.
Previous studies in this university (Elliott et a l, 1993) examining GIP and GLP-1 (7 . 
3 6 )amide secretion in response to various simple and complex carbohydrates have 
found that secretion of the two gut hormones occurs in parallel. The endocrine loop 
hypothesis (Roberge and Brubaker, 1993) suggests that GIP secretion in the proximal 
small intestine initiates a neuro-humoral stimulus to GLP-l^.^am ide secretion in the 
distal intestine. However, studies in this thesis do not support these findings. In 
situations of obesity and hypertriglyceridaemia where circulating GIP levels were
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raised, GLP-1 (7 -3 6 )amide did not follow suit. A dissociation in GIP and GLP-1 (7 . 
3 6 )amide was particularly marked following acarbose, when GIP secretion was 
markedly attenuated yet G L P-l^^am ide secretion was exaggerated.
The studies in this thesis have shown that in the disease states of obesity and 
hypertriglyceridaemia, GIP may play a small part in the hyperinsulinaemia seen, but 
there was no evidence of a role for GLP-l^.3 ^amide. An overactive enteroinsular axis 
did not appear to be involved in the hyperinsulinaemia of polycystic ovarian 
syndrome
9.5. SPECIFIC INSULIN ELISA
The specific ELISA for insulin that was developed during the project was used to 
compare insulin production in android and gynoid obese subjects and to re-examine 
hormone production in a patient with a proinsulinoma tumour.
In the obese subjects, ELISA data, in combination with other RIA data suggested that 
android obese subjects whilst being hyperinsulinaemic, also had greater circulating 
levels of des-31,32 proinsulin. Whilst we did not measure des-31,32-proinsulin 
directly, increased levels could be inferred by comparing the data from the proinsulin 
RIA and insulin ELISA that did not cross-react with des-31,32 proinsulin and RIA 
insulin data where the assay does cross-react.
The specific ELISA for insulin provided a different perspective on hormone 
production in a patient with a proinsulinoma tumour. Whilst the insulin, proinsulin
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and C-peptide radioimmunoassay data alone identified that the tumour was producing 
large amounts of proinsulin, less could be interpreted about the functioning of the 
remaining B-cells in the pancreas. The high levels of proinsulin and the cross­
reactivity of this in the insulin RIA meant that relatively small changes in insulin 
levels in response to B-cell stimuli and suppressants were masked. The ELISA did not 
cross-react with proinsulin, allowing the insulin response of the remaining B-cells to 
be seen. Other workers studying insulinoma tumours have assumed that pancreas 
production of insulin ceases because of the high circulating levels of insulin. 
However, it appears in this patient with a proinsulinoma tumour that the pancreatic B- 
cells were still responsive.
In normal circumstances, proinsulin and the fragments circulate at relatively low 
levels compared to insulin and under these conditions, a specific assay for insulin 
would not be necessary. In states where proinsulin and fragment levels are altered, 
such as obesity, proinsulinoma and non-insulin-dependent diabetes mellitus, a specific 
assay may be of more use to identify true insulin levels by excluding measurement of 
the less biologically active proinsulin or des-31,32 proinsulin.
9.6. FUTURE WORK
Drawing conclusions from the data of all the studies was hampered by the small 
numbers in each of the study groups. The groups may not be a true reflection of the 
populations that they were sampled from and there were some large variances in the 
data. Larger group sizes would increase the power of the statistical analyses and allow 
more statistically significant differences to be found. In any future work, larger
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subject groups would be required.
The differences in GLP-1 (y^amide response to nutrients in obesity should be further 
investigated. Responses to carbohydrate, fat and protein had been examined 
separately and in this study a mixed meal was given. Measuring the GLP-l^.^am ide 
response to different percentages of carbohydrate, fat and protein in a mixed meal 
would provide further information on stimuli to GLP-t^.^amide secretion and help 
us understand why obese subjects appear to have an attenuated response to 
carbohydrate stimulation, but not a mixed meal. Subjective measurements could also 
be made of satiety to investigate the role of GLP-l^.^amide in this. Background diet 
should also be considered.
There appears to be a link between circulating TAG levels and GIP responses to a 
stimulus in both hypertriglyceridaemic and control subjects. Investigating the effects 
of suppressing TAG levels in hypertriglyceridaemic subjects on their circulating GIP 
levels could further support this finding, if GIP levels were also lowered. A study 
such as the one in Chapter 5, where a mixed test meal was administered and hormones 
and metabolites measured, could be undertaken before and after 3 months of 
treatment with a lipid-lowering drug. The role of diet would also be important in this 
and comparisons could be made between those subjects following diet alone, diet and 
drug therapy or drug therapy alone. Single nutrient administration, particularly of fat, 
which is the most potent nutrient stimulus to GDP secretion, would also be of interest 
and provide further information on gut hormone secretion in hypertriglyceridaemia.
A longer term study of NEFA suppression by a lipid-lowering drug in the obese
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subjects would be useful to investigate whether their attenuated GLP-1 (7 -3 6 )amide 
response to carbohydrate was intrinsic or could be altered by continued suppression of 
NEFA levels.
In contrast to the effects of circulating NEFA levels on GLP-1 (7 -3 6 )amide, the reverse 
could also be investigated by infusing G L P-l^^am ide and measuring NEFA levels. 
GLP-1 (7 -3 6 )amide promotes glucose uptake into muscle, so an infusion might have the 
effect of raising NEFA levels through the Randle glucose-fatty acid cycle.
Any investigation of obese subjects should be accompanied by an estimation of 
whether the subjects have an android or gynoid fat distribution. There are differences 
in postprandial hormone and metabolite responses between the two groups, but unless 
methods are standardised, comparison of studies is difficult. Ideally, each subject 
would undergo a direct measurement of body fat distribution such as computerised 
tomography scanning which would remove many of the problems encountered in 
Chapter 4. Advice on weight loss to reduce the risk of disease development, such as 
cardiovascular disease or non-insulin dependent diabetes, could be then directed at the 
appropriate people rather than generalised information being given to all obese 
individuals.
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